RL Prostaat - PICO 2 - Methodology report



Methodology report RL Prostaat PICO 2key questionWat is de aanbevolen 1e lijns behandeling bij pati?nten met een mCRPC?P Chemotherapie-na?eve pati?nten met gemetastaseerd castratie-resistent prostaatcarcinoom (mCRPC) I Pre-chemotherapie (abiraterone of enzalutamide, radium 223, anti-androgeen)C Placebo of prednisonO Progressie-vrije overleving, Algehele overleving, Kwaliteit van leven, Toxiciteitgolden hits1. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014, 371: 424-433. 2. Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy. Eur Urol. 2014 66(5): 815-25.3. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013 Jan 10; 368(2): 138-148; 4. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-na?ve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomized, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 16(2):152-60Search strategyThe searches were run on 16 July 2015. Pubmed Medline, Embase, Cochrane (all libraries) were searched. Detailed search strings are given below. The searches were limited to 2007-2015, English and Dutch. Study types: systematic reviews, meta-analysis and RCTsSearch resultsThe Medline search yielded 1199 hits, while the search in Embase yielded 739 hits, Cochrane yielded 212 hits. After merging the search files into one file and removal of the duplicates 1951 records were screened on title and abstract. Of these 1720 were excluded. The most important reasons for exclusion was that studies werePatient population InterventionOf the remaining 231 studies, the full text was retrieved. Based on the full text, an additional 216 studies were excluded. Table 4.1 provides an overview of the studies, with the reason for exclusion.Table 1. Full text articles and reason for in- or exclusion.#ReferenceIncluded / ExcludedReasons#1Abiraterone. After prostate cancer treatment failure: 4-month survival advantage. Prescrire Int, 2012. 21(128): p. 147-9.ExcludedPost-chemotherapy patients#2First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease. Prescrire Int, 2013. 22(135): p. 48-51.ExcludedNarrative review#3Enzalutamide before chemotherapy prolongs survival. Cancer Discov, 2014. 4(7): p. Of5.ExcludedAbstract#4Agarwal, N., G. Sonpavde, and C.N. Sternberg, Novel molecular targets for the therapy of castration-resistant prostate cancer. Eur Urol, 2012. 61(5): p. 950-60.Excluded(Narrative) review without pooled analysis (all studies included)#5Agota, P., The treatment of castration-resistant prostate cancer. Magyar Onkologia, 2012. 56(4): p. 219-228.ExcludedWritten in Hungarian#6Ahmadi, H. and S. Daneshmand, Androgen deprivation therapy: evidence-based management of side effects. BJU Int, 2013. 111(4): p. 543-8.Excluded(Narrative) review without pooled analysis and different treatments#7Akaza, H., Current status and prospects of androgen depletion therapy for prostate cancer. Best Pract Res Clin Endocrinol Metab, 2008. 22(2): p. 293-302.ExcludedNarrative review#8Akaza, H., et al., Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer, 2009. 115(15): p. 3437-45.IncludedDesign: RCTPatients: untreated prostate cancer patientsIntervention: combined androgen blockade with luteinizing hormone releasing hormone agonist plus bicalutamideControl: combined androgen blockade with luteinizing hormone releasing hormone agonist plus placebo#9Al-Asaaed, S. and E. Winquist, Secondary hormonal manipulation in castration resistant prostate cancer. Can J Urol, 2014. 21(2 Supp 1): p. 37-41.Excluded(Narrative) review without pooled analysis#10Albiges, L., et al., New drugs in metastatic castration-resistant prostate cancer. Bulletin du Cancer, 2010. 97(1): p. 149-159.ExcludedNarrative review#11Aragon-Ching, J.B., Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2012. 14(6): p. 805-806.ExcludedLetter to editor describing other trial#12Arai, Y., et al., Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study. J Cancer Res Clin Oncol, 2008. 134(12): p. 1385-96.IncludedDesign: RCTPatients: untreated prostate cancer patientsIntervention: combined androgen blockade with luteinizing hormone releasing hormone agonist plus bicalutamideControl: combined androgen blockade with luteinizing hormone releasing hormone agonist plus placebo#13Armstrong, A.J., et al. Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). Journal of clinical oncology, 2014. 32.ExcludedAbstract#14Auchus, R.J., et al., Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist, 2014. 19(12): p. 1231-40.Excluded(Narrative) review without pooled analysis (all studies included)#15Basch, E., et al., Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: Patient-reported outcome results of a randomised phase 3 trial. The Lancet Oncology, 2013. 14(12): p. 1193-1199.IncludedDesign: RCTPatients: chemotherapy-naive patients with metastatic castration-resistant prostate cancerIntervention: Abiraterone acetate plus prednisoneControl: prednisone alone#16Basch, E., et al., Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol, 2014. 32(30): p. 3436-48.ExcludedClinical practice guideline without pooled analysis#17Basch, E.M., et al. Pain control and delay in time to skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA): Long-term follow-up. Journal of clinical oncology, 2012. 30.ExcludedAbstract#18Beckett, R.D., K.M. Rodeffer, and R. Snodgrass, Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Annals of Pharmacotherapy, 2012. 46(7-8): p. 1016-1024.Excluded(Narrative) review without pooled analysis (all studies included)#19Beer, T.M., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. The New England journal of medicine, 2014. 371, 424-33 DOI: 10.1056/NEJMoa1405095.IncludedDesign: RCTPatients: metastatic prostate cancer who have not received chemotherapyIntervention: enzalutamide (at a dose of 160 mg)Control: placebo#20Beltran, H., et al., New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol, 2011. 60(2): p. 279-90.Excluded(Narrative) review without pooled analysis (all studies included)#21Bennett, L.L. and A. Ingason, Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer. Ann Pharmacother, 2014. 48(4): p. 530-7.Excluded(Narrative) review without pooled analysis (all studies included)#22Berruti, A., A. Pia, and M. Terzolo, Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 2011. 365(8): p. 766; author reply 767-8.ExcludedLetter to the editor referring to an included study.#23Bishr, M. and F. Saad, Overview of the latest treatments for castration-resistant prostate cancer. Nature Reviews Urology, 2013. 10(9): p. 522-528.Excluded(Narrative) review without pooled analysis (all studies included)#24Bolla, M., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. The Lancet. Oncology, 2010. 11, 1066-73 DOI: 10.1016/S1470-2045(10)70223-0.ExcludedControl is radiotherapy#25Bono, J.S., et al. Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine, 2011. 364, 1995-2005 DOI: 10.1056/NEJMoa1014618.ExcludedPatients previously received docetaxel.#26Borso, E., et al., Radium 223 dichloride: A multidisciplinary approach to metastatic castration-resistant prostate cancer. Future Oncology, 2015. 11(2): p. 323-331.Excluded(Narrative) review without pooled analysis (all studies included)#27Botrel, T.E., et al., Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol, 2014. 14: p. 9.ExcludedDesign: SR with meta-analysisPatients: locally advanced, recurrent ormetastatic hormone-sensitive prostate cancerIntervention: Intermittent androgendeprivationControl: continuous androgendeprivation#28Brodszky, V., et al. Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis (Provisional abstract). Database of Abstracts of Reviews of Effects, 2014. 189-197.ExcludedWritten in Hungarian#29Brungs, D., et al., Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis. Prostate Cancer Prostatic Dis, 2014. 17(2): p. 105-11.ExcludedDesign: SR with meta-analysisPatients: patients diagnosed with any stage of prostate cancerIntervention: Intermittent androgendeprivationControl: continuous androgendeprivation#30Calais da Silva, F., et al., Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. Eur Urol, 2014. 66(2): p. 232-9.ExcludedRCT in which the randomisation was based on a variable (PSA level).#31Calais da Silva, F.E., et al., Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol, 2009. 55(6): p. 1269-77.ExcludedRCT in which the randomisation was based on a variable (PSA level).#32Caley, A. and J. Staffurth, Abiraterone acetate for the treatment of Castrate-Refractory prostate cancer. Aging Health, 2013. 9(1): p. 9-23.Excluded(Narrative) review without pooled analysis (all studies included)#33Carrasquillo, J.A., et al., Phase i pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013. 40(9): p. 1384-1393.ExcludedNo RCT, therefore no control group.#34Cassinello, J., et al., SEOM Clinical guidelines for the treatment of metastatic prostate cancer. Clinical and Translational Oncology, 2014. 16(12): p. 1060-1066.ExcludedClinical practice guideline without pooled analysis#35Cathomas, R., et al. Orteronel maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel therapy: A multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11). Onkologie, 2013. 36, 78 DOI: 10.1159/000356365.ExcludedAbstract#36Cella, D., et al., Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: Additional analyses from the AFFIRM randomized clinical trial. Annals of Oncology, 2015. 26(1): p. 179-185.ExcludedPatients previously received chemotherapy.#37Conti, P.D., et al., Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev, 2007(4): p. Cd005009.ExcludedDesign: SR with meta-analysisPatients: prostatic cancer patientsIntervention: Intermittent androgendeprivationControl: continuous androgendeprivation#38Damber, J.E., et al., The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients. Urology, 2012. 80(1): p. 174-80.ExcludedControl isn’t prednisone or placebo, it’s leuprolide / degarelix.#39Dason, S., et al., Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice. Can J Urol, 2014. 21(2 Supp 1): p. 28-36.Excluded(Narrative) review without pooled analysis (all studies included)#40De Bono, J.S., et al., Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 2011. 364(21): p. 1995-2005.ExcludedPatients previously received docetaxel.#41De Conti, P., et al. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database of Systematic Reviews, 2007. DOI: 10.1002/14651858.CD005009.pub2.ExcludedDesign: SR with meta-analysisPatients: prostatic cancer patientsIntervention: Intermittent androgendeprivationControl: continuous androgendeprivation#42Dearden, L., et al. Comparison of mean overall surviva l (OS) and radiographic progression free survival (RPFS) based on matching adjusted indirect comparison of abiraterone acetate and enzalutamide for the treatment of castration-resistant prostate cancer in chemotherapy naive patients. Value in health, 2014. 17, A616 DOI: 10.1016/j.jval.2014.08.2170.ExcludedAbstract#43Dellis, A. and A.G. Papatsoris, The economics of abiraterone acetate for castration-resistant prostate cancer. Expert Rev Pharmacoecon Outcomes Res, 2014. 14(2): p. 175-9.ExcludedNo RCT (narrative review regarding costs)#44Den, R.B., L.A. Doyle, and K.E. Knudsen, Practical guide to the use of radium 223 dichloride. Can J Urol, 2014. 21(2 Supp 1): p. 70-6.Excluded(Narrative) review without pooled analysis (all studies included)#45Dreicer, R., How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer. Can J Urol, 2014. 21(2 Supp 1): p. 93-7.Excluded(Narrative) review without pooled analysis (all studies included)#46Dreicer, R., et al., Phase I/II trial of orteronel (TAK-700)-an investigational 17,20-lyase inhibitor-in patients with metastatic castration-resistant prostate cancer. Clinical Cancer Research, 2014. 20(5): p. 1335-1344.ExcludedNo RCT (no control)#47Fizazi, K., et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. Journal of clinical oncology, 2015. 33, 723-31 DOI: 10.1200/JCO.2014.56.5119.ExcludedPatients previously received docetaxel.#48Fizazi, K., et al., Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol, 2014. 15(9): p. 975-85.ExcludedNo RCT (no control)#49Fizazi, K., et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. The Lancet. Oncology, 2014. 15, 1147-56 DOI: 10.1016/S1470-2045(14)70303-1.ExcludedPatients previously received docetaxel.#50Fizazi, K., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology, 2012. 13, 983-92 DOI: 10.1016/S1470-2045(12)70379-0.ExcludedPatients previously received docetaxel.#51Fizazi, K., et al. Final overall survival (OS) analysis of COU-AA-301, a phase 3 study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) pretreated with docetaxel. European journal of cancer, 2011. 47, S483-s484 DOI: 10.1016/S0959-8049%2811%2971951-7.ExcludedAbstract#52Fossa, S.D., et al., Circulating tumor cells in patients with metastatic castration resistant prostate cancer: Exploratory findings at a tertiary referral hospital. Research and Reports in Urology, 2014. 6: p. 121-126.ExcludedNo RCT (prospective cohort study)#53Fossa, S.D., et al. Ten-and 15-year prostate cancer-specific survival in patients with nonmetastatic high-risk prostate cancer randomized to lifelong hormone treatment alone or combined with radiotherapy (SPCG VII). Journal of clinical oncology, 2014. 32.ExcludedAbstract#54Froehner, M. and M.P. Wirth, Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med, 2014. 371(18): p. 1755.ExcludedLetter to the editor referring to an included study.#55Gao, X., et al., Neoadjuvant hormonal deprivation for patients undergoing radical prostatectomy. Asian J Androl, 2009. 11(1): p. 127-30.ExcludedControl is radical prostatectomy.#56Gleave, M., L. Klotz, and S.S. Taneja, The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urol Oncol, 2009. 27(1): p. 81-6.Excluded(Narrative) review without pooled analysis#57Goldkorn, A., et al., Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol, 2014. 32(11): p. 1136-42.ExcludedPatients receive docetaxel.#58Gong, C.L. and J.W. Hay, Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. JNCCN Journal of the National Comprehensive Cancer Network, 2014. 12(10): p. 1417-1425.ExcludedNo RCT (model-based cost calculation)#59Gravis, G., et al., Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol, 2013. 14(2): p. 149-58.ExcludedComparison is androgen-deprivation therapy alone or with docetaxel.#60Hahn, N.M., et al., Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event. Clin Genitourin Cancer, 2014. 12(1): p. 33-40.e4.ExcludedComparison is androgen deprivation therapy (ADT) versus ADT + risedronate#61Hamilton, R.J., et al. Effect of concomitant medication use on outcomes of treatment and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). Journal of clinical oncology, 2014. 32.ExcludedAbstract#62Harrison, M.R., et al., Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res, 2013. 5: p. 1-14.Excluded(Narrative) review without pooled analysis (all studies included)#63Hedlund, P.O., et al., Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scandinavian Journal of Urology and Nephrology, 2008. 42(3): p. 220-229.ExcludedComparison is polyestradiol phosphate versus combined androgen deprivation.#64Hedlund, P.O., et al., Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. Scand J Urol Nephrol, 2011. 45(5): p. 346-53.ExcludedComparison is polyestradiol phosphate versus combined androgen deprivation.#65Heinrich, D., et al. Updated analysis of radium-223 dichloride (Ra-223) impact on pain, skeletal-related events (SRE), and survival from the phase 3 randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) and bone metastases. European Urology, Supplements, 2013. 12, e101-e102.ExcludedAbstract#66Heinrich, D., et al. Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase (ALP) and prostate-specific antigen (PSA) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA trial. European Urology, Supplements, 2014. 13, e865.ExcludedAbstract#67Higano, C.S., Intermittent versus continuous androgen deprivation therapy. J Natl Compr Canc Netw, 2014. 12(5): p. 727-33.ExcludedComparison is intermittent versus continuous androgen deprivation therapy#68Hirano, D., et al., Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study. Int Urol Nephrol, 2010. 42(1): p. 81-8.ExcludedComparison is ADT versus ADT + estramustine phosphate.#69Horwitz, E.M., et al., Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol, 2008. 26(15): p. 2497-504.ExcludedControl is radiotherapy#70Hoskin, P., et al., Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. The Lancet Oncology, 2014. 15(12): p. 1397-1406.Included#71Hussain, M., et al., Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med, 2013. 368(14): p. 1314-25.ExcludedComparison is intermittent versus continuous androgen deprivation therapy#72James, N.D., et al., Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: A double-blind, placebo-controlled, randomized Phase II trial. BJU International, 2010. 106(7): p. 966-973.ExcludedComparison is zibotentan versus placebo.#73Klotz, L., Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer. Curr Urol Rep, 2013. 14(3): p. 159-67.Excluded(Narrative) review without pooled analysis #74Klotz, L., et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU international, 2008. 102, 1531-8 DOI: 10.1111/j.1464-410X.2008.08183.x.ExcludedComparison is degarelix versus leuprolide.#75Kluetz, P.G., et al., Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. food and drug administration drug approval summary. Clinical Cancer Research, 2013. 19(24): p. 6650-6656.ExcludedReview of other (included) article#76Kluetz, P.G., et al., Radium Ra 223 dichloride injection: U.S. food and drug administration drug approval summary. Clinical Cancer Research, 2014. 20(1): p. 9-14.ExcludedReview of other (included) article#77Koenig, F., et al. Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who had prior or no-prior docetaxel (D) therapy in the phase 3 ALSYMPCA trial. Onkologie, 2013. 36, 77-8 DOI: 10.1159/000356365.ExcludedAbstract#78Kratiras, Z., C. Konstantinidis, and K. Skriapas, A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ''perpetual dispute''. Int Braz J Urol, 2014. 40(1): p. 3-15; discussion 15.Excluded(Narrative) review without pooled analysis#79Kunath, F., et al., Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review. BMC Cancer, 2013. 13: p. 131.ExcludedComparison is early versus deferred androgen suppression therapy.#80Lam, E.T. and L.M. Glode, Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer. Hematol Oncol Clin North Am, 2013. 27(6): p. 1189-204, viii.Excluded(Narrative) review without pooled analysis (all studies included)#81Langenhuijsen, J.F., et al., Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol, 2013. 31(5): p. 549-56.ExcludedComparison is intermittent versus continuous androgen deprivation therapy#82Langley, R.E., et al., Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol, 2013. 14(4): p. 306-16.ExcludedNo RCT (no control)#83Liu, G., et al., Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin Genitourin Cancer, 2012. 10(2): p. 99-105.ExcludedNo RCT (no control)#84Loblaw, D.A., et al., Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Clin Oncol (R Coll Radiol), 2013. 25(7): p. 406-30.ExcludedMeta-analysis includes solely therapies not of interest.#85Logothetis, C., et al. Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study. Journal of clinical oncology, 2011. 29.ExcludedAbstract#86Logothetis, C.J., et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. The Lancet. Oncology, 2012. 13, 1210-7 DOI: 10.1016/S1470-2045(12)70473-4.ExcludedPatients previously received chemotherapy.#87Logothetis, C.J., et al., Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomised trial. The Lancet Oncology, 2012. 13(12): p. 1210-1217.ExcludedPatients previously received chemotherapy.#88Loriot, Y., et al. Bicalutamide in combination with vandetanib or placebo in patients with castration-refractory metastatic prostate cancer without any clinical symptom related to disease progression - A randomized, double-blind phase II trial. European journal of cancer, 2011. 47, S500 DOI: 10.1016/S0959-8049%2811%2972002-0.ExcludedAbstract#89Loriot, Y., et al., Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol, 2015. 16(5): p. 509-21.IncludedDesign: RCTPatients: asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. Intervention: enzalutamideControl: placebo#90Loriot, Y., et al. Efficacy outcomes by baseline prostate-specific antigen (PSA): Results from the Phase III AFFIRM trial. European Urology, Supplements, 2013. 12, 173 DOI: 10.1016/S1569-9056%2813%2962434-3.ExcludedAbstract#91Machiels, J.P., et al., Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol, 2008. 26(32): p. 5261-8.ExcludedComparison is docetaxel versus docetaxel in combination with estramustine.#92Madan, R.A., et al., Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res, 2008. 14(14): p. 4526-31.ExcludedComparison is poxvirus-based prostate-specific antigen (PSA) vaccine or nilutamide#93Mainwaring, P., et al. Association of alkaline phosphatase with clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. BJU international, 2014. 113, 21.ExcludedAbstract#94Malone, S., et al., Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome. Int J Radiat Oncol Biol Phys, 2007. 68(3): p. 699-706.ExcludedNo RCT (no control)#95Marshall, D.T., et al., Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. Clin Genitourin Cancer, 2014. 12(2): p. 80-6.ExcludedComparison of Docetaxel, TotalAndrogen Blockade, and Radiotherapy#96Mason, M.D., et al., Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst, 2007. 99(10): p. 765-76.ExcludedComparison of clodronate versus or placebo#97McNeel, D.G., et al., Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother, 2012. 61(7): p. 1137-47.ExcludedNo RCT (no control)#98Merseburger, A.S., et al., Enzalutamide in European and North American men participating in the AFFIRM trial. BJU International, 2014. 115(1): p. 41-49.ExcludedPatients previously received docetaxel.#99Meulenbeld, H.J., et al., Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). Eur J Cancer, 2012. 48(16): p. 2993-3000.ExcludedComparison is docetaxel, predinose, and risedronate versus docetaxel and predinose.#100Michaelson, M.D., et al., Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol, 2012. 23(5): p. 1234-40.ExcludedNo RCT (no control)#101Miller, K., et al. Enzalutamide improves health-related quality of life in men with metastatic castration-resistant prostate cancer following docetaxel-based therapy: Results from the affirm study. Urology, 2013. 82, S52.ExcludedAbstract#102Miller, K., et al. Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: Results from the AFFIRM study. Journal of clinical oncology, 2013. 31.ExcludedAbstract#103Millikan, R.E., et al., Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol, 2008. 26(36): p. 5936-42.ExcludedComparison is hormone therapy only versus chemohormonal therapy.#104Montgomery, B., et al., Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: Exploratory analysis from COU-AA-301. European Urology, 2015. 67(5): p. 866-873.ExcludedPatients previously received docetaxel.#105Morris, M.J., et al. A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), +/- docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results. Journal of clinical oncology, 2014. 32.ExcludedAbstract#106Morris, M.J., et al., Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. Journal of Clinical Oncology, 2015. 33(12): p. 1356-1363.IncludedDesign: RCTPatients: chemotherapy-naive patients with mCRPC.Intervention: abiraterone acetateControl: placebo#107Mottet, N., et al., Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol, 2012. 62(2): p. 213-9.ExcludedComparison is ADT plus radiotherapy with ADT alone#108Mottet, N., et al., Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. BJU Int, 2012. 110(9): p. 1262-9.ExcludedComparison is intermittent versus continuous androgen deprivation therapy#109Mulders, P., et al. MDV3100, an androgen receptor signaling inhibitor, improves overall survival in patients with prostate cancer post docetaxel: Results from the Phase 3 AFFIRM study. Urology, 2012. 80, S30 DOI: 10.1016/S0090-4295%2812%2900879-5.ExcludedAbstract#110Mulders, P.F., et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. European urology, 2014. 65, 875-83 DOI: 10.1016/j.eururo.2013.09.005.ExcludedPatients previously received docetaxel.#111Mulders, P.F.A., et al. Improved survival in elderly (>75 yr) metastatic castration-resistant prostate cancer (mCRPC) patients upon treatment with abiraterone acetate (AA) plus prednisone (P) progressing after docetaxel-based chemotherapy: Results from COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study. European Urology, Supplements, 2012. 11, e127-e127a.ExcludedAbstract#112Nakabayashi, M., et al., Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int, 2012. 110(11): p. 1729-35.ExcludedNo RCT (no control)#113Nilsson, S., et al., Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clinical Genitourinary Cancer, 2013. 11(1): p. 20-26.IncludedDesign: RCTPatients: patients with castration-resistant prostate cancer and bone metastasesIntervention: radium-223Control: placebo#114Nilsson, S., et al., Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol, 2007. 8(7): p. 587-94.IncludedDesign: RCTPatients: patients with castration-resistant prostate cancer and bone metastasesIntervention: radium-223Control: placebo#115Nilsson, S., et al. Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223. Journal of clinical oncology, 2011. 29.ExcludedAbstract#116Nilsson, S., et al. Long-termsafety of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bonemetastases from the phase 3 ALSYMPCA study. European Urology, Supplements, 2013. 12, 178 DOI: 10.1016/S1569-9056%2813%2962445-8.ExcludedAbstract#117Nilsson, S., et al., A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. European Journal of Cancer, 2012. 48(5): p. 678-686.ExcludedNo RCT (no control, only different doses)#118Nilsson, S., et al. 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study. Journal of clinical oncology, 2014. 32.ExcludedAbstract#119Niraula, S., L.W. Le, and I.F. Tannock, Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol, 2013. 31(16): p. 2029-36.ExcludedComparison is early versus deferred androgen suppression therapy.#120Noguchi, M., et al., A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunology, Immunotherapy, 2010. 59(7): p. 1001-1009.ExcludedComparison is personalized peptide vaccination plus low-dose estramustine phosphate or standard-dose estramustine phosphate.#121Nozawa, M., et al., Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naive prostate cancer with bone metastasis. Int J Clin Oncol, 2014. 19(4): p. 693-701.ExcludedSingle-arm study#122Ohlmann, C.H., et al. Improved Overall Survival (OS) in patients with metastatic Castration Resistant Prostate Cancer (mCRPC) progressing after docetaxel-based chemotherapy: Results from the phase III study COU-AA-301 with abiraterone acetate. Onkologie, 2011. 34, 9-10 DOI: 10.1159/000333299.ExcludedAbstract#123Okegawa, T., et al. Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naive prostate cancer in a multicenter clinical trial. Anticancer research, 2014. 34, 4415-20.ExcludedComparison is combined androgen blockade versus zoledronic acid and combined androgen blockade#124Oliver Sartor, A., et al. Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA). Journal of clinical oncology, 2012. 30.ExcludedAbstract#125O'Sullivan, J., et al. Hematologic safety of radium-223 dichloride (Ra-223) in the phase 3 ALSYMPCA trial in castration-resistant prostate cancer (CRPC) patients with bone metastases: Baseline prognostic factor subgroup analysis. European journal of cancer, 2013. 49, S688 DOI: 10.1016/S0959-8049%2813%2970064-9.ExcludedAbstract#126O'Sullivan, J.M., et al. Results from a phase III randomized trial (ALSYMPCA) of radium-223 chloride, a first-in-class alpha-emitter, in patients with castration-resistant prostate cancer (CRPC) and bone metastases: Overall survival benefit and safety profile. European journal of nuclear medicine and molecular imaging, 2012. 39, S294 DOI: 10.1007/s00259-012-2221-x.ExcludedAbstract#127Oudard, S., TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol, 2011. 7(4): p. 497-506.ExcludedNarrative review regarding cabazitaxel#128Ozguroglu, M., et al. Impact of G-CSF prophylaxis on the occurrence of neutropenia in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel. Journal of clinical oncology, 2011. 29.ExcludedAbstract#129Parker, C., et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). Journal of clinical oncology, 2012. 30.ExcludedAbstract#130Parker, C., et al. Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223. Journal of clinical oncology, 2011. 29.ExcludedAbstract#131Parker, C., et al., Alpha emitter radium-223 and survival in metastatic prostate cancer. New England Journal of Medicine, 2013. 369(3): p. 213-223.IncludedDesign: RCTPatients: histologically confirmed, progressive castration-resistant prostate cancer with two or more bone metastases and had received docetaxelIntervention: radium-223Control: placebo#132Parker, C.C., et al., A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. European Urology, 2013. 63(2): p. 189-197.ExcludedNo RCT (no control, only different doses)#133Parker, C.C., et al., Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial. BJU Int, 2013. 111(5): p. 697-9.Excluded(Narrative) review without pooled analysis (all studies included)#134Pedley, I.D., et al. Tolerability and efficacy of anti-androgen manipulation versus taxotere and anti-androgen manipulation in patients with hormone-naive, high-risk/metastatic prostate cancer: A phase II, open-labeled, randomized study. Journal of clinical oncology, 2011. 29.ExcludedAbstract#135Petrylak, D.P., et al. A randomized open-label phase 2a study evaluating the efficacy and safety of radium-223 dichloride (Ra-223) in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC) and bone metastases. Journal of clinical oncology, 2014. 32.ExcludedAbstract#136Pienta, K.J., et al., Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs, 2013. 31(3): p. 760-8.ExcludedNo RCT (no control)#137Pili, R., et al., Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol, 2011. 29(30): p. 4022-8.ExcludedComparison is tasquinimod versus placebo#138Pisansky, T.M., et al., Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol, 2015. 33(4): p. 332-9.ExcludedComparison is eight week androgen suppression versus 28 week.#139Pond, G.R., et al., Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials. Urologic Oncology: Seminars and Original Investigations, 2013. 31(8): p. 1457-1463.ExcludedRetrospective study of an RCT regarding the variable ketoconazole use.#140Poppel, H., et al. Updated interim analysis (IA): Results of randomized phase 3 study COUAA-302 of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy. European Urology, Supplements, 2013. 12, e97-e98.ExcludedAbstract#141Pouessel, D., et al., Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: The TROPIC study in France. Bulletin du Cancer, 2012. 99(7-8): p. 731-741.ExcludedComparison of mitxantrone versus cabazitaxe#142Prapotnich, D., et al., A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results. World J Urol, 2009. 27(5): p. 627-35.ExcludedNo RCT#143Prezioso, D., et al., Early versus delayed hormonal treatment in locally advanced or asymptomatic metastatic prostatic cancer patient dilemma. World J Urol, 2014. 32(3): p. 661-7.ExcludedComparison is early versus deferred androgen suppression therapy.#144Quinn, D.I., et al. A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). Journal of clinical oncology, 2014. 32.ExcludedAbstract#145Rajdev, L., et al., Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemother Pharmacol, 2011. 68(5): p. 1119-24.ExcludedNo RCT (no control, only different doses)#146Rathkopf, D.E., et al., Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol, 2013. 31(28): p. 3525-30.ExcludedNo RCT (no control, only different doses)#147Rathkopf, D.E., et al. Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302). Journal of clinical oncology, 2013. 31.ExcludedAbstract#148Rathkopf, D.E., et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). European urology, 2014. 66, 815-25 DOI: 10.1016/j.eururo.2014.02.056.IncludedDesign: RCTPatients: chemotherapy-naive mCRPCIntervention: abiraterone acetate + prednisoneControl: placebo + prednisone#149Ray, M.E., et al., Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. J Natl Cancer Inst, 2009. 101(4): p. 228-36.ExcludedNot metastatic CRPC#150Ridoux, L., et al., A phase i open-label study investigating the disposition of [¹⁴C]-cabazitaxel in patients with advanced solid tumors. Anti-Cancer Drugs, 2015. 26(3): p. 350-358.ExcludedNo RCT (no control, only different doses)#151Roach, M., 3rd, Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both? Strahlenther Onkol, 2007. 183 Spec No 2: p. 26-8.Excluded(Narrative) review without pooled analysis#152Roach, M., 3rd, et al., Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys, 2010. 78(5): p. 1314-22.ExcludedComparison is androgen deprivation therapy versus radiotherapy#153Roach, M., 3rd, et al., Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol, 2008. 26(4): p. 585-91.ExcludedComparison is androgen deprivation therapy versus radiotherapy#154Ryan, C.J., et al., A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int, 2008. 101(4): p. 436-9.ExcludedNo RCT (no control, only different doses)#155Ryan, C.J., et al. Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. Journal of clinical oncology, 2013. 31.ExcludedAbstract#156Ryan, C.J., et al. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. 31, 2791-8 DOI: 10.1200/JCO.2012.45.4595.ExcludedPatients previously received docetaxel.#157Ryan, C.J., et al. Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate cancer and prostatic diseases, 2014. 17, 192-8 DOI: 10.1038/pcan.2014.8.ExcludedPatients previously received docetaxel.#158Ryan, C.J., et al., Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res, 2011. 17(14): p. 4854-61.ExcludedNo RCT (no control, single-arm)#159Ryan, C.J., et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal of clinical oncology, 2012. 30.ExcludedAbstract#160Ryan, C.J., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England journal of medicine, 2013. 368, 138-48 DOI: 10.1056/NEJMoa1209096.IncludedDesign: RCTPatients: patients with mCRPC who had not received chemotherapyIntervention: abiraterone acetate-prednisoneControl: placebo-prednisone#161Ryan, C.J., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology, 2015. 16, 152-60 DOI: 10.1016/S1470-2045(14)71205-7.IncludedDesign: RCTPatients: patients with mCRPC who had not received chemotherapyIntervention: abiraterone acetate-prednisoneControl: placebo-prednisone#162Ryan, C.J., et al., Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. Journal of Clinical Oncology, 2010. 28(9): p. 1481-1488.ExcludedNo RCT (no control, only different doses)#163Saad, F., et al. The prevail study: Primary and non-visceral/visceral disease subgroup results for enzalutamide-treated men with metastatic castration-resistant prostate cancer. Urology, 2014. 84, S98-s99 DOI: 10.1016/S0090-4295%2814%2901017-6.ExcludedAbstract#164Sadetsky, N., et al., Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. Cancer, 2011. 117(19): p. 4406-13.ExcludedNo RCT (observational study)#165Safarinejad, M.R., Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study. Urol Oncol, 2010. 28(1): p. 21-7.ExcludedNo RCT (no control)#166Salonen, A.J., et al., Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII. Scand J Urol, 2014. 48(6): p. 513-22.ExcludedComparison is intermittent versus continuous androgen deprivation therapy#167Salonen, A.J., et al., The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol, 2012. 187(6): p. 2074-81.ExcludedComparison is intermittent versus continuous androgen deprivation therapy#168Salonen, A.J., et al., Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. J Urol, 2008. 180(3): p. 915-9; discussion 919-20.ExcludedComparison is intermittent versus continuous androgen deprivation therapy#169Salzberg, M., et al., An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie, 2007. 30(7): p. 355-60.ExcludedComparison is gefitinib and docetaxel.#170Sartor, A.O., et al. Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA). Journal of clinical oncology, 2012. 30.ExcludedAbstract#171Sartor, A.O., et al. Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial. Journal of clinical oncology, 2011. 29.ExcludedAbstract#172Sartor, A.O., et al., Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer, 2008. 112(11): p. 2393-400.ExcludedSingle-arm post-hoc analysis#173Sartor, O., et al., Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial. The Lancet Oncology, 2014. 15(7): p. 738-746.IncludedDesign: RCTPatients: progressive, symptomatic castration-resistant prostate cancer with two or more bone metastasesIntervention: radium-223Control: placebo#174Satoh, T., et al., A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy. Jpn J Clin Oncol, 2014. 44(12): p. 1206-15.ExcludedSingle-arm study and patients previously received docetaxel.#175Schelman, W.R., et al., A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs, 2011. 29(1): p. 118-25.ExcludedNo RCT#176Scher, H.I., et al., Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. The Lancet, 2010. 375(9724): p. 1437-1446.ExcludedNo RCT#177Scher, H.I., et al., Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med, 2012. 367(13): p. 1187-97.ExcludedPatients previously received chemotherapy.#178Scher, H.I., et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. Journal of clinical oncology, 2011. 29.ExcludedAbstract#179Schmidt-Hansen, M., et al., Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses. Clin Oncol (R Coll Radiol), 2014. 26(10): p. e21-46.ExcludedHormone and Radiotherapy versus Hormone or Radiotherapy Alone#180Schroder, F., et al., Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS). Eur Urol, 2013. 63(5): p. 779-87.ExcludedDesign: RCTPatients: localised prostate cancer patientsIntervention: dutasteride 0.5 mgControl: placebo#181Schroder, F.H., et al., Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol, 2009. 55(1): p. 14-22.ExcludedComparison is delayed endocrine treatment versus endocrine treatment#182Schroder, F.H., et al., Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int, 2010. 106(2): p. 182-7.ExcludedComparison is leuprolide versus degarelix#183Seal, B.S., et al., Efficacy, patient-reported outcomes (PROs), and tolerability of the changing therapeutic landscape in patients with metastatic prostate cancer (MPC): a systematic literature review. Value Health, 2013. 16(5): p. 872-90.ExcludedNot a systematic review on RCTs#184Serretta, V., et al., Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital. Urol Int, 2009. 83(4): p. 452-7.ExcludedComparison is estramustinephosphate (EMP) + etoposide versus EMP#185Sfoungaristos, S., et al., Contemporary pharmacotherapy for the prevention of skeletal complications in patients with prostate cancer. Expert Opinion on Pharmacotherapy, 2014. 15(17): p. 2513-2524.Excluded(Narrative) review without pooled analysis (all studies included)#186Shamash, J., et al., Whole blood stem cell reinfusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 study. Clin Cancer Res, 2012. 18(8): p. 2352-9.ExcludedNo RCT (single-arm study, no control)#187Shamash, J., et al., A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. Br J Cancer, 2011. 104(4): p. 620-8.ExcludedComparison is Diethylstilbestrol versus Dexamethasone and Aspirin#188Shaw, G.L., et al., International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int, 2007. 99(5): p. 1056-65.ExcludedSystematic review with individual patient data from non-RCTs#189Shipley, W.U., et al. Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels. Journal of clinical oncology, 2011. 29.ExcludedAbstract#190Shirakawa, T., et al., Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum Gene Ther, 2007. 18(12): p. 1225-32.Excluded No RCT (no control)#191Silva, F.C.D., et al. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: Results from a randomised phase 3 study by the south european uroncological group. European urology, 2014. 66, 232-9 DOI: 10.1016/j.eururo.2013.03.055.ExcludedContinuation of cyproterone acetate plus triptoreline treatment versus stop treatment#192Small, E., et al. A Phase 2 trial of sipuleucel-T in combination with concurrent or sequential abiraterone acetate (AA) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). European journal of cancer, 2013. 49, S682-s683 DOI: 10.1016/S0959-8049%2813%2970064-9.ExcludedAbstract#193Small, E.J., et al., A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int, 2007. 100(4): p. 765-9.ExcludedNo RCT (Single-arm study)#194Small, E.J., et al., Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer Prostatic Dis, 2014. 17(3): p. 259-64.ExcludedPooled analysis of three trails with comparison of sipuleucel-T versus control.#195Smith, D.C., et al., Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol, 2013. 31(4): p. 412-9.ExcludedComparison is cabozantinib versus placebo#196Smith, D.C., et al., Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032. Urology, 2011. 77(5): p. 1172-6.ExcludedPatients receive chemotherapy during treatment with anti-androgen#197Smith, M.R., et al., Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol, 2014. 32(11): p. 1143-50.ExcludedComparison is zolodronic acid versus placebo#198Smith, M.R., et al. Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302. Journal of clinical oncology, 2014. 32.ExcludedAbstract#199Smith, M.R., et al., Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol, 2013. 31(30): p. 3800-6.ExcludedComparison is denosumab versus placebo.#200Sonpavde, G., et al., Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. Clin Genitourin Cancer, 2008. 6(2): p. 134-7.ExcludedPatients received chemotherapy + no RCT (no control) + Medicine of interest is sunitinib#201Sonpavde, G., et al., Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol, 2010. 21(2): p. 319-24.ExcludedPatients received chemotherapy + no RCT (no control) + Medicine of interest is sunitinib#202Sonpavde, G., et al., The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer, 2011. 117(17): p. 3963-71.ExcludedComparison is docetaxel-prednisone (every 3 weeks) versus weekly docetaxel-prednisone versus mitoxantrone-prednisone#203Souhami, L., et al., Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol, 2009. 27(13): p. 2137-43.ExcludedComparison is RT and adjuvant goserelin(3.6 mg) monthly (arm 1) or RT alone followed by goserelin at time of relapse(arm 2).#204Sridhar, S.S., et al., A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol, 2010. 33(6): p. 609-13.ExcludedNo RCT (single-arm study)#205Sternberg, C.N., et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial. Annals of Oncology, 2014. 25, 429-434 DOI: 10.1093/annonc/mdt571.ExcludedPatients received prior chemotherapy (docetaxel)#206Sternberg, C.N., et al. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. The Lancet. Oncology, 2014. 15, 1263-8 DOI: 10.1016/S1470-2045(14)70417-6.ExcludedPatients received prior chemotherapy (taxane chemotherapy)#207Sternberg, C.N., et al. Fatigue improvement/reduction with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel - Results from the COU-AA-301 phase 3 study. European journal of cancer, 2011. 47, S488-s489 DOI: 10.1016/S0959-8049%2811%2971966-9.ExcludedAbstract#208Suttmann, H., et al. Exploratory analysis of the visceral disease patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). European Urology, Supplements, 2013. 12, e105-e106.ExcludedPatients received prior chemotherapy (docetaxel)#209Suzman, D.L., et al., Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate, 2014. 74(13): p. 1278-1285.ExcludedNo RCT (retrospective analysis)#210Sweeney, C., et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. Journal of clinical oncology, 2014. 32.ExcludedAbstract#211Sydes, M.R., et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials, 2012. 13, 168 DOI: 10.1186/1745-6215-13-168.ExcludedNo RCT (protocol)#212Szmulewitz, R., et al., A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer. European Urology, 2009. 56(1): p. 97-104.ExcludedNo control arm, only different doses (Androderm? transdermal testosterone)#213Taplin, M.E., et al., A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int, 2008. 101(9): p. 1084-9.ExcludedNo control arm (only different doses of Mifepristone)#214Taplin, M.E., et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. 32, 3705-15 DOI: 10.1200/JCO.2013.53.4578.ExcludedNot about patients with metastatic CRPC#215Tombal, B., et al. Enzalutamide in men with chemotherapy-naive metastatic castration resistant prostate cancer (MCRPC): Primary and European regional results of the phase 3 prevail study. European Urology, Supplements, 2014. 13, Lba3.ExcludedAbstract#216Tombal, B., et al., Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol, 2010. 57(5): p. 836-42.ExcludedControl is not placebo or prednisone. Comparison is degarelix versus leuprolide#217Tomlins, S.A., et al. Comprehensive molecular profiling of pretreatment metastatic castration resistant prostate cancer (CRPC): Secondary data from NCI 9012, a randomized ETS fusion-stratified phase II trial. Journal of clinical oncology, 2014. 32.ExcludedAbstract#218Tsai, H.T., et al., Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Urology, 2013. 82(2): p. 327-33.ExcludedComparison is intermittent Androgen Deprivation Therapy vsConventional Continuous Androgen Deprivation Therapy#219Tu, S.M., et al., Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol, 2009. 27(20): p. 3319-24.ExcludedComparison is docetaxel versus Samarium-153 Lexidronam#220Tunn, U., G. Canepa, and E. Kienle Intermittent androgen deprivation in patients with PSA relapse after radical prostatectomy. Urology, 2013. 82, S48.ExcludedAbstract#221Ueno, S., et al., Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study. Anticancer Res, 2013. 33(9): p. 3837-44.ExcludedComparison is combined androgen blockade versus combined androgen blockade and Zoledronic acid#222Verhagen, P., et al. Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: Results of a randomized trial. European Urology, Supplements, 2013. 12, e680.ExcludedAbstract#223Walsh, P.C. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Journal of urology, 2011. 185, 2156-7 DOI: 10.1016/j.juro.2011.02.2681.ExcludedLetter to the editor about an included study.#224West, T.A., B.E. Kiely, and M.R. Stockler, Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials. European Journal of Cancer, 2014. 50(11): p. 1916-1924.ExcludedSystematic review without pooled analysis regarding the outcomes of interest. Identified trials are included here as well.#225Wiechno, P., et al. Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group. European journal of cancer, 2013. 49, S690-s691 DOI: 10.1016/S0959-8049%2813%2970064-9.ExcludedAbstract#226Wirth, M., et al., A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting alphav integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy. Eur Urol, 2014. 65(5): p. 897-904.ExcludedNo control arm (only different doses of EMD 525797)#227Wirth, M., et al., Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up. Prostate Cancer Prostatic Dis, 2007. 10(1): p. 87-93.ExcludedNot patients with metastatic CRPC#228Wit, R., et al. Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial). Journal of clinical oncology, 2014. 32.ExcludedAbstract#229Yu, E.Y., et al. Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. Journal of clinical oncology, 2014. 32.ExcludedAbstract#230Yu, E.Y., et al., Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res, 2009. 15(23): p. 7421-8.ExcludedNo control arm (only different doses of Dasatinib)#231Zapatero, A., et al., High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol, 2015. 16(3): p. 320-7.ExcludedComparison is RT + short-term androgen deprivation versus RT + long-term androgen deprivation.Full-text evaluation of included studies in Seal, 2013 (N = 13)#ReferenceIncluded / ExcludedReasons#1NilssonS,ParkerC,BigginC,etal.Clinicalexperienceandradiationsafety ofthe first-in-class alpha-pharmaceutical,Alpharadin?(radium-223), inpatientswithcastration-resistantprostatecancer(CRPC) andbonemetastases.Posterpresentedat:AmericanSocietyforRadiation Oncology(ASTRO).SanDiego,CA,October21-November4,2010.ExcludedConference abstract#2Michaelson MD,KaufmanDS,KantoffP,SmithMR. Randomized phaseII study of atrasentan alone or in combination with zoledronic acid inmen with metastatic prostate cancer.Cancer 2006;107:530–5.PMID: 16804927ExcludedComparison is atrasentan with or without zoledronic acid#3Nilsson S,FranzenL,ParkerC,etal.Bone-targetedradium-223insymptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlledphaseIIstudy.LancetOncol2007;8(7):587–94.ExcludedDuplicate#4Chi KN,HotteSJ,YuEY,etal.RandomizedphaseIIstudyofdocetaxeland prednisone with or without OGX-011 in patients with metastaticcastration-resistantprostatecancer.JClinOncol2010;28:4247–54.PMID: 20733135ExcludedComparison is docetaxel and prednisone with or without OGX-011#5ParkerC,O’Bryan-Tear CG,BolstadB,etal.Alkalinephosphatase(ALP)normalization andoverallsurvivalinpatientswithbonemetastasesfrom castration-resistantprostatecancer(CRPC)treatedwithradium-223. Posterpresentedat:AmericanSocietyofClinicalOncology(ASCO)Genitourinary CancersSymposium.SanFrancisco,CA,March5–7, 2010.ExcludedConference abstract#6Tannock IF,deWitR,BerryWR,etal. Docetaxel plus prednisone ormitoxantrone plus prednisone for advanced prostate cancer. N Engl JMed 2004;351:1502–12.PMID: 15470213ExcludedComparison is docetaxel with or without mitoxantrone#7Sternberg CN,PetrylakDP,SartorO,etal.Multinational,double-blind,phase III study of prednisone and either satraplatin or placebo inpatients with castrate-refractory prostate cancer progressing after priorchemotherapy: theSPARCtrial.JClinOncol2009;32:5431–8.PMID: 19805692ExcludedComparison is prednisone with or without satraplatin#8Kantoff PW,HiganoCS,ShoreND,etal. Sipuleucel- T immunotherapyfor castration-resistantprostatecancer.NEnglJMed2010;363:411–22.PMID: 20818862Excluded Not right patient population#9KellyWK,HalabiS,CarducciMA,etal.Arandomized,double-blind,placebo-controlled phaseIIItrialcomparingdocetaxel,prednisone,andplacebo withdocetaxel,prednisone,andbevacizumabinmenwithmetastatic castration-resistantprostatecancer(mCRPC):survivalresults ofCALGB90401.Abstractpresentedat:ASCOAnnualMeeting.Chicago, IL,June4–8, 2010.ExcludedConference abstract#10de BonoJS,OudardS,OzgurogluM,etal.Prednisonepluscabazitaxelormitoxantrone for metastatic castration-resistant prostate cancerprogressing afterdocetaxeltreatment:arandomizedopen-labeltrial.Lancet 2010;376:1147–54.PMID: 20888992ExcludedComparison is prednisone with either cabazitaxel or mitoxantrone#11de BonoJS,LogothetisCJ,MolinaA,etal.Abirateroneandincreasedsurvival inmetastaticprostatecancer.NEnglJMed2011;364:1995–2005.ExcludedPatients previously received docetaxel.#12Fizazi K,CarducciM,SmithM,etal. Denosumab versus zoledronic acidfor treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813–22.PMID: 21353695ExcludedComparison is denosumab versus zoledronic acid#13MeulenbeldHJ,vanWerkhovenED,CoenenJLLM,etal.Randomizedphase IIIstudyofdocetaxelwithorwithoutrisedronateinpatientswith bonemetastasesfromcastration-resistantprostatecancer(CRPC):the NetherlandsProstateStudy(NePro).Abstractpresentedat:ASCOAnnual Meeting.Chicago,IL,June3–7, 2011.ExcludedConference abstract#14Tombal B,OudardS,OzgurogluM,etal.Clinicalbenefit of cabazitaxel plus prednisone in the TROPIC trial in men with metastatic castration resistant prostate cancer (mCRPC) who progressed after docetaxel-based treatment. Eur Urol Suppl 2011;10:335–6.ExcludedConference abstract#15SternbergCN,ScherHI,MolinaA,etal.Fatigueimprovement/reductionwith abirateroneacetateinpatientswithmetastaticcastration-resistant prostatecancerpost-docetaxel:resultsfromtheCOU-AA-301phase 3study.Posterpresentedat:EuropeanMultidisciplinaryCancerCongress (EMCC).Stockholm,Sweden,September23–27, 2011.ExcludedConference abstract#16Basch EM,deBonoJS,ScherHI,etal.Paincontrolanddelayintimetoskeletal-related events(SREs)inpatientswithmetastaticcastration-resistant prostatecancer(mCPRC)treatedwithabirateroneacetate(AA): long-termfollow-up.JClinOncol2012(Suppl.5):abstract183ExcludedConference abstract#17deBonoJS,FizaziK,SaadF,etal.Phase3trial(AFFIRM)ofenzalutamide (MDV3100),anandrogenreceptorsignalinginhibitor:primary, secondary,andquality-of-lifeendpointresults.Presentedat:American SocietyofClinicalOncology(ASCO).Chicago,IL,May31-June4, 2012.ExcludedConference abstract#18ParkerC,NilssonS,HeinrichD,etal.UpdatedanalysisofthephaseIII,double-blind, randomized,multinationalstudyofradium-223chloridein castration-resistantprostatecancer(CPRC)patientswithbonemetastases (ALSYMPCA).Presentedat:AmericanSocietyofClinicalOncology (ASCO).Chicago,IL,May31-June4,2012.ExcludedConference abstractRyanCJ,deBonoJS,MolinaA,etal.Interimanalysis(IA)resultsofCOU-AA-302, arandomized,phase3studyofabirateroneacetate(AA)inchemotherapy-na?ve patients(pts)withmetastaticcastration-resistantprostate cancer(mCRPC).Presentationpresentedat:AmericanSocietyof ClinicalOncology(ASCO).Chicago,IL,May31-June4,2012.ExcludedConference abstract#19Sartor AO,HeinrichD,O’Sullivan JM,etal.Radium-223chloride(Ra-223) impactonskeletalrelatedevents(SREs)andECOGperformancestatus (PS)inpatientswithcastration-resistantprostatecancer(CRPC)with bonemetastases:interimresultsofaphaseIIItrial(ALSYMPCA).J ClinOncol2012(Suppl)::abstract4551.ExcludedConference abstractAppendixSearch strategiesMedline via Pubmed1. "prostatic neoplasms"[MeSH Terms]2. "prostate cancer"[Title/Abstract]3. "prostatic cancer"[Title/Abstract] 4. #1 OR #2 OR #35. "neoplasm metastasis"[MeSH Terms]6. metastasi*[Title/Abstract]7. "metastatic disease"[Title/Abstract]8. "metastatic prostate"[Title/Abstract]9. #5 OR #6 OR #7 OR #8 10. "antineoplastic agents"[MeSH Terms]11. "antineoplastic agents"[Title/Abstract]12. "androstadienes"[MeSH Terms]13. "abiraterone"[Supplementary Concept]14. "MDV 3100"[Supplementary Concept]15. Cabazitaxel [Supplementary Concept]16. Cabazitaxel[Title/Abstract]17. Enzalutamide[Title/Abstract]18. Radium-223[Title/Abstract]19. "androgen antagonists"[MeSH Terms]20. "bicalutamide"[Supplementary Concept]21. "nilutamide"[Supplementary Concept]22. "cyproterone"[MeSH Terms]23. #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 24. ((review[tiab] OR "Review"[Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta-analysis[tiab] OR "Meta-Analysis "[Publication Type]) NOT ("Letter"[Publication Type] OR "Editorial"[Publication Type] OR "Comment"[Publication Type])) NOT ("Animals"[Mesh] NOT ("Animals"[Mesh] AND "Humans"[Mesh]))25. randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab] 26. #24 OR #2527. #4 AND #9 AND #23 AND #26 Embase: 1. 'castration resistant prostate cancer'/exp2. 'castration resistant prostate cancer':ab,ti3. 'prostatic cancer':ab,ti4. #1 OR #2 OR #35. 'metastasis'/exp6. 'metastasis':ab,ti7. 'metastatic disease':ab,ti8. 'metastatic prostate':ab,ti9. #5 OR #6 OR #7 OR #810. 'androstane derivative'/exp11. 'abiraterone acetate'/exp12. 'abiraterone'/exp13. 'enzalutamide'/exp14. 'cabazitaxel'/exp15. 'radium chloride ra 223'/exp16. 'antiandrogen'/exp17. 'bicalutamide'/exp18. 'nilutamide'/exp19. 'cyproterone'/exp20. 'cyproterone acetate'/exp21. 'androstane derivative':ab,ti22. 'abiraterone acetate':ab,ti23. 'abiraterone':ab,ti24. 'enzalutamide':ab,ti25. 'cabazitaxel':ab,ti26. 'Radium-223':ab,ti27. 'antiandrogen':ab,ti28. 'bicalutamide':ab,ti29. 'nilutamide':ab,ti30. 'cyproterone':ab,ti31. 'cyproterone acetate':ab,ti32. #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #3133. ([cochrane review]/lim OR [meta analysis]/lim OR [systematic review]/lim)34. ([article]/lim OR [article in press]/lim OR [review]/lim)35. ([controlled clinical trial]/lim OR [randomized controlled trial]/lim) AND ([article]/lim OR [article in press]/lim)36. #33 OR #34 OR #3537. #4 AND #9 AND #32 AND #36 AND [embase]/lim 739Cochrane: 1. MeSH descriptor: [Prostatic Neoplasms, Castration-Resistant] explode all trees2. castration resistant prostate cancer3. prostatic cancer4. #1 OR #2 OR #35. MeSH descriptor: [Neoplasm Metastasis] explode all trees6. metastasis7. metastatic disease8. metastatic prostate9. #5 OR #6 OR #7 OR #810. MeSH descriptor: [Cyproterone] explode all trees11. MeSH descriptor: [Cyproterone Acetate] explode all trees12. androstane derivative13. abiraterone acetate14. abiraterone15. enzalutamide16. cabazitaxel17. Radium-22318. antiandrogen19. bicalutamide20. nilutamide21. cyproterone22. cyproterone acetate23. #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #2224. #4 AND #9 AND #23 212 Reference list of included studiesdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxh

dXRob3JzPjxhdXRob3I+Tm9tZSwgUi48L2F1dGhvcj48YXV0aG9yPkhlcm5lcywgRS48L2F1dGhv

cj48YXV0aG9yPkJvZ3NydWQsIFQuIFYuPC9hdXRob3I+PGF1dGhvcj5Cam9ybywgVC48L2F1dGhv

cj48YXV0aG9yPkZvc3NhLCBTLiBELjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48

YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgTWVkaWNhbCBCaW9jaGVtaXN0cnkgYW5kLjwvYXV0

aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkNoYW5nZXMgaW4gcHJvc3RhdGUtc3BlY2lmaWMgYW50

aWdlbiwgbWFya2VycyBvZiBib25lIG1ldGFib2xpc20gYW5kIGJvbmUgc2NhbnMgYWZ0ZXIgdHJl

YXRtZW50IHdpdGggcmFkaXVtLTIyMzwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5TY2FuZCBKIFVy

b2w8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPlNjYW5kaW5hdmlhbiBqb3VybmFsIG9mIHVy

b2xvZ3k8L2FsdC10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5TY2FuZCBK

IFVyb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5TY2FuZGluYXZpYW4gam91cm5hbCBvZiB1cm9sb2d5

PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5TY2FuZCBK

IFVyb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5TY2FuZGluYXZpYW4gam91cm5hbCBvZiB1cm9sb2d5

PC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+MjExLTc8L3BhZ2VzPjx2b2x1bWU+NDk8

L3ZvbHVtZT48bnVtYmVyPjM8L251bWJlcj48ZGF0ZXM+PHllYXI+MjAxNTwveWVhcj48cHViLWRh

dGVzPjxkYXRlPkp1bjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjIxNjgtMTgxMyAo

RWxlY3Ryb25pYyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjU1MTU5NTI8L2FjY2Vzc2lvbi1udW0+

PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJt

ZWQvMjU1MTU5NTI8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3Vy

Y2UtbnVtPjEwLjMxMDkvMjE2ODE4MDUuMjAxNC45ODIxNjk8L2VsZWN0cm9uaWMtcmVzb3VyY2Ut

bnVtPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPlBhcmtlcjwvQXV0aG9yPjxZZWFyPjIw

MTM8L1llYXI+PFJlY051bT4xNTExPC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xNTExPC9y

ZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0ienp0OTU1c3c1MmR2

dGdlZXN2NjVyMHBnZHd2dDlldmZ3d2VlIiB0aW1lc3RhbXA9IjE0MzcwNDc2NjgiPjE1MTE8L2tl

eT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVm

LXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlBhcmtlciwgQy48L2F1dGhvcj48

YXV0aG9yPk5pbHNzb24sIEQuIEhlaW5yaWNoIFMuPC9hdXRob3I+PGF1dGhvcj5IZWxsZSwgUy4g

SS48L2F1dGhvcj48YXV0aG9yPk8mYXBvcztTdWxsaXZhbiwgSi4gTS48L2F1dGhvcj48YXV0aG9y

PkZvc3NhLCBTLiBELjwvYXV0aG9yPjxhdXRob3I+Q2hvZGFja2ksIEEuPC9hdXRob3I+PGF1dGhv

cj5XaWVjaG5vLCBQLjwvYXV0aG9yPjxhdXRob3I+TG9ndWUsIEouPC9hdXRob3I+PGF1dGhvcj5T

ZWtlLCBNLjwvYXV0aG9yPjxhdXRob3I+V2lkbWFyaywgQS48L2F1dGhvcj48YXV0aG9yPkpvaGFu

bmVzc2VuLCBELiBDLjwvYXV0aG9yPjxhdXRob3I+SG9za2luLCBQLjwvYXV0aG9yPjxhdXRob3I+

Qm90dG9tbGV5LCBELjwvYXV0aG9yPjxhdXRob3I+SmFtZXMsIE4uIEQuPC9hdXRob3I+PGF1dGhv

cj5Tb2xiZXJnLCBBLjwvYXV0aG9yPjxhdXRob3I+U3luZGlrdXMsIEkuPC9hdXRob3I+PGF1dGhv

cj5LbGltZW50LCBKLjwvYXV0aG9yPjxhdXRob3I+V2VkZWwsIFMuPC9hdXRob3I+PGF1dGhvcj5C

b2VobWVyLCBTLjwvYXV0aG9yPjxhdXRob3I+RGFsbCZhcG9zO09nbGlvLCBNLjwvYXV0aG9yPjxh

dXRob3I+RnJhbnplbiwgTC48L2F1dGhvcj48YXV0aG9yPkNvbGVtYW4sIFIuPC9hdXRob3I+PGF1

dGhvcj5Wb2dlbHphbmcsIE4uIEouPC9hdXRob3I+PGF1dGhvcj5PJmFwb3M7QnJ5YW4tVGVhciwg

Qy4gRy48L2F1dGhvcj48YXV0aG9yPlN0YXVkYWNoZXIsIEsuPC9hdXRob3I+PGF1dGhvcj5HYXJj

aWEtVmFyZ2FzLCBKLjwvYXV0aG9yPjxhdXRob3I+U2hhbiwgTS48L2F1dGhvcj48YXV0aG9yPkJy

dWxhbmQsIE8uIFMuPC9hdXRob3I+PGF1dGhvcj5TYXJ0b3IsIE8uPC9hdXRob3I+PC9hdXRob3Jz

PjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+Qy4gUGFya2VyLCBSb3lhbCBNYXJzZGVuIEhv

c3BpdGFsLCBBY2FkZW1pYyBVcm9sb2d5IFVuaXQsIFN1dHRvbiwgU3VycmV5IFNNMiA1UFQsIFVu

aXRlZCBLaW5nZG9tPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+QWxwaGEgZW1pdHRlciBy

YWRpdW0tMjIzIGFuZCBzdXJ2aXZhbCBpbiBtZXRhc3RhdGljIHByb3N0YXRlIGNhbmNlcjwvdGl0

bGU+PHNlY29uZGFyeS10aXRsZT5OZXcgRW5nbGFuZCBKb3VybmFsIG9mIE1lZGljaW5lPC9zZWNv

bmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+TmV3IEVuZ2xhbmQg

Sm91cm5hbCBvZiBNZWRpY2luZTwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjIxMy0y

MjM8L3BhZ2VzPjx2b2x1bWU+MzY5PC92b2x1bWU+PG51bWJlcj4zPC9udW1iZXI+PGtleXdvcmRz

PjxrZXl3b3JkPk5DVDAwNjk5NzUxPC9rZXl3b3JkPjxrZXl3b3JkPk5DVDAxMTA2MzUyPC9rZXl3

b3JkPjxrZXl3b3JkPmFsa2FsaW5lIHBob3NwaGF0YXNlPC9rZXl3b3JkPjxrZXl3b3JkPnBsYWNl

Ym88L2tleXdvcmQ+PGtleXdvcmQ+cHJvc3RhdGUgc3BlY2lmaWMgYW50aWdlbjwva2V5d29yZD48

a2V5d29yZD5yYWRpb2lzb3RvcGU8L2tleXdvcmQ+PGtleXdvcmQ+cmFkaXVtIDIyMzwva2V5d29y

ZD48a2V5d29yZD51bmNsYXNzaWZpZWQgZHJ1Zzwva2V5d29yZD48a2V5d29yZD5hZHVsdDwva2V5

d29yZD48a2V5d29yZD5hZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPmFuZW1pYTwva2V5d29yZD48a2V5

d29yZD5hbm9yZXhpYTwva2V5d29yZD48a2V5d29yZD5hcnRpY2xlPC9rZXl3b3JkPjxrZXl3b3Jk

PmFzdGhlbmlhPC9rZXl3b3JkPjxrZXl3b3JkPmJvbmUgbWFycm93IHN1cHByZXNzaW9uPC9rZXl3

b3JkPjxrZXl3b3JkPmJvbmUgbWV0YXN0YXNpczwva2V5d29yZD48a2V5d29yZD5ib25lIHBhaW48

L2tleXdvcmQ+PGtleXdvcmQ+Y2FuY2VyIHN1cnZpdmFsPC9rZXl3b3JkPjxrZXl3b3JkPmNhc3Ry

YXRpb24gcmVzaXN0YW50IHByb3N0YXRlIGNhbmNlcjwva2V5d29yZD48a2V5d29yZD5jb25zdGlw

YXRpb248L2tleXdvcmQ+PGtleXdvcmQ+Y29udHJvbGxlZCBzdHVkeTwva2V5d29yZD48a2V5d29y

ZD5kYWlseSBsaWZlIGFjdGl2aXR5PC9rZXl3b3JkPjxrZXl3b3JkPmRlY3JlYXNlZCBhcHBldGl0

ZTwva2V5d29yZD48a2V5d29yZD5kaWFycmhlYTwva2V5d29yZD48a2V5d29yZD5kaXNlYXNlIGNv

dXJzZTwva2V5d29yZD48a2V5d29yZD5kaXp6aW5lc3M8L2tleXdvcmQ+PGtleXdvcmQ+ZG91Ymxl

IGJsaW5kIHByb2NlZHVyZTwva2V5d29yZD48a2V5d29yZD5kcnVnIGVmZmljYWN5PC9rZXl3b3Jk

PjxrZXl3b3JkPmRydWcgc2FmZXR5PC9rZXl3b3JkPjxrZXl3b3JkPmRydWcgd2l0aGRyYXdhbDwv

a2V5d29yZD48a2V5d29yZD5keXNwbmVhPC9rZXl3b3JkPjxrZXl3b3JkPmV4dGVybmFsIGJlYW0g

cmFkaW90aGVyYXB5PC9rZXl3b3JkPjxrZXl3b3JkPmZhdGlndWU8L2tleXdvcmQ+PGtleXdvcmQ+

ZmVicmlsZSBuZXV0cm9wZW5pYTwva2V5d29yZD48a2V5d29yZD5mZXZlcjwva2V5d29yZD48a2V5

d29yZD5nZW5lcmFsIGNvbmRpdGlvbiBkZXRlcmlvcmF0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPmhl

bWF0b2xvZ2ljIGRpc2Vhc2U8L2tleXdvcmQ+PGtleXdvcmQ+aGVtYXR1cmlhPC9rZXl3b3JkPjxr

ZXl3b3JkPmh1bWFuPC9rZXl3b3JkPjxrZXl3b3JkPmluc29tbmlhPC9rZXl3b3JkPjxrZXl3b3Jk

Pm1ham9yIGNsaW5pY2FsIHN0dWR5PC9rZXl3b3JkPjxrZXl3b3JkPm1hbGU8L2tleXdvcmQ+PGtl

eXdvcmQ+bXVsdGljZW50ZXIgc3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+bXVzY2xlIHdlYWtuZXNz

PC9rZXl3b3JkPjxrZXl3b3JkPm5hdXNlYTwva2V5d29yZD48a2V5d29yZD5uZXV0cm9wZW5pYTwv

a2V5d29yZD48a2V5d29yZD5vdmVyYWxsIHN1cnZpdmFsPC9rZXl3b3JkPjxrZXl3b3JkPnBhdGhv

bG9naWMgZnJhY3R1cmU8L2tleXdvcmQ+PGtleXdvcmQ+cGVyaXBoZXJhbCBlZGVtYTwva2V5d29y

ZD48a2V5d29yZD5waGFzZSAzIGNsaW5pY2FsIHRyaWFsPC9rZXl3b3JkPjxrZXl3b3JkPnBuZXVt

b25pYTwva2V5d29yZD48a2V5d29yZD5wcmlvcml0eSBqb3VybmFsPC9rZXl3b3JkPjxrZXl3b3Jk

PnF1YWxpdHkgb2YgbGlmZTwva2V5d29yZD48a2V5d29yZD5yYW5kb21pemVkIGNvbnRyb2xsZWQg

dHJpYWw8L2tleXdvcmQ+PGtleXdvcmQ+c2lkZSBlZmZlY3Q8L2tleXdvcmQ+PGtleXdvcmQ+c3Bp

bmFsIGNvcmQgY29tcHJlc3Npb248L2tleXdvcmQ+PGtleXdvcmQ+dGhyb21ib2N5dG9wZW5pYTwv

a2V5d29yZD48a2V5d29yZD50cmVhdG1lbnQgb3V0Y29tZTwva2V5d29yZD48a2V5d29yZD51bnNw

ZWNpZmllZCBzaWRlIGVmZmVjdDwva2V5d29yZD48a2V5d29yZD51cmluYXJ5IHRyYWN0IGluZmVj

dGlvbjwva2V5d29yZD48a2V5d29yZD51cmluZSByZXRlbnRpb248L2tleXdvcmQ+PGtleXdvcmQ+

dm9taXRpbmc8L2tleXdvcmQ+PGtleXdvcmQ+d2VpZ2h0IHJlZHVjdGlvbjwva2V5d29yZD48L2tl

eXdvcmRzPjxkYXRlcz48eWVhcj4yMDEzPC95ZWFyPjwvZGF0ZXM+PGlzYm4+MDAyOC00NzkzJiN4

RDsxNTMzLTQ0MDY8L2lzYm4+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cuZW1i

YXNlLmNvbS9zZWFyY2gvcmVzdWx0cz9zdWJhY3Rpb249dmlld3JlY29yZCZhbXA7ZnJvbT1leHBv

cnQmYW1wO2lkPUwzNjkzNzc4OTg8L3VybD48dXJsPmh0dHA6Ly9keC5kb2kub3JnLzEwLjEwNTYv

TkVKTW9hMTIxMzc1NTwvdXJsPjx1cmw+aHR0cDovL3NmeC5saWJyYXJ5LnV1Lm5sL3V0cmVjaHQ/

c2lkPUVNQkFTRSZhbXA7aXNzbj0wMDI4NDc5MyZhbXA7aWQ9ZG9pOjEwLjEwNTYlMkZORUpNb2Ex

MjEzNzU1JmFtcDthdGl0bGU9QWxwaGErZW1pdHRlcityYWRpdW0tMjIzK2FuZCtzdXJ2aXZhbCtp

bittZXRhc3RhdGljK3Byb3N0YXRlK2NhbmNlciZhbXA7c3RpdGxlPU5ldytFbmdsLitKLitNZWQu

JmFtcDt0aXRsZT1OZXcrRW5nbGFuZCtKb3VybmFsK29mK01lZGljaW5lJmFtcDt2b2x1bWU9MzY5

JmFtcDtpc3N1ZT0zJmFtcDtzcGFnZT0yMTMmYW1wO2VwYWdlPTIyMyZhbXA7YXVsYXN0PVBhcmtl

ciZhbXA7YXVmaXJzdD1DaHJpc3RvcGhlciZhbXA7YXVpbml0PUMuJmFtcDthdWZ1bGw9UGFya2Vy

K0MuJmFtcDtjb2Rlbj1ORUpNQSZhbXA7aXNibj0mYW1wO3BhZ2VzPTIxMy0yMjMmYW1wO2RhdGU9

MjAxMyZhbXA7YXVpbml0MT1DJmFtcDthdWluaXRtPTwvdXJsPjwvcmVsYXRlZC11cmxzPjxwZGYt

dXJscz48dXJsPmh0dHA6Ly93d3cubmVqbS5vcmcvZG9pL3BkZi8xMC4xMDU2L05FSk1vYTEyMTM3

NTU8L3VybD48L3BkZi11cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5S

YXRoa29wZjwvQXV0aG9yPjxZZWFyPjIwMTQ8L1llYXI+PFJlY051bT4xOTg1PC9SZWNOdW0+PHJl

Y29yZD48cmVjLW51bWJlcj4xOTg1PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9

IkVOIiBkYi1pZD0ienp0OTU1c3c1MmR2dGdlZXN2NjVyMHBnZHd2dDlldmZ3d2VlIiB0aW1lc3Rh

bXA9IjE0MzcwNTUxMTgiPjE5ODU8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0i

RWxlY3Ryb25pYyBBcnRpY2xlIj40MzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48

YXV0aG9yPlJhdGhrb3BmLCBELiBFLjwvYXV0aG9yPjxhdXRob3I+U21pdGgsIE0uIFIuPC9hdXRo

b3I+PGF1dGhvcj5Cb25vLCBKLiBTLjwvYXV0aG9yPjxhdXRob3I+TG9nb3RoZXRpcywgQy4gSi48

L2F1dGhvcj48YXV0aG9yPlNob3JlLCBOLiBELjwvYXV0aG9yPjxhdXRob3I+U291emEsIFAuPC9h

dXRob3I+PGF1dGhvcj5GaXphemksIEsuPC9hdXRob3I+PGF1dGhvcj5NdWxkZXJzLCBQLiBGLiBB

LjwvYXV0aG9yPjxhdXRob3I+TWFpbndhcmluZywgUC48L2F1dGhvcj48YXV0aG9yPkhhaW5zd29y

dGgsIEouIEQuPC9hdXRob3I+PGF1dGhvcj5CZWVyLCBULiBNLjwvYXV0aG9yPjxhdXRob3I+Tm9y

dGgsIFMuPC9hdXRob3I+PGF1dGhvcj5GcmFkZXQsIFkuPC9hdXRob3I+PGF1dGhvcj5Qb3BwZWws

IEguPC9hdXRob3I+PGF1dGhvcj5DYXJsZXMsIEouPC9hdXRob3I+PGF1dGhvcj5GbGFpZywgVC4g

Vy48L2F1dGhvcj48YXV0aG9yPkVmc3RhdGhpb3UsIEUuPC9hdXRob3I+PGF1dGhvcj5ZdSwgRS4g

WS48L2F1dGhvcj48YXV0aG9yPkhpZ2FubywgQy4gUy48L2F1dGhvcj48YXV0aG9yPlRhcGxpbiwg

TS4gRS48L2F1dGhvcj48YXV0aG9yPkdyaWZmaW4sIFQuIFcuPC9hdXRob3I+PGF1dGhvcj5Ub2Rk

LCBNLiBCLjwvYXV0aG9yPjxhdXRob3I+WXUsIE0uIEsuPC9hdXRob3I+PGF1dGhvcj5QYXJrLCBZ

LiBDLjwvYXV0aG9yPjxhdXRob3I+S2hlb2gsIFQuPC9hdXRob3I+PGF1dGhvcj5TbWFsbCwgRS4g

Si48L2F1dGhvcj48YXV0aG9yPlNjaGVyLCBILiBJLjwvYXV0aG9yPjxhdXRob3I+TW9saW5hLCBB

LjwvYXV0aG9yPjxhdXRob3I+UnlhbiwgQy4gSi48L2F1dGhvcj48YXV0aG9yPlNhYWQsIEYuPC9h

dXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPlVwZGF0ZWQgaW50

ZXJpbSBlZmZpY2FjeSBhbmFseXNpcyBhbmQgbG9uZy10ZXJtIHNhZmV0eSBvZiBhYmlyYXRlcm9u

ZSBhY2V0YXRlIGluIG1ldGFzdGF0aWMgY2FzdHJhdGlvbi1yZXNpc3RhbnQgcHJvc3RhdGUgY2Fu

Y2VyIHBhdGllbnRzIHdpdGhvdXQgcHJpb3IgY2hlbW90aGVyYXB5IChDT1UtQUEtMzAyKTwvdGl0

bGU+PHNlY29uZGFyeS10aXRsZT5FdXJvcGVhbiB1cm9sb2d5PC9zZWNvbmRhcnktdGl0bGU+PC90

aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+RXVyIFVyb2w8L2Z1bGwtdGl0bGU+PGFiYnIt

MT5FdXJvcGVhbiB1cm9sb2d5PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxwYWdlcz44MTUtMjU8L3Bh

Z2VzPjx2b2x1bWU+NjY8L3ZvbHVtZT48bnVtYmVyPjU8L251bWJlcj48a2V5d29yZHM+PGtleXdv

cmQ+YWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+YWdlZDwva2V5d29yZD48a2V5d29yZD5hbGFuaW5l

IGFtaW5vdHJhbnNmZXJhc2UgYmxvb2QgbGV2ZWw8L2tleXdvcmQ+PGtleXdvcmQ+YXJ0aHJhbGdp

YS9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPmFydGljbGU8L2tleXdvcmQ+PGtl

eXdvcmQ+YXNwYXJ0YXRlIGFtaW5vdHJhbnNmZXJhc2UgYmxvb2QgbGV2ZWw8L2tleXdvcmQ+PGtl

eXdvcmQ+YmFja2FjaGUvc2kgW1NpZGUgRWZmZWN0XTwva2V5d29yZD48a2V5d29yZD5ib25lIHBh

aW4vc2kgW1NpZGUgRWZmZWN0XTwva2V5d29yZD48a2V5d29yZD5jYW5jZXIgY29tYmluYXRpb24g

Y2hlbW90aGVyYXB5PC9rZXl3b3JkPjxrZXl3b3JkPmNhbmNlciBwYXRpZW50PC9rZXl3b3JkPjxr

ZXl3b3JkPmNhbmNlciBwcm9nbm9zaXM8L2tleXdvcmQ+PGtleXdvcmQ+Y2FzdHJhdGlvbiByZXNp

c3RhbnQgcHJvc3RhdGUgY2FuY2VyL2R0IFtEcnVnIFRoZXJhcHldPC9rZXl3b3JkPjxrZXl3b3Jk

PmNvbnN0aXBhdGlvbi9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPmNvbnRyb2xs

ZWQgc3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+Y291Z2hpbmcvc2kgW1NpZGUgRWZmZWN0XTwva2V5

d29yZD48a2V5d29yZD5kaWFycmhlYS9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3Jk

PmRpc2Vhc2UgY291cnNlPC9rZXl3b3JkPjxrZXl3b3JkPmRvdWJsZSBibGluZCBwcm9jZWR1cmU8

L2tleXdvcmQ+PGtleXdvcmQ+ZHJ1ZyBlZmZpY2FjeTwva2V5d29yZD48a2V5d29yZD5kcnVnIHNh

ZmV0eTwva2V5d29yZD48a2V5d29yZD5keXNwbmVhL3NpIFtTaWRlIEVmZmVjdF08L2tleXdvcmQ+

PGtleXdvcmQ+ZmF0aWd1ZS9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPmZsdWlk

IHJldGVudGlvbjwva2V5d29yZD48a2V5d29yZD5mb2xsb3cgdXA8L2tleXdvcmQ+PGtleXdvcmQ+

aGVhcnQgYXJyaHl0aG1pYS9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPmhlYXJ0

IGRpc2Vhc2Uvc2kgW1NpZGUgRWZmZWN0XTwva2V5d29yZD48a2V5d29yZD5oZWFydCBmYWlsdXJl

L3NpIFtTaWRlIEVmZmVjdF08L2tleXdvcmQ+PGtleXdvcmQ+aG90IGZsdXNoL3NpIFtTaWRlIEVm

ZmVjdF08L2tleXdvcmQ+PGtleXdvcmQ+aHVtYW48L2tleXdvcmQ+PGtleXdvcmQ+aHlwZXJnbHlj

ZW1pYS9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPmh5cGVydGVuc2lvbi9zaSBb

U2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPmh5cG9rYWxlbWlhL3NpIFtTaWRlIEVmZmVj

dF08L2tleXdvcmQ+PGtleXdvcmQ+aW5zb21uaWEvc2kgW1NpZGUgRWZmZWN0XTwva2V5d29yZD48

a2V5d29yZD5pc2NoZW1pYyBoZWFydCBkaXNlYXNlL3NpIFtTaWRlIEVmZmVjdF08L2tleXdvcmQ+

PGtleXdvcmQ+bGltYiBwYWluL3NpIFtTaWRlIEVmZmVjdF08L2tleXdvcmQ+PGtleXdvcmQ+bGlt

YiBwYWluL3NpIFtTaWRlIEVmZmVjdF08L2tleXdvcmQ+PGtleXdvcmQ+bWFqb3IgY2xpbmljYWwg

c3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+bWFsZTwva2V5d29yZD48a2V5d29yZD5tZXRhc3Rhc2lz

L2R0IFtEcnVnIFRoZXJhcHldPC9rZXl3b3JkPjxrZXl3b3JkPm11c2NsZSBzcGFzbS9zaSBbU2lk

ZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPm11c2N1bG9za2VsZXRhbCBwYWluL3NpIFtTaWRl

IEVmZmVjdF08L2tleXdvcmQ+PGtleXdvcmQ+bmF1c2VhL3NpIFtTaWRlIEVmZmVjdF08L2tleXdv

cmQ+PGtleXdvcmQ+b3V0Y29tZSBhc3Nlc3NtZW50PC9rZXl3b3JkPjxrZXl3b3JkPm92ZXJhbGwg

c3Vydml2YWw8L2tleXdvcmQ+PGtleXdvcmQ+cGVyaXBoZXJhbCBlZGVtYS9zaSBbU2lkZSBFZmZl

Y3RdPC9rZXl3b3JkPjxrZXl3b3JkPnByb2dyZXNzaW9uIGZyZWUgc3Vydml2YWw8L2tleXdvcmQ+

PGtleXdvcmQ+cmFuZG9taXplZCBjb250cm9sbGVkIHRyaWFsPC9rZXl3b3JkPjxrZXl3b3JkPnNp

ZGUgZWZmZWN0L3NpIFtTaWRlIEVmZmVjdF08L2tleXdvcmQ+PGtleXdvcmQ+d2VpZ2h0IGdhaW48

L2tleXdvcmQ+PGtleXdvcmQ+YWJpcmF0ZXJvbmUvZHQgW0RydWcgVGhlcmFweV08L2tleXdvcmQ+

PGtleXdvcmQ+YWJpcmF0ZXJvbmUgYWNldGF0ZS9hZSBbQWR2ZXJzZSBEcnVnIFJlYWN0aW9uXTwv

a2V5d29yZD48a2V5d29yZD5hYmlyYXRlcm9uZSBhY2V0YXRlL2NiIFtEcnVnIENvbWJpbmF0aW9u

XTwva2V5d29yZD48a2V5d29yZD5hYmlyYXRlcm9uZSBhY2V0YXRlL2NtIFtEcnVnIENvbXBhcmlz

b25dPC9rZXl3b3JkPjxrZXl3b3JkPmFiaXJhdGVyb25lIGFjZXRhdGUvY20gW0RydWcgQ29tcGFy

aXNvbl08L2tleXdvcmQ+PGtleXdvcmQ+YWJpcmF0ZXJvbmUgYWNldGF0ZS9kdCBbRHJ1ZyBUaGVy

YXB5XTwva2V5d29yZD48a2V5d29yZD5hYmlyYXRlcm9uZSBhY2V0YXRlL2N0IFtDbGluaWNhbCBU

cmlhbF08L2tleXdvcmQ+PGtleXdvcmQ+YWxhbmluZSBhbWlub3RyYW5zZmVyYXNlL2VjIFtFbmRv

Z2Vub3VzIENvbXBvdW5kXTwva2V5d29yZD48a2V5d29yZD5hc3BhcnRhdGUgYW1pbm90cmFuc2Zl

cmFzZS9lYyBbRW5kb2dlbm91cyBDb21wb3VuZF08L2tleXdvcmQ+PGtleXdvcmQ+Y2FiYXppdGF4

ZWwvZHQgW0RydWcgVGhlcmFweV08L2tleXdvcmQ+PGtleXdvcmQ+ZG9jZXRheGVsL2R0IFtEcnVn

IFRoZXJhcHldPC9rZXl3b3JkPjxrZXl3b3JkPmtldG9jb25hem9sZS9kdCBbRHJ1ZyBUaGVyYXB5

XTwva2V5d29yZD48a2V5d29yZD5wbGFjZWJvPC9rZXl3b3JkPjxrZXl3b3JkPnByZWRuaXNvbmUv

YWUgW0FkdmVyc2UgRHJ1ZyBSZWFjdGlvbl08L2tleXdvcmQ+PGtleXdvcmQ+cHJlZG5pc29uZS9j

YiBbRHJ1ZyBDb21iaW5hdGlvbl08L2tleXdvcmQ+PGtleXdvcmQ+cHJlZG5pc29uZS9jbSBbRHJ1

ZyBDb21wYXJpc29uXTwva2V5d29yZD48a2V5d29yZD5wcmVkbmlzb25lL2NtIFtEcnVnIENvbXBh

cmlzb25dPC9rZXl3b3JkPjxrZXl3b3JkPnByZWRuaXNvbmUvZHQgW0RydWcgVGhlcmFweV08L2tl

eXdvcmQ+PGtleXdvcmQ+cHJlZG5pc29uZS9wbyBbT3JhbCBEcnVnIEFkbWluaXN0cmF0aW9uXTwv

a2V5d29yZD48a2V5d29yZD5wcmVkbmlzb25lL2N0IFtDbGluaWNhbCBUcmlhbF08L2tleXdvcmQ+

PGtleXdvcmQ+c2lwdWxldWNlbCBUL2R0IFtEcnVnIFRoZXJhcHldPC9rZXl3b3JkPjwva2V5d29y

ZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8L3llYXI+PC9kYXRlcz48YWNjZXNzaW9uLW51bT5DTi0wMTAx

NDE4NjwvYWNjZXNzaW9uLW51bT48d29yay10eXBlPkpvdXJuYWw6IEFydGljbGU8L3dvcmstdHlw

ZT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL29ubGluZWxpYnJhcnkud2lsZXkuY29t

L28vY29jaHJhbmUvY2xjZW50cmFsL2FydGljbGVzLzE4Ni9DTi0wMTAxNDE4Ni9mcmFtZS5odG1s

PC91cmw+PHVybD5odHRwOi8vYWMuZWxzLWNkbi5jb20vUzAzMDIyODM4MTQwMDE4NTcvMS1zMi4w

LVMwMzAyMjgzODE0MDAxODU3LW1haW4ucGRmP190aWQ9NTg4YWM3NWEtMmM2NS0xMWU1LTk1YmIt

MDAwMDBhYWIwZjAxJmFtcDthY2RuYXQ9MTQzNzEyNTEyOV9lMzRkMWZiZjQ5YTk4ZTI1OTRkMzMx

ODhjNjU4YWE4OTwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJj

ZS1udW0+MTAuMTAxNi9qLmV1cnVyby4yMDE0LjAyLjA1NjwvZWxlY3Ryb25pYy1yZXNvdXJjZS1u

dW0+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+UnlhbjwvQXV0aG9yPjxZZWFyPjIwMTM8

L1llYXI+PFJlY051bT4xOTYxPC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xOTYxPC9yZWMt

bnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0ienp0OTU1c3c1MmR2dGdl

ZXN2NjVyMHBnZHd2dDlldmZ3d2VlIiB0aW1lc3RhbXA9IjE0MzcwNTUxMTgiPjE5NjE8L2tleT48

L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iRWxlY3Ryb25pYyBBcnRpY2xlIj40MzwvcmVm

LXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlJ5YW4sIEMuIEouPC9hdXRob3I+

PGF1dGhvcj5TbWl0aCwgTS4gUi48L2F1dGhvcj48YXV0aG9yPkJvbm8sIEouIFMuPC9hdXRob3I+

PGF1dGhvcj5Nb2xpbmEsIEEuPC9hdXRob3I+PGF1dGhvcj5Mb2dvdGhldGlzLCBDLiBKLjwvYXV0

aG9yPjxhdXRob3I+U291emEsIFAuPC9hdXRob3I+PGF1dGhvcj5GaXphemksIEsuPC9hdXRob3I+

PGF1dGhvcj5NYWlud2FyaW5nLCBQLjwvYXV0aG9yPjxhdXRob3I+UGl1bGF0cywgSi4gTS48L2F1

dGhvcj48YXV0aG9yPk5nLCBTLjwvYXV0aG9yPjxhdXRob3I+Q2FybGVzLCBKLjwvYXV0aG9yPjxh

dXRob3I+TXVsZGVycywgUC4gRi48L2F1dGhvcj48YXV0aG9yPkJhc2NoLCBFLjwvYXV0aG9yPjxh

dXRob3I+U21hbGwsIEUuIEouPC9hdXRob3I+PGF1dGhvcj5TYWFkLCBGLjwvYXV0aG9yPjxhdXRo

b3I+U2NocmlqdmVycywgRC48L2F1dGhvcj48YXV0aG9yPlBvcHBlbCwgSC48L2F1dGhvcj48YXV0

aG9yPk11a2hlcmplZSwgUy4gRC48L2F1dGhvcj48YXV0aG9yPlN1dHRtYW5uLCBILjwvYXV0aG9y

PjxhdXRob3I+R2Vycml0c2VuLCBXLiBSLjwvYXV0aG9yPjxhdXRob3I+RmxhaWcsIFQuIFcuPC9h

dXRob3I+PGF1dGhvcj5HZW9yZ2UsIEQuIEouPC9hdXRob3I+PGF1dGhvcj5ZdSwgRS4gWS48L2F1

dGhvcj48YXV0aG9yPkVmc3RhdGhpb3UsIEUuPC9hdXRob3I+PGF1dGhvcj5QYW50dWNrLCBBLjwv

YXV0aG9yPjxhdXRob3I+V2lucXVpc3QsIEUuPC9hdXRob3I+PGF1dGhvcj5IaWdhbm8sIEMuIFMu

PC9hdXRob3I+PGF1dGhvcj5UYXBsaW4sIE0uIEUuPC9hdXRob3I+PGF1dGhvcj5QYXJrLCBZLjwv

YXV0aG9yPjxhdXRob3I+S2hlb2gsIFQuPC9hdXRob3I+PGF1dGhvcj5HcmlmZmluLCBULjwvYXV0

aG9yPjxhdXRob3I+U2NoZXIsIEguIEkuPC9hdXRob3I+PGF1dGhvcj5SYXRoa29wZiwgRC4gRS48

L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+QWJpcmF0ZXJv

bmUgaW4gbWV0YXN0YXRpYyBwcm9zdGF0ZSBjYW5jZXIgd2l0aG91dCBwcmV2aW91cyBjaGVtb3Ro

ZXJhcHk8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+VGhlIE5ldyBFbmdsYW5kIGpvdXJuYWwgb2Yg

bWVkaWNpbmU8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs

ZT5OIEVuZ2wgSiBNZWQ8L2Z1bGwtdGl0bGU+PGFiYnItMT5UaGUgTmV3IEVuZ2xhbmQgam91cm5h

bCBvZiBtZWRpY2luZTwvYWJici0xPjwvcGVyaW9kaWNhbD48cGFnZXM+MTM4LTQ4PC9wYWdlcz48

dm9sdW1lPjM2ODwvdm9sdW1lPjxudW1iZXI+MjwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5B

bmRyb3N0YWRpZW5lcyBbYWR2ZXJzZSBlZmZlY3RzXSBbdGhlcmFwZXV0aWMgdXNlXTwva2V5d29y

ZD48a2V5d29yZD5BbnRpbmVvcGxhc3RpYyBBZ2VudHMsIEhvcm1vbmFsIFthZHZlcnNlIGVmZmVj

dHNdIFt0aGVyYXBldXRpYyB1c2VdPC9rZXl3b3JkPjxrZXl3b3JkPkFudGluZW9wbGFzdGljIENv

bWJpbmVkIENoZW1vdGhlcmFweSBQcm90b2NvbHMgW2FkdmVyc2UgZWZmZWN0c10gW3RoZXJhcGV1

dGljIHVzZV08L2tleXdvcmQ+PGtleXdvcmQ+RGlzZWFzZS1GcmVlIFN1cnZpdmFsPC9rZXl3b3Jk

PjxrZXl3b3JkPkRvdWJsZS1CbGluZCBNZXRob2Q8L2tleXdvcmQ+PGtleXdvcmQ+TmVvcGxhc20g

TWV0YXN0YXNpczwva2V5d29yZD48a2V5d29yZD5QcmVkbmlzb25lIFthZHZlcnNlIGVmZmVjdHNd

IFt0aGVyYXBldXRpYyB1c2VdPC9rZXl3b3JkPjxrZXl3b3JkPlByb3N0YXRpYyBOZW9wbGFzbXMg

W2RydWcgdGhlcmFweV0gW21vcnRhbGl0eV0gW3NlY29uZGFyeV08L2tleXdvcmQ+PGtleXdvcmQ+

U3Vydml2YWwgQW5hbHlzaXM8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zW2NoZWNrd29yZF08L2tl

eXdvcmQ+PGtleXdvcmQ+TWFsZVtjaGVja3dvcmRdPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVz

Pjx5ZWFyPjIwMTM8L3llYXI+PC9kYXRlcz48YWNjZXNzaW9uLW51bT5DTi0wMDg0MDEzMDwvYWNj

ZXNzaW9uLW51bT48d29yay10eXBlPk11bHRpY2VudGVyIFN0dWR5OyBSYW5kb21pemVkIENvbnRy

b2xsZWQgVHJpYWw7IFJlc2VhcmNoIFN1cHBvcnQsIE5vbi1VLlMuIEdvdiZhcG9zO3Q8L3dvcmst

dHlwZT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL29ubGluZWxpYnJhcnkud2lsZXku

Y29tL28vY29jaHJhbmUvY2xjZW50cmFsL2FydGljbGVzLzEzMC9DTi0wMDg0MDEzMC9mcmFtZS5o

dG1sPC91cmw+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcG1jL2FydGljbGVzL1BN

QzM2ODM1NzAvcGRmL25paG1zNDcyMjc1LnBkZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48

Y3VzdG9tMz5QdWJtZWQgMjMyMjgxNzI8L2N1c3RvbTM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVt

PjEwLjEwNTYvTkVKTW9hMTIwOTA5NjwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+

PC9DaXRlPjxDaXRlPjxBdXRob3I+UnlhbjwvQXV0aG9yPjxZZWFyPjIwMTU8L1llYXI+PFJlY051

bT4xOTU1PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xOTU1PC9yZWMtbnVtYmVyPjxmb3Jl

aWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0ienp0OTU1c3c1MmR2dGdlZXN2NjVyMHBnZHd2

dDlldmZ3d2VlIiB0aW1lc3RhbXA9IjE0MzcwNTUxMTgiPjE5NTU8L2tleT48L2ZvcmVpZ24ta2V5

cz48cmVmLXR5cGUgbmFtZT0iRWxlY3Ryb25pYyBBcnRpY2xlIj40MzwvcmVmLXR5cGU+PGNvbnRy

aWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlJ5YW4sIEMuIEouPC9hdXRob3I+PGF1dGhvcj5TbWl0

aCwgTS4gUi48L2F1dGhvcj48YXV0aG9yPkZpemF6aSwgSy48L2F1dGhvcj48YXV0aG9yPlNhYWQs

IEYuPC9hdXRob3I+PGF1dGhvcj5NdWxkZXJzLCBQLiBGLjwvYXV0aG9yPjxhdXRob3I+U3Rlcm5i

ZXJnLCBDLiBOLjwvYXV0aG9yPjxhdXRob3I+TWlsbGVyLCBLLjwvYXV0aG9yPjxhdXRob3I+TG9n

b3RoZXRpcywgQy4gSi48L2F1dGhvcj48YXV0aG9yPlNob3JlLCBOLiBELjwvYXV0aG9yPjxhdXRo

b3I+U21hbGwsIEUuIEouPC9hdXRob3I+PGF1dGhvcj5DYXJsZXMsIEouPC9hdXRob3I+PGF1dGhv

cj5GbGFpZywgVC4gVy48L2F1dGhvcj48YXV0aG9yPlRhcGxpbiwgTS4gRS48L2F1dGhvcj48YXV0

aG9yPkhpZ2FubywgQy4gUy48L2F1dGhvcj48YXV0aG9yPlNvdXphLCBQLjwvYXV0aG9yPjxhdXRo

b3I+Qm9ubywgSi4gUy48L2F1dGhvcj48YXV0aG9yPkdyaWZmaW4sIFQuIFcuPC9hdXRob3I+PGF1

dGhvcj5Qb3JyZSwgUC48L2F1dGhvcj48YXV0aG9yPll1LCBNLiBLLjwvYXV0aG9yPjxhdXRob3I+

UGFyaywgWS4gQy48L2F1dGhvcj48YXV0aG9yPkxpLCBKLjwvYXV0aG9yPjxhdXRob3I+S2hlb2gs

IFQuPC9hdXRob3I+PGF1dGhvcj5OYWluaSwgVi48L2F1dGhvcj48YXV0aG9yPk1vbGluYSwgQS48

L2F1dGhvcj48YXV0aG9yPlJhdGhrb3BmLCBELiBFLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRy

aWJ1dG9ycz48dGl0bGVzPjx0aXRsZT5BYmlyYXRlcm9uZSBhY2V0YXRlIHBsdXMgcHJlZG5pc29u

ZSB2ZXJzdXMgcGxhY2VibyBwbHVzIHByZWRuaXNvbmUgaW4gY2hlbW90aGVyYXB5LW5haXZlIG1l

biB3aXRoIG1ldGFzdGF0aWMgY2FzdHJhdGlvbi1yZXNpc3RhbnQgcHJvc3RhdGUgY2FuY2VyIChD

T1UtQUEtMzAyKTogZmluYWwgb3ZlcmFsbCBzdXJ2aXZhbCBhbmFseXNpcyBvZiBhIHJhbmRvbWlz

ZWQsIGRvdWJsZS1ibGluZCwgcGxhY2Viby1jb250cm9sbGVkIHBoYXNlIDMgc3R1ZHk8L3RpdGxl

PjxzZWNvbmRhcnktdGl0bGU+VGhlIExhbmNldC4gT25jb2xvZ3k8L3NlY29uZGFyeS10aXRsZT48

L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5MYW5jZXQgT25jb2w8L2Z1bGwtdGl0bGU+

PGFiYnItMT5UaGUgTGFuY2V0LiBPbmNvbG9neTwvYWJici0xPjwvcGVyaW9kaWNhbD48cGFnZXM+

MTUyLTYwPC9wYWdlcz48dm9sdW1lPjE2PC92b2x1bWU+PG51bWJlcj4yPC9udW1iZXI+PGtleXdv

cmRzPjxrZXl3b3JkPkFuZHJvc3RlbmVzIFt0aGVyYXBldXRpYyB1c2VdPC9rZXl3b3JkPjxrZXl3

b3JkPkFudGluZW9wbGFzdGljIEFnZW50cywgSG9ybW9uYWwgW3RoZXJhcGV1dGljIHVzZV08L2tl

eXdvcmQ+PGtleXdvcmQ+QW50aW5lb3BsYXN0aWMgQ29tYmluZWQgQ2hlbW90aGVyYXB5IFByb3Rv

Y29sczwva2V5d29yZD48a2V5d29yZD5Cb25lIE5lb3BsYXNtcyBbZHJ1ZyB0aGVyYXB5XSBbbW9y

dGFsaXR5XSBbc2Vjb25kYXJ5XTwva2V5d29yZD48a2V5d29yZD5EaXNlYXNlIFByb2dyZXNzaW9u

PC9rZXl3b3JkPjxrZXl3b3JkPkRvdWJsZS1CbGluZCBNZXRob2Q8L2tleXdvcmQ+PGtleXdvcmQ+

Rm9sbG93LVVwIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+TmVvcGxhc20gU3RhZ2luZzwva2V5

d29yZD48a2V5d29yZD5QcmVkbmlzb25lIFt0aGVyYXBldXRpYyB1c2VdPC9rZXl3b3JkPjxrZXl3

b3JkPlByb2dub3Npczwva2V5d29yZD48a2V5d29yZD5Qcm9zdGF0aWMgTmVvcGxhc21zLCBDYXN0

cmF0aW9uLVJlc2lzdGFudCBbZHJ1ZyB0aGVyYXB5XSBbbW9ydGFsaXR5XSBbcGF0aG9sb2d5XTwv

a2V5d29yZD48a2V5d29yZD5TdXJ2aXZhbCBSYXRlPC9rZXl3b3JkPjxrZXl3b3JkPkFnZWRbY2hl

Y2t3b3JkXTwva2V5d29yZD48a2V5d29yZD5IdW1hbnNbY2hlY2t3b3JkXTwva2V5d29yZD48a2V5

d29yZD5NYWxlW2NoZWNrd29yZF08L2tleXdvcmQ+PGtleXdvcmQ+YWR1bHQ8L2tleXdvcmQ+PGtl

eXdvcmQ+YWdlZDwva2V5d29yZD48a2V5d29yZD5hcnRpY2xlPC9rZXl3b3JkPjxrZXl3b3JkPmNh

bmNlciBtb3J0YWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+Y2FuY2VyIHByb2dub3Npczwva2V5d29y

ZD48a2V5d29yZD5jYW5jZXIgcmVzaXN0YW5jZTwva2V5d29yZD48a2V5d29yZD5jYXN0cmF0aW9u

IHJlc2lzdGFudCBwcm9zdGF0ZSBjYW5jZXIvZHIgW0RydWcgUmVzaXN0YW5jZV08L2tleXdvcmQ+

PGtleXdvcmQ+Y2FzdHJhdGlvbiByZXNpc3RhbnQgcHJvc3RhdGUgY2FuY2VyL2R0IFtEcnVnIFRo

ZXJhcHldPC9rZXl3b3JkPjxrZXl3b3JkPmNvbXB1dGVyIGFzc2lzdGVkIHRvbW9ncmFwaHk8L2tl

eXdvcmQ+PGtleXdvcmQ+Y29udHJvbGxlZCBzdHVkeTwva2V5d29yZD48a2V5d29yZD5jcm9zc292

ZXIgcHJvY2VkdXJlPC9rZXl3b3JkPjxrZXl3b3JkPmRvdWJsZSBibGluZCBwcm9jZWR1cmU8L2tl

eXdvcmQ+PGtleXdvcmQ+ZHJ1ZyBkb3NlIHJlZHVjdGlvbjwva2V5d29yZD48a2V5d29yZD5kcnVn

IGVmZmVjdDwva2V5d29yZD48a2V5d29yZD5kcnVnIGVmZmljYWN5PC9rZXl3b3JkPjxrZXl3b3Jk

PmRydWcgaW5kaWNhdGlvbjwva2V5d29yZD48a2V5d29yZD5kcnVnIHNhZmV0eTwva2V5d29yZD48

a2V5d29yZD5kcnVnIHdpdGhkcmF3YWw8L2tleXdvcmQ+PGtleXdvcmQ+ZWRlbWEvc2kgW1NpZGUg

RWZmZWN0XTwva2V5d29yZD48a2V5d29yZD5mb2xsb3cgdXA8L2tleXdvcmQ+PGtleXdvcmQ+aGVh

cnQgYXRyaXVtIGZpYnJpbGxhdGlvbi9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3Jk

PmhlYXJ0IGRpc2Vhc2Uvc2kgW1NpZGUgRWZmZWN0XTwva2V5d29yZD48a2V5d29yZD5odW1hbjwv

a2V5d29yZD48a2V5d29yZD5oeXBlcnRlbnNpb24vc2kgW1NpZGUgRWZmZWN0XTwva2V5d29yZD48

a2V5d29yZD5oeXBva2FsZW1pYS9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPmlu

dGVudGlvbiB0byB0cmVhdCBhbmFseXNpczwva2V5d29yZD48a2V5d29yZD5tYWpvciBjbGluaWNh

bCBzdHVkeTwva2V5d29yZD48a2V5d29yZD5tYWxlPC9rZXl3b3JkPjxrZXl3b3JkPm1ldGFzdGFz

aXMvZHIgW0RydWcgUmVzaXN0YW5jZV08L2tleXdvcmQ+PGtleXdvcmQ+bWV0YXN0YXNpcy9kdCBb

RHJ1ZyBUaGVyYXB5XTwva2V5d29yZD48a2V5d29yZD5udWNsZWFyIG1hZ25ldGljIHJlc29uYW5j

ZSBpbWFnaW5nPC9rZXl3b3JkPjxrZXl3b3JkPm92ZXJhbGwgc3Vydml2YWw8L2tleXdvcmQ+PGtl

eXdvcmQ+cGhhc2UgMyBjbGluaWNhbCB0cmlhbDwva2V5d29yZD48a2V5d29yZD5wcm9ncmVzc2lv

biBmcmVlIHN1cnZpdmFsPC9rZXl3b3JkPjxrZXl3b3JkPnJhbmRvbWl6ZWQgY29udHJvbGxlZCB0

cmlhbDwva2V5d29yZD48a2V5d29yZD5yaXNrIGJlbmVmaXQgYW5hbHlzaXM8L2tleXdvcmQ+PGtl

eXdvcmQ+dHJlYXRtZW50IGR1cmF0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPnVuc3BlY2lmaWVkIHNp

ZGUgZWZmZWN0L3NpIFtTaWRlIEVmZmVjdF08L2tleXdvcmQ+PGtleXdvcmQ+YWJpcmF0ZXJvbmUg

YWNldGF0ZS9jdCBbQ2xpbmljYWwgVHJpYWxdPC9rZXl3b3JkPjxrZXl3b3JkPmFiaXJhdGVyb25l

IGFjZXRhdGUvYWUgW0FkdmVyc2UgRHJ1ZyBSZWFjdGlvbl08L2tleXdvcmQ+PGtleXdvcmQ+YWJp

cmF0ZXJvbmUgYWNldGF0ZS9jYiBbRHJ1ZyBDb21iaW5hdGlvbl08L2tleXdvcmQ+PGtleXdvcmQ+

YWJpcmF0ZXJvbmUgYWNldGF0ZS9jbSBbRHJ1ZyBDb21wYXJpc29uXTwva2V5d29yZD48a2V5d29y

ZD5hYmlyYXRlcm9uZSBhY2V0YXRlL3BvIFtPcmFsIERydWcgQWRtaW5pc3RyYXRpb25dPC9rZXl3

b3JkPjxrZXl3b3JkPmFiaXJhdGVyb25lIGFjZXRhdGUvZHQgW0RydWcgVGhlcmFweV08L2tleXdv

cmQ+PGtleXdvcmQ+YWxhbmluZSBhbWlub3RyYW5zZmVyYXNlL2VjIFtFbmRvZ2Vub3VzIENvbXBv

dW5kXTwva2V5d29yZD48a2V5d29yZD5hc3BhcnRhdGUgYW1pbm90cmFuc2ZlcmFzZS9lYyBbRW5k

b2dlbm91cyBDb21wb3VuZF08L2tleXdvcmQ+PGtleXdvcmQ+cGxhY2Vibzwva2V5d29yZD48a2V5

d29yZD5wcmVkbmlzb25lL3BvIFtPcmFsIERydWcgQWRtaW5pc3RyYXRpb25dPC9rZXl3b3JkPjxr

ZXl3b3JkPnByZWRuaXNvbmUvY3QgW0NsaW5pY2FsIFRyaWFsXTwva2V5d29yZD48a2V5d29yZD5w

cmVkbmlzb25lL2NiIFtEcnVnIENvbWJpbmF0aW9uXTwva2V5d29yZD48a2V5d29yZD5wcmVkbmlz

b25lL2R0IFtEcnVnIFRoZXJhcHldPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIw

MTU8L3llYXI+PC9kYXRlcz48YWNjZXNzaW9uLW51bT5DTi0wMTA0ODUzNDwvYWNjZXNzaW9uLW51

bT48d29yay10eXBlPkNsaW5pY2FsIFRyaWFsLCBQaGFzZSBJSUk7IENvbXBhcmF0aXZlIFN0dWR5

OyBNdWx0aWNlbnRlciBTdHVkeTsgUmFuZG9taXplZCBDb250cm9sbGVkIFRyaWFsOyBSZXNlYXJj

aCBTdXBwb3J0LCBOb24tVS5TLiBHb3YmYXBvczt0PC93b3JrLXR5cGU+PHVybHM+PHJlbGF0ZWQt

dXJscz48dXJsPmh0dHA6Ly9vbmxpbmVsaWJyYXJ5LndpbGV5LmNvbS9vL2NvY2hyYW5lL2NsY2Vu

dHJhbC9hcnRpY2xlcy81MzQvQ04tMDEwNDg1MzQvZnJhbWUuaHRtbDwvdXJsPjx1cmw+aHR0cDov

L3d3dy50aGVsYW5jZXQuY29tL2pvdXJuYWxzL2xhbm9uYy9hcnRpY2xlL1BJSVMxNDcwLTIwNDUo

MTQpNzEyMDUtNy9hYnN0cmFjdDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3VzdG9tMz5Q

dWJtZWQgMjU2MDEzNDE8L2N1c3RvbTM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwMTYv

UzE0NzAtMjA0NSgxNCk3MTIwNS03PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48

L0NpdGU+PENpdGU+PEF1dGhvcj5TYXJ0b3I8L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFyPjxSZWNO

dW0+MTM2ODwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+MTM2ODwvcmVjLW51bWJlcj48Zm9y

ZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9Inp6dDk1NXN3NTJkdnRnZWVzdjY1cjBwZ2R3

dnQ5ZXZmd3dlZSIgdGltZXN0YW1wPSIxNDM3MDQ3NjY3Ij4xMzY4PC9rZXk+PC9mb3JlaWduLWtl

eXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmli

dXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5TYXJ0b3IsIE8uPC9hdXRob3I+PGF1dGhvcj5Db2xlbWFu

LCBSLjwvYXV0aG9yPjxhdXRob3I+Tmlsc3NvbiwgUy48L2F1dGhvcj48YXV0aG9yPkhlaW5yaWNo

LCBELjwvYXV0aG9yPjxhdXRob3I+SGVsbGUsIFMuIEkuPC9hdXRob3I+PGF1dGhvcj5PJmFwb3M7

U3VsbGl2YW4sIEouIE0uPC9hdXRob3I+PGF1dGhvcj5Gb3NzYSwgUy4gRC48L2F1dGhvcj48YXV0

aG9yPkNob2RhY2tpLCBBLjwvYXV0aG9yPjxhdXRob3I+V2llY2hubywgUC48L2F1dGhvcj48YXV0

aG9yPkxvZ3VlLCBKLjwvYXV0aG9yPjxhdXRob3I+V2lkbWFyaywgQS48L2F1dGhvcj48YXV0aG9y

PkpvaGFubmVzc2VuLCBELiBDLjwvYXV0aG9yPjxhdXRob3I+SG9za2luLCBQLjwvYXV0aG9yPjxh

dXRob3I+SmFtZXMsIE4uIEQuPC9hdXRob3I+PGF1dGhvcj5Tb2xiZXJnLCBBLjwvYXV0aG9yPjxh

dXRob3I+U3luZGlrdXMsIEkuPC9hdXRob3I+PGF1dGhvcj5Wb2dlbHphbmcsIE4uIEouPC9hdXRo

b3I+PGF1dGhvcj5PJmFwb3M7QnJ5YW4tVGVhciwgQy4gRy48L2F1dGhvcj48YXV0aG9yPlNoYW4s

IE0uPC9hdXRob3I+PGF1dGhvcj5CcnVsYW5kLCBULiBTLjwvYXV0aG9yPjxhdXRob3I+UGFya2Vy

LCBDLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPk8uIFNh

cnRvciwgTWVkaWNhbCBEaXJlY3RvciBUdWxhbmUgQ2FuY2VyIENlbnRlciwgRGVwYXJ0bWVudHMg

b2YgTWVkaWNpbmUgYW5kIFVyb2xvZ3ksIFR1bGFuZSBNZWRpY2FsIFNjaG9vbCwgTmV3IE9ybGVh

bnMsIExBIDcwMTEyLCBVbml0ZWQgU3RhdGVzPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+

RWZmZWN0IG9mIHJhZGl1bS0yMjMgZGljaGxvcmlkZSBvbiBzeW1wdG9tYXRpYyBza2VsZXRhbCBl

dmVudHMgaW4gcGF0aWVudHMgd2l0aCBjYXN0cmF0aW9uLXJlc2lzdGFudCBwcm9zdGF0ZSBjYW5j

ZXIgYW5kIGJvbmUgbWV0YXN0YXNlczogUmVzdWx0cyBmcm9tIGEgcGhhc2UgMywgZG91YmxlLWJs

aW5kLCByYW5kb21pc2VkIHRyaWFsPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPlRoZSBMYW5jZXQg

T25jb2xvZ3k8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs

ZT5UaGUgTGFuY2V0IE9uY29sb2d5PC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+NzM4

LTc0NjwvcGFnZXM+PHZvbHVtZT4xNTwvdm9sdW1lPjxudW1iZXI+NzwvbnVtYmVyPjxrZXl3b3Jk

cz48a2V5d29yZD5OQ1QwMDY5OTc1MTwva2V5d29yZD48a2V5d29yZD5hbGthbGluZSBwaG9zcGhh

dGFzZTwva2V5d29yZD48a2V5d29yZD5kb2NldGF4ZWw8L2tleXdvcmQ+PGtleXdvcmQ+cGxhY2Vi

bzwva2V5d29yZD48a2V5d29yZD5yYWRpdW0gY2hsb3JpZGUgcmEgMjIzPC9rZXl3b3JkPjxrZXl3

b3JkPnpvbGVkcm9uaWMgYWNpZDwva2V5d29yZD48a2V5d29yZD5hZHVsdDwva2V5d29yZD48a2V5

d29yZD5hZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPmFydGljbGU8L2tleXdvcmQ+PGtleXdvcmQ+Ym9u

ZSBtZXRhc3Rhc2lzPC9rZXl3b3JkPjxrZXl3b3JkPmJvbmUgcGFpbjwva2V5d29yZD48a2V5d29y

ZD5jYW5jZXIgY2hlbW90aGVyYXB5PC9rZXl3b3JkPjxrZXl3b3JkPmNhc3RyYXRpb24gcmVzaXN0

YW50IHByb3N0YXRlIGNhbmNlcjwva2V5d29yZD48a2V5d29yZD5jbGluaWNhbCBlZmZlY3RpdmVu

ZXNzPC9rZXl3b3JkPjxrZXl3b3JkPmNvbnRyb2xsZWQgc3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+

ZG91YmxlIGJsaW5kIHByb2NlZHVyZTwva2V5d29yZD48a2V5d29yZD5kcnVnIGVmZmVjdDwva2V5

d29yZD48a2V5d29yZD5kcnVnIGVmZmljYWN5PC9rZXl3b3JkPjxrZXl3b3JkPmRydWcgc2FmZXR5

PC9rZXl3b3JkPjxrZXl3b3JkPmRydWcgdG9sZXJhYmlsaXR5PC9rZXl3b3JkPjxrZXl3b3JkPmRy

dWcgd2l0aGRyYXdhbDwva2V5d29yZD48a2V5d29yZD5ldmVudCBmcmVlIHN1cnZpdmFsPC9rZXl3

b3JkPjxrZXl3b3JkPmV4dGVybmFsIGJlYW0gcmFkaW90aGVyYXB5PC9rZXl3b3JkPjxrZXl3b3Jk

PmhlYWx0aCBjYXJlIHF1YWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+aHVtYW48L2tleXdvcmQ+PGtl

eXdvcmQ+aW50ZW50aW9uIHRvIHRyZWF0IGFuYWx5c2lzPC9rZXl3b3JkPjxrZXl3b3JkPm1ham9y

IGNsaW5pY2FsIHN0dWR5PC9rZXl3b3JkPjxrZXl3b3JkPm1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+

bXVsdGljZW50ZXIgc3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+b3J0aG9wZWRpYyBzdXJnZXJ5PC9r

ZXl3b3JkPjxrZXl3b3JkPm92ZXJhbGwgc3Vydml2YWw8L2tleXdvcmQ+PGtleXdvcmQ+cGF0aG9s

b2dpYyBmcmFjdHVyZTwva2V5d29yZD48a2V5d29yZD5waGFzZSAzIGNsaW5pY2FsIHRyaWFsPC9r

ZXl3b3JkPjxrZXl3b3JkPnBvc3QgaG9jIGFuYWx5c2lzPC9rZXl3b3JkPjxrZXl3b3JkPnByaW9y

aXR5IGpvdXJuYWw8L2tleXdvcmQ+PGtleXdvcmQ+cmFuZG9taXplZCBjb250cm9sbGVkIHRyaWFs

PC9rZXl3b3JkPjxrZXl3b3JkPnJpc2sgcmVkdWN0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPnNwaW5h

bCBjb3JkIGNvbXByZXNzaW9uPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8

L3llYXI+PC9kYXRlcz48aXNibj4xNDc0LTU0ODgmI3hEOzE0NzAtMjA0NTwvaXNibj48dXJscz48

cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5lbWJhc2UuY29tL3NlYXJjaC9yZXN1bHRzP3N1

YmFjdGlvbj12aWV3cmVjb3JkJmFtcDtmcm9tPWV4cG9ydCZhbXA7aWQ9TDUzMTM0MDMzPC91cmw+

PHVybD5odHRwOi8vZHguZG9pLm9yZy8xMC4xMDE2L1MxNDcwLTIwNDUoMTQpNzAxODMtNDwvdXJs

Pjx1cmw+aHR0cDovL3NmeC5saWJyYXJ5LnV1Lm5sL3V0cmVjaHQ/c2lkPUVNQkFTRSZhbXA7aXNz

bj0xNDc0NTQ4OCZhbXA7aWQ9ZG9pOjEwLjEwMTYlMkZTMTQ3MC0yMDQ1JTI4MTQlMjk3MDE4My00

JmFtcDthdGl0bGU9RWZmZWN0K29mK3JhZGl1bS0yMjMrZGljaGxvcmlkZStvbitzeW1wdG9tYXRp

Yytza2VsZXRhbCtldmVudHMraW4rcGF0aWVudHMrd2l0aCtjYXN0cmF0aW9uLXJlc2lzdGFudCtw

cm9zdGF0ZStjYW5jZXIrYW5kK2JvbmUrbWV0YXN0YXNlcyUzQStSZXN1bHRzK2Zyb20rYStwaGFz

ZSszJTJDK2RvdWJsZS1ibGluZCUyQytyYW5kb21pc2VkK3RyaWFsJmFtcDtzdGl0bGU9TGFuY2V0

K09uY29sLiZhbXA7dGl0bGU9VGhlK0xhbmNldCtPbmNvbG9neSZhbXA7dm9sdW1lPTE1JmFtcDtp

c3N1ZT03JmFtcDtzcGFnZT03MzgmYW1wO2VwYWdlPTc0NiZhbXA7YXVsYXN0PVNhcnRvciZhbXA7

YXVmaXJzdD1PbGl2ZXImYW1wO2F1aW5pdD1PLiZhbXA7YXVmdWxsPVNhcnRvcitPLiZhbXA7Y29k

ZW49TE9BTkImYW1wO2lzYm49JmFtcDtwYWdlcz03MzgtNzQ2JmFtcDtkYXRlPTIwMTQmYW1wO2F1

aW5pdDE9TyZhbXA7YXVpbml0bT08L3VybD48dXJsPmh0dHA6Ly93d3cudGhlbGFuY2V0LmNvbS9q

b3VybmFscy9sYW5vbmMvYXJ0aWNsZS9QSUlTMTQ3MC0yMDQ1KDE0KTcwMTgzLTQvYWJzdHJhY3Q8

L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ba2F6YTwvQXV0aG9yPjxZZWFyPjIwMDk8L1llYXI+PFJl

Y051bT44OTc8L1JlY051bT48RGlzcGxheVRleHQ+WzEtMTZdPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjg5NzwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIg

ZGItaWQ9Inp6dDk1NXN3NTJkdnRnZWVzdjY1cjBwZ2R3dnQ5ZXZmd3dlZSIgdGltZXN0YW1wPSIx

NDM3MDQ3MDg2Ij44OTc8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5h

bCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkFr

YXphLCBILjwvYXV0aG9yPjxhdXRob3I+SGlub3RzdSwgUy48L2F1dGhvcj48YXV0aG9yPlVzYW1p

LCBNLjwvYXV0aG9yPjxhdXRob3I+QXJhaSwgWS48L2F1dGhvcj48YXV0aG9yPkthbmV0YWtlLCBI

LjwvYXV0aG9yPjxhdXRob3I+TmFpdG8sIFMuPC9hdXRob3I+PGF1dGhvcj5IaXJhbywgWS48L2F1

dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9m

IFVyb2xvZ3ksIEluc3RpdHV0ZSBvZiBDbGluaWNhbCBNZWRpY2luZSwgVW5pdmVyc2l0eSBvZiBU

c3VrdWJhLCBJYmFyYWtpLCBKYXBhbi4gYWthemFoQG1kLnRzdWt1YmEuYWMuanA8L2F1dGgtYWRk

cmVzcz48dGl0bGVzPjx0aXRsZT5Db21iaW5lZCBhbmRyb2dlbiBibG9ja2FkZSB3aXRoIGJpY2Fs

dXRhbWlkZSBmb3IgYWR2YW5jZWQgcHJvc3RhdGUgY2FuY2VyOiBsb25nLXRlcm0gZm9sbG93LXVw

IG9mIGEgcGhhc2UgMywgZG91YmxlLWJsaW5kLCByYW5kb21pemVkIHN0dWR5IGZvciBzdXJ2aXZh

bDwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5DYW5jZXI8L3NlY29uZGFyeS10aXRsZT48YWx0LXRp

dGxlPkNhbmNlcjwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkNh

bmNlcjwvZnVsbC10aXRsZT48YWJici0xPkNhbmNlcjwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0

LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+Q2FuY2VyPC9mdWxsLXRpdGxlPjxhYmJyLTE+Q2FuY2Vy

PC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+MzQzNy00NTwvcGFnZXM+PHZvbHVtZT4x

MTU8L3ZvbHVtZT48bnVtYmVyPjE1PC9udW1iZXI+PGVkaXRpb24+MjAwOS8wNi8xOTwvZWRpdGlv

bj48a2V5d29yZHM+PGtleXdvcmQ+QWdlZDwva2V5d29yZD48a2V5d29yZD5BbmRyb2dlbiBBbnRh

Z29uaXN0cy8qdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPkFuaWxpZGVzLyphZG1p

bmlzdHJhdGlvbiAmYW1wOyBkb3NhZ2U8L2tleXdvcmQ+PGtleXdvcmQ+QW50aW5lb3BsYXN0aWMg

QWdlbnRzLCBIb3Jtb25hbC8qdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPkFudGlu

ZW9wbGFzdGljIENvbWJpbmVkIENoZW1vdGhlcmFweSBQcm90b2NvbHMvdGhlcmFwZXV0aWMgdXNl

PC9rZXl3b3JkPjxrZXl3b3JkPkRpc2Vhc2UgUHJvZ3Jlc3Npb248L2tleXdvcmQ+PGtleXdvcmQ+

RG91YmxlLUJsaW5kIE1ldGhvZDwva2V5d29yZD48a2V5d29yZD5Gb2xsb3ctVXAgU3R1ZGllczwv

a2V5d29yZD48a2V5d29yZD5Hb25hZG90cm9waW4tUmVsZWFzaW5nIEhvcm1vbmUvKmFkbWluaXN0

cmF0aW9uICZhbXA7IGRvc2FnZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtl

eXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5OaXRyaWxlcy8qYWRtaW5pc3RyYXRpb24gJmFt

cDsgZG9zYWdlPC9rZXl3b3JkPjxrZXl3b3JkPlByb3N0YXRlLVNwZWNpZmljIEFudGlnZW4vYW5h

bHlzaXM8L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3RhdGljIE5lb3BsYXNtcy8qZHJ1ZyB0aGVyYXB5

L21vcnRhbGl0eTwva2V5d29yZD48a2V5d29yZD5TdXJ2aXZhbCBBbmFseXNpczwva2V5d29yZD48

a2V5d29yZD5Ub3N5bCBDb21wb3VuZHMvKmFkbWluaXN0cmF0aW9uICZhbXA7IGRvc2FnZTwva2V5

d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDA5PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+

QXVnIDE8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wMDA4LTU0M1ggKFByaW50KSYj

eEQ7MDAwOC01NDN4PC9pc2JuPjxhY2Nlc3Npb24tbnVtPjE5NTM2ODg5PC9hY2Nlc3Npb24tbnVt

Pjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vb25saW5lbGlicmFyeS53aWxleS5jb20v

c3RvcmUvMTAuMTAwMi9jbmNyLjI0Mzk1L2Fzc2V0LzI0Mzk1X2Z0cC5wZGY/dj0xJmFtcDt0PWlj

N2NidWdvJmFtcDtzPWY4OTYyMDliMjY2ZjRmYmVkZTVlNGNlMTk3OGM2YTE2MzZiZThhODM8L3Vy

bD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwMDIv

Y25jci4yNDM5NTwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PHJlbW90ZS1kYXRhYmFzZS1wcm92

aWRlcj5ObG08L3JlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFn

ZT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5BcmFpPC9BdXRob3I+PFllYXI+MjAwODwv

WWVhcj48UmVjTnVtPjEwMzY8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjEwMzY8L3JlYy1u

dW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ6enQ5NTVzdzUyZHZ0Z2Vl

c3Y2NXIwcGdkd3Z0OWV2Znd3ZWUiIHRpbWVzdGFtcD0iMTQzNzA0NzA4NiI+MTAzNjwva2V5Pjwv

Zm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlw

ZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+QXJhaSwgWS48L2F1dGhvcj48YXV0aG9y

PkFrYXphLCBILjwvYXV0aG9yPjxhdXRob3I+RGVndWNoaSwgVC48L2F1dGhvcj48YXV0aG9yPkZ1

amlzYXdhLCBNLjwvYXV0aG9yPjxhdXRob3I+SGF5YXNoaSwgTS48L2F1dGhvcj48YXV0aG9yPkhp

cmFvLCBZLjwvYXV0aG9yPjxhdXRob3I+S2FuZXRha2UsIEguPC9hdXRob3I+PGF1dGhvcj5OYWl0

bywgUy48L2F1dGhvcj48YXV0aG9yPk5hbWlraSwgTS48L2F1dGhvcj48YXV0aG9yPlRhY2hpYmFu

YSwgTS48L2F1dGhvcj48YXV0aG9yPlVzYW1pLCBNLjwvYXV0aG9yPjxhdXRob3I+T2hhc2hpLCBZ

LjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPlRvaG9rdSBV

bml2ZXJzaXR5IFNjaG9vbCBvZiBNZWRpY2luZSwgMS0xIFNlaXJ5by1tYWNoaSwgQW9iYS1rdSwg

U2VuZGFpLCBNaXlhZ2kgOTgwLTg1NzQsIEphcGFuLiB5YXJhaUB1cm8ubWVkLnRvaG9rdS5hYy5q

cDwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkV2YWx1YXRpb24gb2YgcXVhbGl0eSBvZiBs

aWZlIGluIHBhdGllbnRzIHdpdGggcHJldmlvdXNseSB1bnRyZWF0ZWQgYWR2YW5jZWQgcHJvc3Rh

dGUgY2FuY2VyIHJlY2VpdmluZyBtYXhpbXVtIGFuZHJvZ2VuIGJsb2NrYWRlIHRoZXJhcHkgb3Ig

TEhSSGEgbW9ub3RoZXJhcHk6IGEgbXVsdGljZW50ZXIsIHJhbmRvbWl6ZWQsIGRvdWJsZS1ibGlu

ZCwgY29tcGFyYXRpdmUgc3R1ZHk8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+SiBDYW5jZXIgUmVz

IENsaW4gT25jb2w8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkpvdXJuYWwgb2YgY2FuY2Vy

IHJlc2VhcmNoIGFuZCBjbGluaWNhbCBvbmNvbG9neTwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJp

b2RpY2FsPjxmdWxsLXRpdGxlPkogQ2FuY2VyIFJlcyBDbGluIE9uY29sPC9mdWxsLXRpdGxlPjxh

YmJyLTE+Sm91cm5hbCBvZiBjYW5jZXIgcmVzZWFyY2ggYW5kIGNsaW5pY2FsIG9uY29sb2d5PC9h

YmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIENhbmNlciBS

ZXMgQ2xpbiBPbmNvbDwvZnVsbC10aXRsZT48YWJici0xPkpvdXJuYWwgb2YgY2FuY2VyIHJlc2Vh

cmNoIGFuZCBjbGluaWNhbCBvbmNvbG9neTwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2Vz

PjEzODUtOTY8L3BhZ2VzPjx2b2x1bWU+MTM0PC92b2x1bWU+PG51bWJlcj4xMjwvbnVtYmVyPjxl

ZGl0aW9uPjIwMDgvMDUvMjE8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkFnZWQ8L2tleXdv

cmQ+PGtleXdvcmQ+QW5kcm9nZW4gQW50YWdvbmlzdHMvKnRoZXJhcGV1dGljIHVzZTwva2V5d29y

ZD48a2V5d29yZD5BbmlsaWRlcy8qdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPkJv

bmUgTmVvcGxhc21zLypkcnVnIHRoZXJhcHkvc2Vjb25kYXJ5PC9rZXl3b3JkPjxrZXl3b3JkPkRv

dWJsZS1CbGluZCBNZXRob2Q8L2tleXdvcmQ+PGtleXdvcmQ+R29uYWRvdHJvcGluLVJlbGVhc2lu

ZyBIb3Jtb25lLyp0aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3

b3JkPjxrZXl3b3JkPkx5bXBoYXRpYyBNZXRhc3Rhc2lzPC9rZXl3b3JkPjxrZXl3b3JkPk1hbGU8

L2tleXdvcmQ+PGtleXdvcmQ+TmVvcGxhc20gU3RhZ2luZzwva2V5d29yZD48a2V5d29yZD5OaXRy

aWxlcy8qdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPlByb2dub3Npczwva2V5d29y

ZD48a2V5d29yZD5Qcm9zdGF0aWMgTmVvcGxhc21zLypkcnVnIHRoZXJhcHkvbWV0YWJvbGlzbS9w

YXRob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+KlF1YWxpdHkgb2YgTGlmZTwva2V5d29yZD48a2V5

d29yZD5TdXJ2aXZhbCBSYXRlPC9rZXl3b3JkPjxrZXl3b3JkPlRvc3lsIENvbXBvdW5kcy8qdGhl

cmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPlRyZWF0bWVudCBPdXRjb21lPC9rZXl3b3Jk

Pjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDg8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5EZWM8

L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wMTcxLTUyMTY8L2lzYm4+PGFjY2Vzc2lv

bi1udW0+MTg0OTExMzc8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0

dHA6Ly9kb3dubG9hZC5zcHJpbmdlci5jb20vc3RhdGljL3BkZi85NzQvYXJ0JTI1M0ExMC4xMDA3

JTI1MkZzMDA0MzItMDA4LTA0MDktei5wZGY/b3JpZ2luVXJsPWh0dHAlM0ElMkYlMkZsaW5rLnNw

cmluZ2VyLmNvbSUyRmFydGljbGUlMkYxMC4xMDA3JTJGczAwNDMyLTAwOC0wNDA5LXomYW1wO3Rv

a2VuMj1leHA9MTQzNzEyMTY5M35hY2w9JTJGc3RhdGljJTJGcGRmJTJGOTc0JTJGYXJ0JTI1MjUz

QTEwLjEwMDclMjUyNTJGczAwNDMyLTAwOC0wNDA5LXoucGRmJTNGb3JpZ2luVXJsJTNEaHR0cCUy

NTNBJTI1MkYlMjUyRmxpbmsuc3ByaW5nZXIuY29tJTI1MkZhcnRpY2xlJTI1MkYxMC4xMDA3JTI1

MkZzMDA0MzItMDA4LTA0MDkteip+aG1hYz0xNjBmOTgxNjYwZmFmZmI3MDhiZGRiNjQ0ZDExOTY4

ZDQyYzJlNjY0ZTJjZmExNTFlY2U3YTliMTdiMGNiOTBiPC91cmw+PC9yZWxhdGVkLXVybHM+PC91

cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDA3L3MwMDQzMi0wMDgtMDQwOS16PC9l

bGVjdHJvbmljLXJlc291cmNlLW51bT48cmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVyPk5sbTwvcmVt

b3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxsYW5ndWFnZT5lbmc8L2xhbmd1YWdlPjwvcmVjb3JkPjwv

Q2l0ZT48Q2l0ZT48QXV0aG9yPkJhc2NoPC9BdXRob3I+PFllYXI+MjAxMzwvWWVhcj48UmVjTnVt

PjE0NzU8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjE0NzU8L3JlYy1udW1iZXI+PGZvcmVp

Z24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ6enQ5NTVzdzUyZHZ0Z2Vlc3Y2NXIwcGdkd3Z0

OWV2Znd3ZWUiIHRpbWVzdGFtcD0iMTQzNzA0NzY2OCI+MTQ3NTwva2V5PjwvZm9yZWlnbi1rZXlz

PjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0

b3JzPjxhdXRob3JzPjxhdXRob3I+QmFzY2gsIEUuPC9hdXRob3I+PGF1dGhvcj5BdXRpbywgSy48

L2F1dGhvcj48YXV0aG9yPlJ5YW4sIEMuIEouPC9hdXRob3I+PGF1dGhvcj5NdWxkZXJzLCBQLjwv

YXV0aG9yPjxhdXRob3I+U2hvcmUsIE4uPC9hdXRob3I+PGF1dGhvcj5LaGVvaCwgVC48L2F1dGhv

cj48YXV0aG9yPkZpemF6aSwgSy48L2F1dGhvcj48YXV0aG9yPkxvZ290aGV0aXMsIEMuIEouPC9h

dXRob3I+PGF1dGhvcj5SYXRoa29wZiwgRC48L2F1dGhvcj48YXV0aG9yPlNtaXRoLCBNLiBSLjwv

YXV0aG9yPjxhdXRob3I+TWFpbndhcmluZywgUC4gTi48L2F1dGhvcj48YXV0aG9yPkhhbywgWS48

L2F1dGhvcj48YXV0aG9yPkdyaWZmaW4sIFQuPC9hdXRob3I+PGF1dGhvcj5MaSwgUy48L2F1dGhv

cj48YXV0aG9yPk1leWVycywgTS4gTC48L2F1dGhvcj48YXV0aG9yPk1vbGluYSwgQS48L2F1dGhv

cj48YXV0aG9yPkNsZWVsYW5kLCBDLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48

YXV0aC1hZGRyZXNzPkUuIEJhc2NoLCBEZXBhcnRtZW50IG9mIE1lZGljaW5lLCBUaGUgVW5pdmVy

c2l0eSBvZiBOb3J0aCBDYXJvbGluYSBhdCBDaGFwZWwgSGlsbCwgQ2hhcGVsIEhpbGwsIE5DIDI3

NTk5LCBVbml0ZWQgU3RhdGVzPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+QWJpcmF0ZXJv

bmUgYWNldGF0ZSBwbHVzIHByZWRuaXNvbmUgdmVyc3VzIHByZWRuaXNvbmUgYWxvbmUgaW4gY2hl

bW90aGVyYXB5LW5haXZlIG1lbiB3aXRoIG1ldGFzdGF0aWMgY2FzdHJhdGlvbi1yZXNpc3RhbnQg

cHJvc3RhdGUgY2FuY2VyOiBQYXRpZW50LXJlcG9ydGVkIG91dGNvbWUgcmVzdWx0cyBvZiBhIHJh

bmRvbWlzZWQgcGhhc2UgMyB0cmlhbDwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5UaGUgTGFuY2V0

IE9uY29sb2d5PC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0

bGU+VGhlIExhbmNldCBPbmNvbG9neTwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjEx

OTMtMTE5OTwvcGFnZXM+PHZvbHVtZT4xNDwvdm9sdW1lPjxudW1iZXI+MTI8L251bWJlcj48a2V5

d29yZHM+PGtleXdvcmQ+TkNUMDA4ODcxOTg8L2tleXdvcmQ+PGtleXdvcmQ+YWJpcmF0ZXJvbmUg

YWNldGF0ZTwva2V5d29yZD48a2V5d29yZD5hbmFsZ2VzaWMgYWdlbnQ8L2tleXdvcmQ+PGtleXdv

cmQ+bmFyY290aWMgYW5hbGdlc2ljIGFnZW50PC9rZXl3b3JkPjxrZXl3b3JkPnBsYWNlYm88L2tl

eXdvcmQ+PGtleXdvcmQ+cHJlZG5pc29uZTwva2V5d29yZD48a2V5d29yZD5hcnRpY2xlPC9rZXl3

b3JkPjxrZXl3b3JkPmFzeW1wdG9tYXRpYyBkaXNlYXNlPC9rZXl3b3JkPjxrZXl3b3JkPmJyaWVm

IHBhaW4gaW52ZW50b3J5IHNob3J0IGZvcm08L2tleXdvcmQ+PGtleXdvcmQ+Y2FuY2VyIGNoZW1v

dGhlcmFweTwva2V5d29yZD48a2V5d29yZD5jYW5jZXIgZ3Jvd3RoPC9rZXl3b3JkPjxrZXl3b3Jk

PmNhbmNlciBwYWluPC9rZXl3b3JkPjxrZXl3b3JkPmNhc3RyYXRpb24gcmVzaXN0YW50IHByb3N0

YXRlIGNhbmNlcjwva2V5d29yZD48a2V5d29yZD5jb250cm9sbGVkIHN0dWR5PC9rZXl3b3JkPjxr

ZXl3b3JkPmRhaWx5IGxpZmUgYWN0aXZpdHk8L2tleXdvcmQ+PGtleXdvcmQ+ZG91YmxlIGJsaW5k

IHByb2NlZHVyZTwva2V5d29yZD48a2V5d29yZD5GdW5jdGlvbmFsIEFzc2Vzc21lbnQgb2YgQ2Fu

Y2VyIFRoZXJhcHkgUHJvc3RhdGU8L2tleXdvcmQ+PGtleXdvcmQ+ZnVuY3Rpb25hbCBzdGF0dXM8

L2tleXdvcmQ+PGtleXdvcmQ+aHVtYW48L2tleXdvcmQ+PGtleXdvcmQ+bWFqb3IgY2xpbmljYWwg

c3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+bWFsZTwva2V5d29yZD48a2V5d29yZD5tZXRhc3Rhc2lz

IHBvdGVudGlhbDwva2V5d29yZD48a2V5d29yZD5tdWx0aXBsZSBjeWNsZSB0cmVhdG1lbnQ8L2tl

eXdvcmQ+PGtleXdvcmQ+b3V0Y29tZSBhc3Nlc3NtZW50PC9rZXl3b3JkPjxrZXl3b3JkPnBoYXNl

IDMgY2xpbmljYWwgdHJpYWw8L2tleXdvcmQ+PGtleXdvcmQ+cHJpb3JpdHkgam91cm5hbDwva2V5

d29yZD48a2V5d29yZD5wc3ljaG9sb2dpY2FsIHdlbGwgYmVpbmc8L2tleXdvcmQ+PGtleXdvcmQ+

cXVhbGl0eSBvZiBsaWZlPC9rZXl3b3JkPjxrZXl3b3JkPnF1ZXN0aW9ubmFpcmU8L2tleXdvcmQ+

PGtleXdvcmQ+c2NvcmluZyBzeXN0ZW08L2tleXdvcmQ+PGtleXdvcmQ+d2VsbGJlaW5nPC9rZXl3

b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTM8L3llYXI+PC9kYXRlcz48aXNibj4xNDcw

LTIwNDUmI3hEOzE0NzQtNTQ4ODwvaXNibj48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDov

L3d3dy5lbWJhc2UuY29tL3NlYXJjaC9yZXN1bHRzP3N1YmFjdGlvbj12aWV3cmVjb3JkJmFtcDtm

cm9tPWV4cG9ydCZhbXA7aWQ9TDUyNzkyMjc0PC91cmw+PHVybD5odHRwOi8vZHguZG9pLm9yZy8x

MC4xMDE2L1MxNDcwLTIwNDUoMTMpNzA0MjQtODwvdXJsPjx1cmw+aHR0cDovL3NmeC5saWJyYXJ5

LnV1Lm5sL3V0cmVjaHQ/c2lkPUVNQkFTRSZhbXA7aXNzbj0xNDcwMjA0NSZhbXA7aWQ9ZG9pOjEw

LjEwMTYlMkZTMTQ3MC0yMDQ1JTI4MTMlMjk3MDQyNC04JmFtcDthdGl0bGU9QWJpcmF0ZXJvbmUr

YWNldGF0ZStwbHVzK3ByZWRuaXNvbmUrdmVyc3VzK3ByZWRuaXNvbmUrYWxvbmUraW4rY2hlbW90

aGVyYXB5LW5haXZlK21lbit3aXRoK21ldGFzdGF0aWMrY2FzdHJhdGlvbi1yZXNpc3RhbnQrcHJv

c3RhdGUrY2FuY2VyJTNBK1BhdGllbnQtcmVwb3J0ZWQrb3V0Y29tZStyZXN1bHRzK29mK2ErcmFu

ZG9taXNlZCtwaGFzZSszK3RyaWFsJmFtcDtzdGl0bGU9TGFuY2V0K09uY29sLiZhbXA7dGl0bGU9

VGhlK0xhbmNldCtPbmNvbG9neSZhbXA7dm9sdW1lPTE0JmFtcDtpc3N1ZT0xMiZhbXA7c3BhZ2U9

MTE5MyZhbXA7ZXBhZ2U9MTE5OSZhbXA7YXVsYXN0PUJhc2NoJmFtcDthdWZpcnN0PUV0aGFuJmFt

cDthdWluaXQ9RS4mYW1wO2F1ZnVsbD1CYXNjaCtFLiZhbXA7Y29kZW49TE9BTkImYW1wO2lzYm49

JmFtcDtwYWdlcz0xMTkzLTExOTkmYW1wO2RhdGU9MjAxMyZhbXA7YXVpbml0MT1FJmFtcDthdWlu

aXRtPTwvdXJsPjx1cmw+aHR0cDovL3d3dy50aGVsYW5jZXQuY29tL2pvdXJuYWxzL2xhbm9uYy9h

cnRpY2xlL1BJSVMxNDcwLTIwNDUoMTMpNzA0MjQtOC9hYnN0cmFjdDwvdXJsPjwvcmVsYXRlZC11

cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5CZWVyPC9BdXRob3I+PFll

YXI+MjAxNDwvWWVhcj48UmVjTnVtPjE5NjM8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjE5

NjM8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ6enQ5NTVz

dzUyZHZ0Z2Vlc3Y2NXIwcGdkd3Z0OWV2Znd3ZWUiIHRpbWVzdGFtcD0iMTQzNzA1NTExOCI+MTk2

Mzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJFbGVjdHJvbmljIEFydGljbGUi

PjQzPC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+QmVlciwgVC4gTS48

L2F1dGhvcj48YXV0aG9yPkFybXN0cm9uZywgQS4gSi48L2F1dGhvcj48YXV0aG9yPlJhdGhrb3Bm

LCBELiBFLjwvYXV0aG9yPjxhdXRob3I+TG9yaW90LCBZLjwvYXV0aG9yPjxhdXRob3I+U3Rlcm5i

ZXJnLCBDLiBOLjwvYXV0aG9yPjxhdXRob3I+SGlnYW5vLCBDLiBTLjwvYXV0aG9yPjxhdXRob3I+

SXZlcnNlbiwgUC48L2F1dGhvcj48YXV0aG9yPkJoYXR0YWNoYXJ5YSwgUy48L2F1dGhvcj48YXV0

aG9yPkNhcmxlcywgSi48L2F1dGhvcj48YXV0aG9yPkNob3dkaHVyeSwgUy48L2F1dGhvcj48YXV0

aG9yPkRhdmlzLCBJLiBELjwvYXV0aG9yPjxhdXRob3I+Qm9ubywgSi4gUy48L2F1dGhvcj48YXV0

aG9yPkV2YW5zLCBDLiBQLjwvYXV0aG9yPjxhdXRob3I+Rml6YXppLCBLLjwvYXV0aG9yPjxhdXRo

b3I+Sm9zaHVhLCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+S2ltLCBDLiBTLjwvYXV0aG9yPjxhdXRo

b3I+S2ltdXJhLCBHLjwvYXV0aG9yPjxhdXRob3I+TWFpbndhcmluZywgUC48L2F1dGhvcj48YXV0

aG9yPk1hbnNiYWNoLCBILjwvYXV0aG9yPjxhdXRob3I+TWlsbGVyLCBLLjwvYXV0aG9yPjxhdXRo

b3I+Tm9vbmJlcmcsIFMuIEIuPC9hdXRob3I+PGF1dGhvcj5QZXJhYm8sIEYuPC9hdXRob3I+PGF1

dGhvcj5QaHVuZywgRC48L2F1dGhvcj48YXV0aG9yPlNhYWQsIEYuPC9hdXRob3I+PGF1dGhvcj5T

Y2hlciwgSC4gSS48L2F1dGhvcj48YXV0aG9yPlRhcGxpbiwgTS4gRS48L2F1dGhvcj48YXV0aG9y

PlZlbm5lciwgUC4gTS48L2F1dGhvcj48YXV0aG9yPlRvbWJhbCwgQi48L2F1dGhvcj48L2F1dGhv

cnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+RW56YWx1dGFtaWRlIGluIG1ldGFzdGF0

aWMgcHJvc3RhdGUgY2FuY2VyIGJlZm9yZSBjaGVtb3RoZXJhcHk8L3RpdGxlPjxzZWNvbmRhcnkt

dGl0bGU+VGhlIE5ldyBFbmdsYW5kIGpvdXJuYWwgb2YgbWVkaWNpbmU8L3NlY29uZGFyeS10aXRs

ZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5OIEVuZ2wgSiBNZWQ8L2Z1bGwtdGl0

bGU+PGFiYnItMT5UaGUgTmV3IEVuZ2xhbmQgam91cm5hbCBvZiBtZWRpY2luZTwvYWJici0xPjwv

cGVyaW9kaWNhbD48cGFnZXM+NDI0LTMzPC9wYWdlcz48dm9sdW1lPjM3MTwvdm9sdW1lPjxudW1i

ZXI+NTwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZGVub2NhcmNpbm9tYSBbZHJ1ZyB0aGVy

YXB5XSBbbW9ydGFsaXR5XSBbc2Vjb25kYXJ5XTwva2V5d29yZD48a2V5d29yZD5BZG1pbmlzdHJh

dGlvbiwgT3JhbDwva2V5d29yZD48a2V5d29yZD5BbmRyb2dlbiBSZWNlcHRvciBBbnRhZ29uaXN0

cyBbYWR2ZXJzZSBlZmZlY3RzXSBbdGhlcmFwZXV0aWMgdXNlXTwva2V5d29yZD48a2V5d29yZD5B

bnRpbmVvcGxhc3RpYyBBZ2VudHMsIEhvcm1vbmFsIFthZHZlcnNlIGVmZmVjdHNdIFt0aGVyYXBl

dXRpYyB1c2VdPC9rZXl3b3JkPjxrZXl3b3JkPkRpc2Vhc2UgUHJvZ3Jlc3Npb248L2tleXdvcmQ+

PGtleXdvcmQ+RG91YmxlLUJsaW5kIE1ldGhvZDwva2V5d29yZD48a2V5d29yZD5OZW9wbGFzbSBN

ZXRhc3Rhc2lzIFtyYWRpb2dyYXBoeV08L2tleXdvcmQ+PGtleXdvcmQ+UGhlbnlsdGhpb2h5ZGFu

dG9pbiBbYWR2ZXJzZSBlZmZlY3RzXSBbYW5hbG9ncyAmYW1wOyBkZXJpdmF0aXZlc10gW3RoZXJh

cGV1dGljIHVzZV08L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3RhdGljIE5lb3BsYXNtcyBbZHJ1ZyB0

aGVyYXB5XSBbbW9ydGFsaXR5XSBbcGF0aG9sb2d5XTwva2V5d29yZD48a2V5d29yZD5SZWNlcHRv

cnMsIEFuZHJvZ2VuPC9rZXl3b3JkPjxrZXl3b3JkPlN1cnZpdmFsIEFuYWx5c2lzPC9rZXl3b3Jk

PjxrZXl3b3JkPkh1bWFuc1tjaGVja3dvcmRdPC9rZXl3b3JkPjxrZXl3b3JkPk1hbGVbY2hlY2t3

b3JkXTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDE0PC95ZWFyPjwvZGF0ZXM+

PGFjY2Vzc2lvbi1udW0+Q04tMDA5OTY2ODU8L2FjY2Vzc2lvbi1udW0+PHdvcmstdHlwZT5DbGlu

aWNhbCBUcmlhbCwgUGhhc2UgSUlJOyBNdWx0aWNlbnRlciBTdHVkeTsgUmFuZG9taXplZCBDb250

cm9sbGVkIFRyaWFsOyBSZXNlYXJjaCBTdXBwb3J0LCBOb24tVS5TLiBHb3YmYXBvczt0PC93b3Jr

LXR5cGU+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly9vbmxpbmVsaWJyYXJ5LndpbGV5

LmNvbS9vL2NvY2hyYW5lL2NsY2VudHJhbC9hcnRpY2xlcy82ODUvQ04tMDA5OTY2ODUvZnJhbWUu

aHRtbDwvdXJsPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L3BtYy9hcnRpY2xlcy9Q

TUM0NDE4OTMxL3BkZi9uaWhtczY3Nzc2MS5wZGY8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+

PGN1c3RvbTM+UHVibWVkIDI0ODgxNzMwPC9jdXN0b20zPjxlbGVjdHJvbmljLXJlc291cmNlLW51

bT4xMC4xMDU2L05FSk1vYTE0MDUwOTU8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwvcmVjb3Jk

PjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPkhvc2tpbjwvQXV0aG9yPjxZZWFyPjIwMTQ8L1llYXI+PFJl

Y051bT4xMzY3PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xMzY3PC9yZWMtbnVtYmVyPjxm

b3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0ienp0OTU1c3c1MmR2dGdlZXN2NjVyMHBn

ZHd2dDlldmZ3d2VlIiB0aW1lc3RhbXA9IjE0MzcwNDc2NjciPjEzNjc8L2tleT48L2ZvcmVpZ24t

a2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRy

aWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkhvc2tpbiwgUC48L2F1dGhvcj48YXV0aG9yPlNhcnRv

ciwgTy48L2F1dGhvcj48YXV0aG9yPk8mYXBvcztTdWxsaXZhbiwgSi4gTS48L2F1dGhvcj48YXV0

aG9yPkpvaGFubmVzc2VuLCBELiBDLjwvYXV0aG9yPjxhdXRob3I+SGVsbGUsIFMuIEkuPC9hdXRo

b3I+PGF1dGhvcj5Mb2d1ZSwgSi48L2F1dGhvcj48YXV0aG9yPkJvdHRvbWxleSwgRC48L2F1dGhv

cj48YXV0aG9yPk5pbHNzb24sIFMuPC9hdXRob3I+PGF1dGhvcj5Wb2dlbHphbmcsIE4uIEouPC9h

dXRob3I+PGF1dGhvcj5GYW5nLCBGLjwvYXV0aG9yPjxhdXRob3I+V2FoYmEsIE0uPC9hdXRob3I+

PGF1dGhvcj5Ba3NuZXMsIEEuIEsuPC9hdXRob3I+PGF1dGhvcj5QYXJrZXIsIEMuPC9hdXRob3I+

PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+UC4gSG9za2luLCBNb3VudCBW

ZXJub24gQ2FuY2VyIENlbnRyZSwgTm9ydGh3b29kLCBNaWRkbGVzZXgsIFVuaXRlZCBLaW5nZG9t

PC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+RWZmaWNhY3kgYW5kIHNhZmV0eSBvZiByYWRp

dW0tMjIzIGRpY2hsb3JpZGUgaW4gcGF0aWVudHMgd2l0aCBjYXN0cmF0aW9uLXJlc2lzdGFudCBw

cm9zdGF0ZSBjYW5jZXIgYW5kIHN5bXB0b21hdGljIGJvbmUgbWV0YXN0YXNlcywgd2l0aCBvciB3

aXRob3V0IHByZXZpb3VzIGRvY2V0YXhlbCB1c2U6IEEgcHJlc3BlY2lmaWVkIHN1Ymdyb3VwIGFu

YWx5c2lzIGZyb20gdGhlIHJhbmRvbWlzZWQsIGRvdWJsZS1ibGluZCwgcGhhc2UgMyBBTFNZTVBD

QSB0cmlhbDwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5UaGUgTGFuY2V0IE9uY29sb2d5PC9zZWNv

bmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+VGhlIExhbmNldCBP

bmNvbG9neTwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjEzOTctMTQwNjwvcGFnZXM+

PHZvbHVtZT4xNTwvdm9sdW1lPjxudW1iZXI+MTI8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+

TkNUMDA2OTk3NTE8L2tleXdvcmQ+PGtleXdvcmQ+ZG9jZXRheGVsPC9rZXl3b3JkPjxrZXl3b3Jk

PnBsYWNlYm88L2tleXdvcmQ+PGtleXdvcmQ+cmFkaXVtIGNobG9yaWRlIHJhIDIyMzwva2V5d29y

ZD48a2V5d29yZD5hZHVsdDwva2V5d29yZD48a2V5d29yZD5hZ2VkPC9rZXl3b3JkPjxrZXl3b3Jk

PmFuZW1pYTwva2V5d29yZD48a2V5d29yZD5hbm9yZXhpYTwva2V5d29yZD48a2V5d29yZD5hcnRp

Y2xlPC9rZXl3b3JkPjxrZXl3b3JkPmJsb29kIHRveGljaXR5PC9rZXl3b3JkPjxrZXl3b3JkPmJv

bmUgbWFycm93IHN1cHByZXNzaW9uPC9rZXl3b3JkPjxrZXl3b3JkPmJvbmUgbWV0YXN0YXNpczwv

a2V5d29yZD48a2V5d29yZD5ib25lIHBhaW48L2tleXdvcmQ+PGtleXdvcmQ+Y2FuY2VyIGdyb3d0

aDwva2V5d29yZD48a2V5d29yZD5jYXN0cmF0aW9uIHJlc2lzdGFudCBwcm9zdGF0ZSBjYW5jZXI8

L2tleXdvcmQ+PGtleXdvcmQ+Y29uc3RpcGF0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPmNvbnRyb2xs

ZWQgc3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+ZGlhcnJoZWE8L2tleXdvcmQ+PGtleXdvcmQ+ZG91

YmxlIGJsaW5kIHByb2NlZHVyZTwva2V5d29yZD48a2V5d29yZD5kcnVnIGVmZmljYWN5PC9rZXl3

b3JkPjxrZXl3b3JkPmRydWcgZmF0YWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+ZHJ1ZyBzYWZldHk8

L2tleXdvcmQ+PGtleXdvcmQ+ZHJ1ZyB0b2xlcmFiaWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+ZHJ1

ZyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+ZHJ1ZyB3aXRoZHJhd2FsPC9rZXl3b3JkPjxrZXl3b3Jk

PmZhdGlndWU8L2tleXdvcmQ+PGtleXdvcmQ+ZmVicmlsZSBuZXV0cm9wZW5pYTwva2V5d29yZD48

a2V5d29yZD5odW1hbjwva2V5d29yZD48a2V5d29yZD5pbnRlbnRpb24gdG8gdHJlYXQgYW5hbHlz

aXM8L2tleXdvcmQ+PGtleXdvcmQ+aW50ZXJhY3RpdmUgdm9pY2UgcmVzcG9uc2Ugc3lzdGVtPC9r

ZXl3b3JkPjxrZXl3b3JkPkthcm5vZnNreSBQZXJmb3JtYW5jZSBTdGF0dXM8L2tleXdvcmQ+PGtl

eXdvcmQ+bGV1a29wZW5pYTwva2V5d29yZD48a2V5d29yZD5tYWpvciBjbGluaWNhbCBzdHVkeTwv

a2V5d29yZD48a2V5d29yZD5tYWxlPC9rZXl3b3JkPjxrZXl3b3JkPm11bHRpY2VudGVyIHN0dWR5

PC9rZXl3b3JkPjxrZXl3b3JkPm5hdXNlYTwva2V5d29yZD48a2V5d29yZD5uZXV0cm9wZW5pYTwv

a2V5d29yZD48a2V5d29yZD5vdXRjb21lIGFzc2Vzc21lbnQ8L2tleXdvcmQ+PGtleXdvcmQ+b3Zl

cmFsbCBzdXJ2aXZhbDwva2V5d29yZD48a2V5d29yZD5wYW5jeXRvcGVuaWE8L2tleXdvcmQ+PGtl

eXdvcmQ+cGVyaXBoZXJhbCBlZGVtYTwva2V5d29yZD48a2V5d29yZD5waGFzZSAzIGNsaW5pY2Fs

IHRyaWFsPC9rZXl3b3JkPjxrZXl3b3JkPnJhbmRvbWl6ZWQgY29udHJvbGxlZCB0cmlhbDwva2V5

d29yZD48a2V5d29yZD5zaWRlIGVmZmVjdDwva2V5d29yZD48a2V5d29yZD5zdXJ2aXZhbCB0aW1l

PC9rZXl3b3JkPjxrZXl3b3JkPnRocm9tYm9jeXRvcGVuaWE8L2tleXdvcmQ+PGtleXdvcmQ+dXJp

bmFyeSB0cmFjdCBpbmZlY3Rpb248L2tleXdvcmQ+PGtleXdvcmQ+dmlzY2VyYWwgbWV0YXN0YXNp

czwva2V5d29yZD48a2V5d29yZD52b21pdGluZzwva2V5d29yZD48a2V5d29yZD53ZWlnaHQgcmVk

dWN0aW9uPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8L3llYXI+PC9kYXRl

cz48aXNibj4xNDc0LTU0ODgmI3hEOzE0NzAtMjA0NTwvaXNibj48dXJscz48cmVsYXRlZC11cmxz

Pjx1cmw+aHR0cDovL3d3dy5lbWJhc2UuY29tL3NlYXJjaC9yZXN1bHRzP3N1YmFjdGlvbj12aWV3

cmVjb3JkJmFtcDtmcm9tPWV4cG9ydCZhbXA7aWQ9TDYwMDM2NzIyOTwvdXJsPjx1cmw+aHR0cDov

L2R4LmRvaS5vcmcvMTAuMTAxNi9TMTQ3MC0yMDQ1KDE0KTcwNDc0LTc8L3VybD48dXJsPmh0dHA6

Ly9zZngubGlicmFyeS51dS5ubC91dHJlY2h0P3NpZD1FTUJBU0UmYW1wO2lzc249MTQ3NDU0ODgm

YW1wO2lkPWRvaToxMC4xMDE2JTJGUzE0NzAtMjA0NSUyODE0JTI5NzA0NzQtNyZhbXA7YXRpdGxl

PUVmZmljYWN5K2FuZCtzYWZldHkrb2YrcmFkaXVtLTIyMytkaWNobG9yaWRlK2luK3BhdGllbnRz

K3dpdGgrY2FzdHJhdGlvbi1yZXNpc3RhbnQrcHJvc3RhdGUrY2FuY2VyK2FuZCtzeW1wdG9tYXRp

Yytib25lK21ldGFzdGFzZXMlMkMrd2l0aCtvcit3aXRob3V0K3ByZXZpb3VzK2RvY2V0YXhlbCt1

c2UlM0ErQStwcmVzcGVjaWZpZWQrc3ViZ3JvdXArYW5hbHlzaXMrZnJvbSt0aGUrcmFuZG9taXNl

ZCUyQytkb3VibGUtYmxpbmQlMkMrcGhhc2UrMytBTFNZTVBDQSt0cmlhbCZhbXA7c3RpdGxlPUxh

bmNldCtPbmNvbC4mYW1wO3RpdGxlPVRoZStMYW5jZXQrT25jb2xvZ3kmYW1wO3ZvbHVtZT0xNSZh

bXA7aXNzdWU9MTImYW1wO3NwYWdlPTEzOTcmYW1wO2VwYWdlPTE0MDYmYW1wO2F1bGFzdD1Ib3Nr

aW4mYW1wO2F1Zmlyc3Q9UGV0ZXImYW1wO2F1aW5pdD1QLiZhbXA7YXVmdWxsPUhvc2tpbitQLiZh

bXA7Y29kZW49TE9BTkImYW1wO2lzYm49JmFtcDtwYWdlcz0xMzk3LTE0MDYmYW1wO2RhdGU9MjAx

NCZhbXA7YXVpbml0MT1QJmFtcDthdWluaXRtPTwvdXJsPjx1cmw+aHR0cDovL3d3dy50aGVsYW5j

ZXQuY29tL2pvdXJuYWxzL2xhbm9uYy9hcnRpY2xlL1BJSVMxNDcwLTIwNDUoMTQpNzA0NzQtNy9h

YnN0cmFjdDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PENpdGU+

PEF1dGhvcj5LYW50b2ZmPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48UmVjTnVtPjIyMDE8L1Jl

Y051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjIyMDE8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48

a2V5IGFwcD0iRU4iIGRiLWlkPSJ6enQ5NTVzdzUyZHZ0Z2Vlc3Y2NXIwcGdkd3Z0OWV2Znd3ZWUi

IHRpbWVzdGFtcD0iMTQ0MDY2NDM4MyI+MjIwMTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlw

ZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRo

b3JzPjxhdXRob3I+S2FudG9mZiwgUC4gVy48L2F1dGhvcj48YXV0aG9yPkhpZ2FubywgQy4gUy48

L2F1dGhvcj48YXV0aG9yPlNob3JlLCBOLiBELjwvYXV0aG9yPjxhdXRob3I+QmVyZ2VyLCBFLiBS

LjwvYXV0aG9yPjxhdXRob3I+U21hbGwsIEUuIEouPC9hdXRob3I+PGF1dGhvcj5QZW5zb24sIEQu

IEYuPC9hdXRob3I+PGF1dGhvcj5SZWRmZXJuLCBDLiBILjwvYXV0aG9yPjxhdXRob3I+RmVycmFy

aSwgQS4gQy48L2F1dGhvcj48YXV0aG9yPkRyZWljZXIsIFIuPC9hdXRob3I+PGF1dGhvcj5TaW1z

LCBSLiBCLjwvYXV0aG9yPjxhdXRob3I+WHUsIFkuPC9hdXRob3I+PGF1dGhvcj5Gcm9obGljaCwg

TS4gVy48L2F1dGhvcj48YXV0aG9yPlNjaGVsbGhhbW1lciwgUC4gRi48L2F1dGhvcj48L2F1dGhv

cnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EYW5hLUZhcmJlciBDYW5jZXIgSW5zdGl0

dXRlLCBIYXJ2YXJkIE1lZGljYWwgU2Nob29sLCBCb3N0b24sIE1BIDAyMTE1LCBVU0EuIHBoaWxp

cF9rYW50b2ZmQGRmY2kuaGFydmFyZC5lZHU8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5T

aXB1bGV1Y2VsLVQgaW1tdW5vdGhlcmFweSBmb3IgY2FzdHJhdGlvbi1yZXNpc3RhbnQgcHJvc3Rh

dGUgY2FuY2VyPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPk4gRW5nbCBKIE1lZDwvc2Vjb25kYXJ5

LXRpdGxlPjxhbHQtdGl0bGU+VGhlIE5ldyBFbmdsYW5kIGpvdXJuYWwgb2YgbWVkaWNpbmU8L2Fs

dC10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5OIEVuZ2wgSiBNZWQ8L2Z1

bGwtdGl0bGU+PGFiYnItMT5UaGUgTmV3IEVuZ2xhbmQgam91cm5hbCBvZiBtZWRpY2luZTwvYWJi

ci0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+TiBFbmdsIEogTWVk

PC9mdWxsLXRpdGxlPjxhYmJyLTE+VGhlIE5ldyBFbmdsYW5kIGpvdXJuYWwgb2YgbWVkaWNpbmU8

L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz40MTEtMjI8L3BhZ2VzPjx2b2x1bWU+MzYz

PC92b2x1bWU+PG51bWJlcj41PC9udW1iZXI+PGVkaXRpb24+MjAxMC8wOS8wODwvZWRpdGlvbj48

a2V5d29yZHM+PGtleXdvcmQ+QWdlZDwva2V5d29yZD48a2V5d29yZD5BZ2VkLCA4MCBhbmQgb3Zl

cjwva2V5d29yZD48a2V5d29yZD5BbmRyb2dlbiBBbnRhZ29uaXN0cy90aGVyYXBldXRpYyB1c2U8

L2tleXdvcmQ+PGtleXdvcmQ+QW50aWdlbi1QcmVzZW50aW5nIENlbGxzPC9rZXl3b3JkPjxrZXl3

b3JkPkFudGluZW9wbGFzdGljIEFnZW50cy90aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdv

cmQ+Q2FuY2VyIFZhY2NpbmVzL2FkdmVyc2UgZWZmZWN0cy8gdGhlcmFwZXV0aWMgdXNlPC9rZXl3

b3JkPjxrZXl3b3JkPkNlbGwgQ3VsdHVyZSBUZWNobmlxdWVzPC9rZXl3b3JkPjxrZXl3b3JkPkNv

bWJpbmVkIE1vZGFsaXR5IFRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+RGlzZWFzZSBQcm9ncmVz

c2lvbjwva2V5d29yZD48a2V5d29yZD5Eb3VibGUtQmxpbmQgTWV0aG9kPC9rZXl3b3JkPjxrZXl3

b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5JbW11bm90aGVyYXB5L2FkdmVyc2UgZWZmZWN0

czwva2V5d29yZD48a2V5d29yZD5JbmZ1c2lvbnMsIEludHJhdmVub3VzPC9rZXl3b3JkPjxrZXl3

b3JkPkludGVyY2VsbHVsYXIgQWRoZXNpb24gTW9sZWN1bGUtMS9hZHZlcnNlIGVmZmVjdHMvIHRo

ZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5LYXBsYW4tTWVpZXIgRXN0aW1hdGU8L2tl

eXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NaWRkbGUgQWdlZDwva2V5d29y

ZD48a2V5d29yZD5Qcm9wb3J0aW9uYWwgSGF6YXJkcyBNb2RlbHM8L2tleXdvcmQ+PGtleXdvcmQ+

UHJvc3RhdGljIE5lb3BsYXNtcy9kcnVnIHRoZXJhcHkvbW9ydGFsaXR5LyB0aGVyYXB5PC9rZXl3

b3JkPjxrZXl3b3JkPlRpc3N1ZSBFeHRyYWN0cy9hZHZlcnNlIGVmZmVjdHMvIHRoZXJhcGV1dGlj

IHVzZTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDEwPC95ZWFyPjxwdWItZGF0

ZXM+PGRhdGU+SnVsIDI5PC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTUzMy00NDA2

IChFbGVjdHJvbmljKSYjeEQ7MDAyOC00NzkzIChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51

bT4yMDgxODg2MjwvYWNjZXNzaW9uLW51bT48dXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3Vy

Y2UtbnVtPjEwLjEwNTYvTkVKTW9hMTAwMTI5NDwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PHJl

bW90ZS1kYXRhYmFzZS1wcm92aWRlcj5OTE08L3JlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj48bGFu

Z3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5Mb3Jpb3Q8

L0F1dGhvcj48WWVhcj4yMDE1PC9ZZWFyPjxSZWNOdW0+OTwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1u

dW1iZXI+OTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9Inp6

dDk1NXN3NTJkdnRnZWVzdjY1cjBwZ2R3dnQ5ZXZmd3dlZSIgdGltZXN0YW1wPSIxNDM3MDQ3MDgz

Ij45PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+

MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5Mb3Jpb3QsIFkuPC9h

dXRob3I+PGF1dGhvcj5NaWxsZXIsIEsuPC9hdXRob3I+PGF1dGhvcj5TdGVybmJlcmcsIEMuIE4u

PC9hdXRob3I+PGF1dGhvcj5GaXphemksIEsuPC9hdXRob3I+PGF1dGhvcj5EZSBCb25vLCBKLiBT

LjwvYXV0aG9yPjxhdXRob3I+Q2hvd2RodXJ5LCBTLjwvYXV0aG9yPjxhdXRob3I+SGlnYW5vLCBD

LiBTLjwvYXV0aG9yPjxhdXRob3I+Tm9vbmJlcmcsIFMuPC9hdXRob3I+PGF1dGhvcj5Ib2xtc3Ry

b20sIFMuPC9hdXRob3I+PGF1dGhvcj5NYW5zYmFjaCwgSC48L2F1dGhvcj48YXV0aG9yPlBlcmFi

bywgRi4gRy48L2F1dGhvcj48YXV0aG9yPlBodW5nLCBELjwvYXV0aG9yPjxhdXRob3I+SXZhbmVz

Y3UsIEMuPC9hdXRob3I+PGF1dGhvcj5Ta2FsdHNhLCBLLjwvYXV0aG9yPjxhdXRob3I+QmVlciwg

VC4gTS48L2F1dGhvcj48YXV0aG9yPlRvbWJhbCwgQi48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250

cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIENhbmNlciBNZWRpY2luZSwgSW5z

dGl0dXQgR3VzdGF2ZSBSb3Vzc3ksIFVuaXZlcnNpdHkgb2YgUGFyaXMgU3VkLCBWaWxsZWp1aWYs

IEZyYW5jZS4gRWxlY3Ryb25pYyBhZGRyZXNzOiB5b2hhbm4ubG9yaW90QGd1c3RhdmVyb3Vzc3ku

ZnIuJiN4RDtEZXBhcnRtZW50IG9mIFVyb2xvZ3ksIENoYXJpdGUtVW5pdmVyc2l0YXRzbWVkaXpp

biBCZXJsaW4sIEJlcmxpbiwgR2VybWFueS4mI3hEO0RlcGFydG1lbnQgb2YgTWVkaWNhbCBPbmNv

bG9neSwgU2FuIENhbWlsbG8gYW5kIEZvcmxhbmluaSBIb3NwaXRhbHMsIFJvbWUsIEl0YWx5LiYj

eEQ7RGVwYXJ0bWVudCBvZiBDYW5jZXIgTWVkaWNpbmUsIEluc3RpdHV0IEd1c3RhdmUgUm91c3N5

LCBVbml2ZXJzaXR5IG9mIFBhcmlzIFN1ZCwgVmlsbGVqdWlmLCBGcmFuY2UuJiN4RDtEcnVnIERl

dmVsb3BtZW50IFVuaXQsIFJveWFsIE1hcnNkZW4gSG9zcGl0YWwgYW5kIEluc3RpdHV0ZSBvZiBD

YW5jZXIgUmVzZWFyY2gsIExvbmRvbiwgVUsuJiN4RDtEZXBhcnRtZW50IG9mIFVyb2xvZ3ksIEd1

eXMgYW5kIFN0IFRob21hcyZhcG9zOyBIb3NwaXRhbCwgTG9uZG9uLCBVSy4mI3hEO0RlcGFydG1l

bnQgb2YgTWVkaWNpbmUsIERpdmlzaW9uIG9mIE1lZGljYWwgT25jb2xvZ3ksIFVuaXZlcnNpdHkg

b2YgV2FzaGluZ3Rvbi9GcmVkIEh1dGNoaW5zb24gQ2FuY2VyIFJlc2VhcmNoIENlbnRlciwgU2Vh

dHRsZSwgV0EsIFVTQS4mI3hEO0RlcGFydG1lbnQgb2YgRWFybHkgQ2xpbmljYWwgRGV2ZWxvcG1l

bnQsIE1lZGl2YXRpb24sIFNhbiBGcmFuY2lzY28sIENBLCBVU0EuJiN4RDtIZWFsdGggRWNvbm9t

aWNzIGFuZCBPdXRjb21lcyBSZXNlYXJjaCwgQXN0ZWxsYXMgUGhhcm1hIEV1cm9wZSwgTGVpZGVu

LCBOZXRoZXJsYW5kcy4mI3hEO0RlcGFydG1lbnQgb2YgTWVkaWNhbCBBZmZhaXJzLCBNZWRpdmF0

aW9uLCBTYW4gRnJhbmNpc2NvLCBDQSwgVVNBLiYjeEQ7QXN0ZWxsYXMgUGhhcm1hIEdsb2JhbCBE

ZXZlbG9wbWVudCwgTm9ydGhicm9vaywgSUwsIFVTQS4mI3hEO0NvbnN1bHRpbmcsIFF1aW50aWxl

cywgSG9vZmRkb3JwLCBOZXRoZXJsYW5kcy4mI3hEO0NvbnN1bHRpbmcsIFF1aW50aWxlcywgQmFy

Y2Vsb25hLCBTcGFpbjsgRGVwYXJ0bWVudCBvZiBQdWJsaWMgSGVhbHRoLCBVbml2ZXJzaXR5IG9m

IEJhcmNlbG9uYSwgQmFyY2Vsb25hLCBTcGFpbi4mI3hEO0RpdmlzaW9uIG9mIEhlbWF0b2xvZ3kg

YW5kIE1lZGljYWwgT25jb2xvZ3ksIE9IU1UgS25pZ2h0IENhbmNlciBJbnN0aXR1dGUsIE9yZWdv

biBIZWFsdGggJmFtcDsgU2NpZW5jZSBVbml2ZXJzaXR5LCBQb3J0bGFuZCwgT1IsIFVTQS4mI3hE

O0RlcGFydG1lbnQgb2YgVXJvbG9neSwgQ2xpbmlxdWVzIFVuaXZlcnNpdGFpcmVzIFNhaW50LUx1

YywgQnJ1c3NlbHMsIEJlbGdpdW0uPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+RWZmZWN0

IG9mIGVuemFsdXRhbWlkZSBvbiBoZWFsdGgtcmVsYXRlZCBxdWFsaXR5IG9mIGxpZmUsIHBhaW4s

IGFuZCBza2VsZXRhbC1yZWxhdGVkIGV2ZW50cyBpbiBhc3ltcHRvbWF0aWMgYW5kIG1pbmltYWxs

eSBzeW1wdG9tYXRpYywgY2hlbW90aGVyYXB5LW5haXZlIHBhdGllbnRzIHdpdGggbWV0YXN0YXRp

YyBjYXN0cmF0aW9uLXJlc2lzdGFudCBwcm9zdGF0ZSBjYW5jZXIgKFBSRVZBSUwpOiByZXN1bHRz

IGZyb20gYSByYW5kb21pc2VkLCBwaGFzZSAzIHRyaWFsPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxl

PkxhbmNldCBPbmNvbDwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+VGhlIExhbmNldC4gT25j

b2xvZ3k8L2FsdC10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5MYW5jZXQg

T25jb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5UaGUgTGFuY2V0LiBPbmNvbG9neTwvYWJici0xPjwv

cGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+TGFuY2V0IE9uY29sPC9mdWxs

LXRpdGxlPjxhYmJyLTE+VGhlIExhbmNldC4gT25jb2xvZ3k8L2FiYnItMT48L2FsdC1wZXJpb2Rp

Y2FsPjxwYWdlcz41MDktMjE8L3BhZ2VzPjx2b2x1bWU+MTY8L3ZvbHVtZT48bnVtYmVyPjU8L251

bWJlcj48ZWRpdGlvbj4yMDE1LzA0LzE5PC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5BZG9s

ZXNjZW50PC9rZXl3b3JkPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxrZXl3b3JkPkFnZWQ8L2tl

eXdvcmQ+PGtleXdvcmQ+QW50aW5lb3BsYXN0aWMgQ29tYmluZWQgQ2hlbW90aGVyYXB5IFByb3Rv

Y29scy8qYWRtaW5pc3RyYXRpb24gJmFtcDsgZG9zYWdlL2FkdmVyc2U8L2tleXdvcmQ+PGtleXdv

cmQ+ZWZmZWN0czwva2V5d29yZD48a2V5d29yZD5EaXNlYXNlLUZyZWUgU3Vydml2YWw8L2tleXdv

cmQ+PGtleXdvcmQ+RG91YmxlLUJsaW5kIE1ldGhvZDwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8

L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NaWRkbGUgQWdlZDwva2V5

d29yZD48a2V5d29yZD5OZW9wbGFzbSBNZXRhc3Rhc2lzPC9rZXl3b3JkPjxrZXl3b3JkPlBhaW4v

KmRydWcgdGhlcmFweS9wYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+UGhlbnlsdGhpb2h5ZGFu

dG9pbi9hZG1pbmlzdHJhdGlvbiAmYW1wOyBkb3NhZ2UvYWR2ZXJzZSBlZmZlY3RzLyphbmFsb2dz

ICZhbXA7PC9rZXl3b3JkPjxrZXl3b3JkPmRlcml2YXRpdmVzPC9rZXl3b3JkPjxrZXl3b3JkPlBy

b3N0YXRpYyBOZW9wbGFzbXMsIENhc3RyYXRpb24tUmVzaXN0YW50LypkcnVnIHRoZXJhcHkvcGF0

aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPlF1YWxpdHkgb2YgTGlmZTwva2V5d29yZD48L2tleXdv

cmRzPjxkYXRlcz48eWVhcj4yMDE1PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+TWF5PC9kYXRlPjwv

cHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTQ3MC0yMDQ1PC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI1

ODg4MjYzPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3

LnRoZWxhbmNldC5jb20vam91cm5hbHMvbGFub25jL2FydGljbGUvUElJUzE0NzAtMjA0NSgxNSk3

MDExMy0wL2Fic3RyYWN0PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJl

c291cmNlLW51bT4xMC4xMDE2L3MxNDcwLTIwNDUoMTUpNzAxMTMtMDwvZWxlY3Ryb25pYy1yZXNv

dXJjZS1udW0+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5ObG08L3JlbW90ZS1kYXRhYmFzZS1w

cm92aWRlcj48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1

dGhvcj5Nb3JyaXM8L0F1dGhvcj48WWVhcj4yMDE1PC9ZZWFyPjxSZWNOdW0+MTIwODwvUmVjTnVt

PjxyZWNvcmQ+PHJlYy1udW1iZXI+MTIwODwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkg

YXBwPSJFTiIgZGItaWQ9Inp6dDk1NXN3NTJkdnRnZWVzdjY1cjBwZ2R3dnQ5ZXZmd3dlZSIgdGlt

ZXN0YW1wPSIxNDM3MDQ3NjY3Ij4xMjA4PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5h

bWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+

PGF1dGhvcj5Nb3JyaXMsIE0uIEouPC9hdXRob3I+PGF1dGhvcj5Nb2xpbmEsIEEuPC9hdXRob3I+

PGF1dGhvcj5TbWFsbCwgRS4gSi48L2F1dGhvcj48YXV0aG9yPkRlIEJvbm8sIEouIFMuPC9hdXRo

b3I+PGF1dGhvcj5Mb2dvdGhldGlzLCBDLiBKLjwvYXV0aG9yPjxhdXRob3I+Rml6YXppLCBLLjwv

YXV0aG9yPjxhdXRob3I+RGUgU291emEsIFAuPC9hdXRob3I+PGF1dGhvcj5LYW50b2ZmLCBQLiBX

LjwvYXV0aG9yPjxhdXRob3I+SGlnYW5vLCBDLiBTLjwvYXV0aG9yPjxhdXRob3I+TGksIEouPC9h

dXRob3I+PGF1dGhvcj5LaGVvaCwgVC48L2F1dGhvcj48YXV0aG9yPkxhcnNvbiwgUy4gTS48L2F1

dGhvcj48YXV0aG9yPk1hdGhlbnksIFMuIEwuPC9hdXRob3I+PGF1dGhvcj5OYWluaSwgVi48L2F1

dGhvcj48YXV0aG9yPkJ1cnp5a293c2tpLCBULjwvYXV0aG9yPjxhdXRob3I+R3JpZmZpbiwgVC4g

Vy48L2F1dGhvcj48YXV0aG9yPlNjaGVyLCBILiBJLjwvYXV0aG9yPjxhdXRob3I+UnlhbiwgQy4g

Si48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5NLkouIE1v

cnJpcywgR2VuaXRvdXJpbmFyeSBPbmNvbG9neSBTZXJ2aWNlLCBNZW1vcmlhbCBTbG9hbiBLZXR0

ZXJpbmcgQ2FuY2VyIENlbnRlciwgU2lkbmV5IEtpbW1lbCBDZW50ZXIgZm9yIFByb3N0YXRlIGFu

ZCBVcm9sb2dpYyBDYW5jZXJzLCBOZXcgWW9yaywgVW5pdGVkIFN0YXRlczwvYXV0aC1hZGRyZXNz

Pjx0aXRsZXM+PHRpdGxlPlJhZGlvZ3JhcGhpYyBwcm9ncmVzc2lvbi1mcmVlIHN1cnZpdmFsIGFz

IGEgcmVzcG9uc2UgYmlvbWFya2VyIGluIG1ldGFzdGF0aWMgY2FzdHJhdGlvbi1yZXNpc3RhbnQg

cHJvc3RhdGUgY2FuY2VyOiBDT1UtQUEtMzAyIHJlc3VsdHM8L3RpdGxlPjxzZWNvbmRhcnktdGl0

bGU+Sm91cm5hbCBvZiBDbGluaWNhbCBPbmNvbG9neTwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVz

PjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkpvdXJuYWwgb2YgQ2xpbmljYWwgT25jb2xvZ3k8L2Z1

bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz4xMzU2LTEzNjM8L3BhZ2VzPjx2b2x1bWU+MzM8

L3ZvbHVtZT48bnVtYmVyPjEyPC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPmFiaXJhdGVyb25l

IGFjZXRhdGU8L2tleXdvcmQ+PGtleXdvcmQ+YmlvbG9naWNhbCBtYXJrZXI8L2tleXdvcmQ+PGtl

eXdvcmQ+cHJlZG5pc29uZTwva2V5d29yZD48a2V5d29yZD5hcnRpY2xlPC9rZXl3b3JkPjxrZXl3

b3JkPmJvbmUgc2NpbnRpc2Nhbm5pbmc8L2tleXdvcmQ+PGtleXdvcmQ+Y2FuY2VyIHBhdGllbnQ8

L2tleXdvcmQ+PGtleXdvcmQ+Y2FuY2VyIHN0YWdpbmc8L2tleXdvcmQ+PGtleXdvcmQ+Y2FzdHJh

dGlvbiByZXNpc3RhbnQgcHJvc3RhdGUgY2FuY2VyPC9rZXl3b3JkPjxrZXl3b3JkPmh1bWFuPC9r

ZXl3b3JkPjxrZXl3b3JkPm1ham9yIGNsaW5pY2FsIHN0dWR5PC9rZXl3b3JkPjxrZXl3b3JkPm1h

bGU8L2tleXdvcmQ+PGtleXdvcmQ+bWV0YXN0YXNpczwva2V5d29yZD48a2V5d29yZD5vdmVyYWxs

IHN1cnZpdmFsPC9rZXl3b3JkPjxrZXl3b3JkPnByaW9yaXR5IGpvdXJuYWw8L2tleXdvcmQ+PGtl

eXdvcmQ+cHJvZ3Jlc3Npb24gZnJlZSBzdXJ2aXZhbDwva2V5d29yZD48a2V5d29yZD5xdWFudGl0

YXRpdmUgYW5hbHlzaXM8L2tleXdvcmQ+PGtleXdvcmQ+cmFkaW9ncmFwaGljIHByb2dyZXNzaW9u

IGZyZWUgc3Vydml2YWw8L2tleXdvcmQ+PGtleXdvcmQ+cmFuZG9taXplZCBjb250cm9sbGVkIHRy

aWFsICh0b3BpYyk8L2tleXdvcmQ+PGtleXdvcmQ+cmVwcm9kdWNpYmlsaXR5PC9rZXl3b3JkPjxr

ZXl3b3JkPnRyZWF0bWVudCByZXNwb25zZTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVh

cj4yMDE1PC95ZWFyPjwvZGF0ZXM+PGlzYm4+MTUyNy03NzU1JiN4RDswNzMyLTE4M1g8L2lzYm4+

PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cuZW1iYXNlLmNvbS9zZWFyY2gvcmVz

dWx0cz9zdWJhY3Rpb249dmlld3JlY29yZCZhbXA7ZnJvbT1leHBvcnQmYW1wO2lkPUw2MDQ0MjU1

NDc8L3VybD48dXJsPmh0dHA6Ly9keC5kb2kub3JnLzEwLjEyMDAvSkNPLjIwMTQuNTUuMzg3NTwv

dXJsPjx1cmw+aHR0cDovL3NmeC5saWJyYXJ5LnV1Lm5sL3V0cmVjaHQ/c2lkPUVNQkFTRSZhbXA7

aXNzbj0xNTI3Nzc1NSZhbXA7aWQ9ZG9pOjEwLjEyMDAlMkZKQ08uMjAxNC41NS4zODc1JmFtcDth

dGl0bGU9UmFkaW9ncmFwaGljK3Byb2dyZXNzaW9uLWZyZWUrc3Vydml2YWwrYXMrYStyZXNwb25z

ZStiaW9tYXJrZXIraW4rbWV0YXN0YXRpYytjYXN0cmF0aW9uLXJlc2lzdGFudCtwcm9zdGF0ZStj

YW5jZXIlM0ErQ09VLUFBLTMwMityZXN1bHRzJmFtcDtzdGl0bGU9Si4rQ2xpbi4rT25jb2wuJmFt

cDt0aXRsZT1Kb3VybmFsK29mK0NsaW5pY2FsK09uY29sb2d5JmFtcDt2b2x1bWU9MzMmYW1wO2lz

c3VlPTEyJmFtcDtzcGFnZT0xMzU2JmFtcDtlcGFnZT0xMzYzJmFtcDthdWxhc3Q9TW9ycmlzJmFt

cDthdWZpcnN0PU1pY2hhZWwrSi4mYW1wO2F1aW5pdD1NLkouJmFtcDthdWZ1bGw9TW9ycmlzK00u

Si4mYW1wO2NvZGVuPUpDT05EJmFtcDtpc2JuPSZhbXA7cGFnZXM9MTM1Ni0xMzYzJmFtcDtkYXRl

PTIwMTUmYW1wO2F1aW5pdDE9TSZhbXA7YXVpbml0bT1KLjwvdXJsPjx1cmw+aHR0cDovL2pjby5h

c2NvcHVicy5vcmcvY29udGVudC8zMy8xMi8xMzU2Lmxvbmc8L3VybD48L3JlbGF0ZWQtdXJscz48

L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+Tmlsc3NvbjwvQXV0aG9yPjxZZWFy

PjIwMTM8L1llYXI+PFJlY051bT4xNTg3PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xNTg3

PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0ienp0OTU1c3c1

MmR2dGdlZXN2NjVyMHBnZHd2dDlldmZ3d2VlIiB0aW1lc3RhbXA9IjE0MzcwNDc2NjgiPjE1ODc8

L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwv

cmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPk5pbHNzb24sIFMuPC9hdXRo

b3I+PGF1dGhvcj5GcmFuemVuLCBMLjwvYXV0aG9yPjxhdXRob3I+UGFya2VyLCBDLjwvYXV0aG9y

PjxhdXRob3I+VHlycmVsbCwgQy48L2F1dGhvcj48YXV0aG9yPkJsb20sIFIuPC9hdXRob3I+PGF1

dGhvcj5UZW5udmFsbCwgSi48L2F1dGhvcj48YXV0aG9yPkxlbm5lcm5hcywgQi48L2F1dGhvcj48

YXV0aG9yPlBldGVyc3NvbiwgVS48L2F1dGhvcj48YXV0aG9yPkpvaGFubmVzc2VuLCBELiBDLjwv

YXV0aG9yPjxhdXRob3I+U29rYWwsIE0uPC9hdXRob3I+PGF1dGhvcj5QaWdvdHQsIEsuPC9hdXRo

b3I+PGF1dGhvcj5PJmFwb3M7QnJ5YW4tVGVhciwgQy4gRy48L2F1dGhvcj48YXV0aG9yPlRodXJl

c3NvbiwgTS48L2F1dGhvcj48YXV0aG9yPkJvbHN0YWQsIEIuPC9hdXRob3I+PGF1dGhvcj5CcnVs

YW5kLCBPLiBTLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNz

PlMuIE5pbHNzb24sIERlcGFydG1lbnQgb2YgT25jb2xvZ3ksIFJhZGl1bWhlbW1ldCwgS2Fyb2xp

bnNrYSBVbml2ZXJzaXR5IEhvc3BpdGFsLCBTRS0xNzE3NiBTdG9ja2hvbG0sIFN3ZWRlbjwvYXV0

aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlR3by15ZWFyIHN1cnZpdmFsIGZvbGxvdy11cCBvZiB0

aGUgcmFuZG9taXplZCwgZG91YmxlLWJsaW5kLCBwbGFjZWJvLWNvbnRyb2xsZWQgcGhhc2UgSUkg

c3R1ZHkgb2YgcmFkaXVtLTIyMyBjaGxvcmlkZSBpbiBwYXRpZW50cyB3aXRoIGNhc3RyYXRpb24t

cmVzaXN0YW50IHByb3N0YXRlIGNhbmNlciBhbmQgYm9uZSBtZXRhc3Rhc2VzPC90aXRsZT48c2Vj

b25kYXJ5LXRpdGxlPkNsaW5pY2FsIEdlbml0b3VyaW5hcnkgQ2FuY2VyPC9zZWNvbmRhcnktdGl0

bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+Q2xpbiBHZW5pdG91cmluIENhbmNl

cjwvZnVsbC10aXRsZT48YWJici0xPkNsaW5pY2FsIGdlbml0b3VyaW5hcnkgY2FuY2VyPC9hYmJy

LTE+PC9wZXJpb2RpY2FsPjxwYWdlcz4yMC0yNjwvcGFnZXM+PHZvbHVtZT4xMTwvdm9sdW1lPjxu

dW1iZXI+MTwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5wbGFjZWJvPC9rZXl3b3JkPjxrZXl3

b3JkPnJhZGlvaXNvdG9wZTwva2V5d29yZD48a2V5d29yZD5yYWRpdW0gMjIzPC9rZXl3b3JkPjxr

ZXl3b3JkPnVuY2xhc3NpZmllZCBkcnVnPC9rZXl3b3JkPjxrZXl3b3JkPmFkdWx0PC9rZXl3b3Jk

PjxrZXl3b3JkPmFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+YXJ0aWNsZTwva2V5d29yZD48a2V5d29y

ZD5ibG9vZCB0b3hpY2l0eTwva2V5d29yZD48a2V5d29yZD5ib25lIG1ldGFzdGFzaXM8L2tleXdv

cmQ+PGtleXdvcmQ+Ym9uZSBwYWluPC9rZXl3b3JkPjxrZXl3b3JkPmNhbmNlciBzdXJ2aXZhbDwv

a2V5d29yZD48a2V5d29yZD5jYXN0cmF0aW9uIHJlc2lzdGFudCBwcm9zdGF0ZSBjYW5jZXI8L2tl

eXdvcmQ+PGtleXdvcmQ+Y2F1c2Ugb2YgZGVhdGg8L2tleXdvcmQ+PGtleXdvcmQ+Y29udHJvbGxl

ZCBzdHVkeTwva2V5d29yZD48a2V5d29yZD5kaXNlYXNlIGNvdXJzZTwva2V5d29yZD48a2V5d29y

ZD5kcnVnIHNhZmV0eTwva2V5d29yZD48a2V5d29yZD5leHRlcm5hbCBiZWFtIHJhZGlvdGhlcmFw

eTwva2V5d29yZD48a2V5d29yZD5mb2xsb3cgdXA8L2tleXdvcmQ+PGtleXdvcmQ+aHVtYW48L2tl

eXdvcmQ+PGtleXdvcmQ+aHVtYW4gY2VsbDwva2V5d29yZD48a2V5d29yZD5odW1hbiB0aXNzdWU8

L2tleXdvcmQ+PGtleXdvcmQ+bWFqb3IgY2xpbmljYWwgc3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+

bWFsZTwva2V5d29yZD48a2V5d29yZD5vdmVyYWxsIHN1cnZpdmFsPC9rZXl3b3JkPjxrZXl3b3Jk

PnBoYXNlIDIgY2xpbmljYWwgdHJpYWw8L2tleXdvcmQ+PGtleXdvcmQ+cHJvc3RhdGUgYWRlbm9j

YXJjaW5vbWE8L2tleXdvcmQ+PGtleXdvcmQ+cmFuZG9taXplZCBjb250cm9sbGVkIHRyaWFsPC9r

ZXl3b3JkPjxrZXl3b3JkPnN1cnZpdmFsIHRpbWU8L2tleXdvcmQ+PGtleXdvcmQ+dHJlYXRtZW50

IGR1cmF0aW9uPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTM8L3llYXI+PC9k

YXRlcz48aXNibj4xNTU4LTc2NzMmI3hEOzE5MzgtMDY4MjwvaXNibj48dXJscz48cmVsYXRlZC11

cmxzPjx1cmw+aHR0cDovL3d3dy5lbWJhc2UuY29tL3NlYXJjaC9yZXN1bHRzP3N1YmFjdGlvbj12

aWV3cmVjb3JkJmFtcDtmcm9tPWV4cG9ydCZhbXA7aWQ9TDM2ODQ0MjEwNjwvdXJsPjx1cmw+aHR0

cDovL2R4LmRvaS5vcmcvMTAuMTAxNi9qLmNsZ2MuMjAxMi4wNy4wMDI8L3VybD48dXJsPmh0dHA6

Ly9zZngubGlicmFyeS51dS5ubC91dHJlY2h0P3NpZD1FTUJBU0UmYW1wO2lzc249MTU1ODc2NzMm

YW1wO2lkPWRvaToxMC4xMDE2JTJGai5jbGdjLjIwMTIuMDcuMDAyJmFtcDthdGl0bGU9VHdvLXll

YXIrc3Vydml2YWwrZm9sbG93LXVwK29mK3RoZStyYW5kb21pemVkJTJDK2RvdWJsZS1ibGluZCUy

QytwbGFjZWJvLWNvbnRyb2xsZWQrcGhhc2UrSUkrc3R1ZHkrb2YrcmFkaXVtLTIyMytjaGxvcmlk

ZStpbitwYXRpZW50cyt3aXRoK2Nhc3RyYXRpb24tcmVzaXN0YW50K3Byb3N0YXRlK2NhbmNlcith

bmQrYm9uZSttZXRhc3Rhc2VzJmFtcDtzdGl0bGU9Q2xpbi4rR2VuaXRvdXJpbi4rQ2FuY2VyJmFt

cDt0aXRsZT1DbGluaWNhbCtHZW5pdG91cmluYXJ5K0NhbmNlciZhbXA7dm9sdW1lPTExJmFtcDtp

c3N1ZT0xJmFtcDtzcGFnZT0yMCZhbXA7ZXBhZ2U9MjYmYW1wO2F1bGFzdD1OaWxzc29uJmFtcDth

dWZpcnN0PVN0ZW4mYW1wO2F1aW5pdD1TLiZhbXA7YXVmdWxsPU5pbHNzb24rUy4mYW1wO2NvZGVu

PSZhbXA7aXNibj0mYW1wO3BhZ2VzPTIwLTI2JmFtcDtkYXRlPTIwMTMmYW1wO2F1aW5pdDE9UyZh

bXA7YXVpbml0bT08L3VybD48dXJsPmh0dHA6Ly93d3cuY2xpbmljYWwtZ2VuaXRvdXJpbmFyeS1j

YW5jZXIuY29tL2FydGljbGUvUzE1NTgtNzY3MygxMikwMDE2OC0xL2Fic3RyYWN0PC91cmw+PC9y

ZWxhdGVkLXVybHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPk5pbHNzb248

L0F1dGhvcj48WWVhcj4yMDA3PC9ZZWFyPjxSZWNOdW0+MTE0ODwvUmVjTnVtPjxyZWNvcmQ+PHJl

Yy1udW1iZXI+MTE0ODwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGIt

aWQ9Inp6dDk1NXN3NTJkdnRnZWVzdjY1cjBwZ2R3dnQ5ZXZmd3dlZSIgdGltZXN0YW1wPSIxNDM3

MDQ3MDg3Ij4xMTQ4PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwg

QXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5OaWxz

c29uLCBTLjwvYXV0aG9yPjxhdXRob3I+RnJhbnplbiwgTC48L2F1dGhvcj48YXV0aG9yPlBhcmtl

ciwgQy48L2F1dGhvcj48YXV0aG9yPlR5cnJlbGwsIEMuPC9hdXRob3I+PGF1dGhvcj5CbG9tLCBS

LjwvYXV0aG9yPjxhdXRob3I+VGVubnZhbGwsIEouPC9hdXRob3I+PGF1dGhvcj5MZW5uZXJuYXMs

IEIuPC9hdXRob3I+PGF1dGhvcj5QZXRlcnNzb24sIFUuPC9hdXRob3I+PGF1dGhvcj5Kb2hhbm5l

c3NlbiwgRC4gQy48L2F1dGhvcj48YXV0aG9yPlNva2FsLCBNLjwvYXV0aG9yPjxhdXRob3I+UGln

b3R0LCBLLjwvYXV0aG9yPjxhdXRob3I+WWFjaG5pbiwgSi48L2F1dGhvcj48YXV0aG9yPkdhcmth

dmlqLCBNLjwvYXV0aG9yPjxhdXRob3I+U3RyYW5nLCBQLjwvYXV0aG9yPjxhdXRob3I+SGFybWVu

YmVyZywgSi48L2F1dGhvcj48YXV0aG9yPkJvbHN0YWQsIEIuPC9hdXRob3I+PGF1dGhvcj5CcnVs

YW5kLCBPLiBTLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNz

Pkthcm9saW5za2EgSG9zcGl0YWwsIFN0b2NraG9sbSwgU3dlZGVuLjwvYXV0aC1hZGRyZXNzPjx0

aXRsZXM+PHRpdGxlPkJvbmUtdGFyZ2V0ZWQgcmFkaXVtLTIyMyBpbiBzeW1wdG9tYXRpYywgaG9y

bW9uZS1yZWZyYWN0b3J5IHByb3N0YXRlIGNhbmNlcjogYSByYW5kb21pc2VkLCBtdWx0aWNlbnRy

ZSwgcGxhY2Viby1jb250cm9sbGVkIHBoYXNlIElJIHN0dWR5PC90aXRsZT48c2Vjb25kYXJ5LXRp

dGxlPkxhbmNldCBPbmNvbDwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+VGhlIExhbmNldC4g

T25jb2xvZ3k8L2FsdC10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5MYW5j

ZXQgT25jb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5UaGUgTGFuY2V0LiBPbmNvbG9neTwvYWJici0x

PjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+TGFuY2V0IE9uY29sPC9m

dWxsLXRpdGxlPjxhYmJyLTE+VGhlIExhbmNldC4gT25jb2xvZ3k8L2FiYnItMT48L2FsdC1wZXJp

b2RpY2FsPjxwYWdlcz41ODctOTQ8L3BhZ2VzPjx2b2x1bWU+ODwvdm9sdW1lPjxudW1iZXI+Nzwv

bnVtYmVyPjxlZGl0aW9uPjIwMDcvMDYvMDU8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkFk

ZW5vY2FyY2lub21hL3JhZGlvdGhlcmFweS9zZWNvbmRhcnk8L2tleXdvcmQ+PGtleXdvcmQ+QWdl

ZDwva2V5d29yZD48a2V5d29yZD5BZ2VkLCA4MCBhbmQgb3Zlcjwva2V5d29yZD48a2V5d29yZD5B

bGthbGluZSBQaG9zcGhhdGFzZS9ibG9vZDwva2V5d29yZD48a2V5d29yZD5Cb25lIE5lb3BsYXNt

cy8qcmFkaW90aGVyYXB5L3NlY29uZGFyeTwva2V5d29yZD48a2V5d29yZD5Eb3VibGUtQmxpbmQg

TWV0aG9kPC9rZXl3b3JkPjxrZXl3b3JkPipEcnVnIFJlc2lzdGFuY2UsIE5lb3BsYXNtPC9rZXl3

b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3

b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPlBsYWNlYm9zPC9rZXl3b3JkPjxrZXl3

b3JkPlByb2dub3Npczwva2V5d29yZD48a2V5d29yZD5Qcm9zdGF0ZS1TcGVjaWZpYyBBbnRpZ2Vu

PC9rZXl3b3JkPjxrZXl3b3JkPlByb3N0YXRpYyBOZW9wbGFzbXMvcGF0aG9sb2d5LypyYWRpb3Ro

ZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+UmFkaXVtLyp0aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+

PGtleXdvcmQ+U3Vydml2YWwgUmF0ZTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4y

MDA3PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVsPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+

PGlzYm4+MTQ3MC0yMDQ1IChQcmludCkmI3hEOzE0NzAtMjA0NTwvaXNibj48YWNjZXNzaW9uLW51

bT4xNzU0NDg0NTwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDov

L3d3dy50aGVsYW5jZXQuY29tL2pvdXJuYWxzL2xhbm9uYy9hcnRpY2xlL1BJSVMxNDcwLTIwNDUo

MDcpNzAxNDctWC9hYnN0cmFjdDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25p

Yy1yZXNvdXJjZS1udW0+MTAuMTAxNi9zMTQ3MC0yMDQ1KDA3KTcwMTQ3LXg8L2VsZWN0cm9uaWMt

cmVzb3VyY2UtbnVtPjxyZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+TmxtPC9yZW1vdGUtZGF0YWJh

c2UtcHJvdmlkZXI+PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjxDaXRl

PjxBdXRob3I+Tm9tZTwvQXV0aG9yPjxZZWFyPjIwMTU8L1llYXI+PFJlY051bT4yMjAwPC9SZWNO

dW0+PHJlY29yZD48cmVjLW51bWJlcj4yMjAwPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtl

eSBhcHA9IkVOIiBkYi1pZD0ienp0OTU1c3c1MmR2dGdlZXN2NjVyMHBnZHd2dDlldmZ3d2VlIiB0

aW1lc3RhbXA9IjE0NDA2NjM5MDIiPjIyMDA8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLW==

ADDIN EN.CITE.DATA dHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxh

dXRob3JzPjxhdXRob3I+Tm9tZSwgUi48L2F1dGhvcj48YXV0aG9yPkhlcm5lcywgRS48L2F1dGhv

cj48YXV0aG9yPkJvZ3NydWQsIFQuIFYuPC9hdXRob3I+PGF1dGhvcj5Cam9ybywgVC48L2F1dGhv

cj48YXV0aG9yPkZvc3NhLCBTLiBELjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48

YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgTWVkaWNhbCBCaW9jaGVtaXN0cnkgYW5kLjwvYXV0

aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkNoYW5nZXMgaW4gcHJvc3RhdGUtc3BlY2lmaWMgYW50

aWdlbiwgbWFya2VycyBvZiBib25lIG1ldGFib2xpc20gYW5kIGJvbmUgc2NhbnMgYWZ0ZXIgdHJl

YXRtZW50IHdpdGggcmFkaXVtLTIyMzwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5TY2FuZCBKIFVy

b2w8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPlNjYW5kaW5hdmlhbiBqb3VybmFsIG9mIHVy

b2xvZ3k8L2FsdC10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5TY2FuZCBK

IFVyb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5TY2FuZGluYXZpYW4gam91cm5hbCBvZiB1cm9sb2d5

PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5TY2FuZCBK

IFVyb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5TY2FuZGluYXZpYW4gam91cm5hbCBvZiB1cm9sb2d5

PC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+MjExLTc8L3BhZ2VzPjx2b2x1bWU+NDk8

L3ZvbHVtZT48bnVtYmVyPjM8L251bWJlcj48ZGF0ZXM+PHllYXI+MjAxNTwveWVhcj48cHViLWRh

dGVzPjxkYXRlPkp1bjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjIxNjgtMTgxMyAo

RWxlY3Ryb25pYyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjU1MTU5NTI8L2FjY2Vzc2lvbi1udW0+

PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJt

ZWQvMjU1MTU5NTI8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3Vy

Y2UtbnVtPjEwLjMxMDkvMjE2ODE4MDUuMjAxNC45ODIxNjk8L2VsZWN0cm9uaWMtcmVzb3VyY2Ut

bnVtPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPlBhcmtlcjwvQXV0aG9yPjxZZWFyPjIw

MTM8L1llYXI+PFJlY051bT4xNTExPC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xNTExPC9y

ZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0ienp0OTU1c3c1MmR2

dGdlZXN2NjVyMHBnZHd2dDlldmZ3d2VlIiB0aW1lc3RhbXA9IjE0MzcwNDc2NjgiPjE1MTE8L2tl

eT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVm

LXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlBhcmtlciwgQy48L2F1dGhvcj48

YXV0aG9yPk5pbHNzb24sIEQuIEhlaW5yaWNoIFMuPC9hdXRob3I+PGF1dGhvcj5IZWxsZSwgUy4g

SS48L2F1dGhvcj48YXV0aG9yPk8mYXBvcztTdWxsaXZhbiwgSi4gTS48L2F1dGhvcj48YXV0aG9y

PkZvc3NhLCBTLiBELjwvYXV0aG9yPjxhdXRob3I+Q2hvZGFja2ksIEEuPC9hdXRob3I+PGF1dGhv

cj5XaWVjaG5vLCBQLjwvYXV0aG9yPjxhdXRob3I+TG9ndWUsIEouPC9hdXRob3I+PGF1dGhvcj5T

ZWtlLCBNLjwvYXV0aG9yPjxhdXRob3I+V2lkbWFyaywgQS48L2F1dGhvcj48YXV0aG9yPkpvaGFu

bmVzc2VuLCBELiBDLjwvYXV0aG9yPjxhdXRob3I+SG9za2luLCBQLjwvYXV0aG9yPjxhdXRob3I+

Qm90dG9tbGV5LCBELjwvYXV0aG9yPjxhdXRob3I+SmFtZXMsIE4uIEQuPC9hdXRob3I+PGF1dGhv

cj5Tb2xiZXJnLCBBLjwvYXV0aG9yPjxhdXRob3I+U3luZGlrdXMsIEkuPC9hdXRob3I+PGF1dGhv

cj5LbGltZW50LCBKLjwvYXV0aG9yPjxhdXRob3I+V2VkZWwsIFMuPC9hdXRob3I+PGF1dGhvcj5C

b2VobWVyLCBTLjwvYXV0aG9yPjxhdXRob3I+RGFsbCZhcG9zO09nbGlvLCBNLjwvYXV0aG9yPjxh

dXRob3I+RnJhbnplbiwgTC48L2F1dGhvcj48YXV0aG9yPkNvbGVtYW4sIFIuPC9hdXRob3I+PGF1

dGhvcj5Wb2dlbHphbmcsIE4uIEouPC9hdXRob3I+PGF1dGhvcj5PJmFwb3M7QnJ5YW4tVGVhciwg

Qy4gRy48L2F1dGhvcj48YXV0aG9yPlN0YXVkYWNoZXIsIEsuPC9hdXRob3I+PGF1dGhvcj5HYXJj

aWEtVmFyZ2FzLCBKLjwvYXV0aG9yPjxhdXRob3I+U2hhbiwgTS48L2F1dGhvcj48YXV0aG9yPkJy

dWxhbmQsIE8uIFMuPC9hdXRob3I+PGF1dGhvcj5TYXJ0b3IsIE8uPC9hdXRob3I+PC9hdXRob3Jz

PjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+Qy4gUGFya2VyLCBSb3lhbCBNYXJzZGVuIEhv

c3BpdGFsLCBBY2FkZW1pYyBVcm9sb2d5IFVuaXQsIFN1dHRvbiwgU3VycmV5IFNNMiA1UFQsIFVu

aXRlZCBLaW5nZG9tPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+QWxwaGEgZW1pdHRlciBy

YWRpdW0tMjIzIGFuZCBzdXJ2aXZhbCBpbiBtZXRhc3RhdGljIHByb3N0YXRlIGNhbmNlcjwvdGl0

bGU+PHNlY29uZGFyeS10aXRsZT5OZXcgRW5nbGFuZCBKb3VybmFsIG9mIE1lZGljaW5lPC9zZWNv

bmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+TmV3IEVuZ2xhbmQg

Sm91cm5hbCBvZiBNZWRpY2luZTwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjIxMy0y

MjM8L3BhZ2VzPjx2b2x1bWU+MzY5PC92b2x1bWU+PG51bWJlcj4zPC9udW1iZXI+PGtleXdvcmRz

PjxrZXl3b3JkPk5DVDAwNjk5NzUxPC9rZXl3b3JkPjxrZXl3b3JkPk5DVDAxMTA2MzUyPC9rZXl3

b3JkPjxrZXl3b3JkPmFsa2FsaW5lIHBob3NwaGF0YXNlPC9rZXl3b3JkPjxrZXl3b3JkPnBsYWNl

Ym88L2tleXdvcmQ+PGtleXdvcmQ+cHJvc3RhdGUgc3BlY2lmaWMgYW50aWdlbjwva2V5d29yZD48

a2V5d29yZD5yYWRpb2lzb3RvcGU8L2tleXdvcmQ+PGtleXdvcmQ+cmFkaXVtIDIyMzwva2V5d29y

ZD48a2V5d29yZD51bmNsYXNzaWZpZWQgZHJ1Zzwva2V5d29yZD48a2V5d29yZD5hZHVsdDwva2V5

d29yZD48a2V5d29yZD5hZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPmFuZW1pYTwva2V5d29yZD48a2V5

d29yZD5hbm9yZXhpYTwva2V5d29yZD48a2V5d29yZD5hcnRpY2xlPC9rZXl3b3JkPjxrZXl3b3Jk

PmFzdGhlbmlhPC9rZXl3b3JkPjxrZXl3b3JkPmJvbmUgbWFycm93IHN1cHByZXNzaW9uPC9rZXl3

b3JkPjxrZXl3b3JkPmJvbmUgbWV0YXN0YXNpczwva2V5d29yZD48a2V5d29yZD5ib25lIHBhaW48

L2tleXdvcmQ+PGtleXdvcmQ+Y2FuY2VyIHN1cnZpdmFsPC9rZXl3b3JkPjxrZXl3b3JkPmNhc3Ry

YXRpb24gcmVzaXN0YW50IHByb3N0YXRlIGNhbmNlcjwva2V5d29yZD48a2V5d29yZD5jb25zdGlw

YXRpb248L2tleXdvcmQ+PGtleXdvcmQ+Y29udHJvbGxlZCBzdHVkeTwva2V5d29yZD48a2V5d29y

ZD5kYWlseSBsaWZlIGFjdGl2aXR5PC9rZXl3b3JkPjxrZXl3b3JkPmRlY3JlYXNlZCBhcHBldGl0

ZTwva2V5d29yZD48a2V5d29yZD5kaWFycmhlYTwva2V5d29yZD48a2V5d29yZD5kaXNlYXNlIGNv

dXJzZTwva2V5d29yZD48a2V5d29yZD5kaXp6aW5lc3M8L2tleXdvcmQ+PGtleXdvcmQ+ZG91Ymxl

IGJsaW5kIHByb2NlZHVyZTwva2V5d29yZD48a2V5d29yZD5kcnVnIGVmZmljYWN5PC9rZXl3b3Jk

PjxrZXl3b3JkPmRydWcgc2FmZXR5PC9rZXl3b3JkPjxrZXl3b3JkPmRydWcgd2l0aGRyYXdhbDwv

a2V5d29yZD48a2V5d29yZD5keXNwbmVhPC9rZXl3b3JkPjxrZXl3b3JkPmV4dGVybmFsIGJlYW0g

cmFkaW90aGVyYXB5PC9rZXl3b3JkPjxrZXl3b3JkPmZhdGlndWU8L2tleXdvcmQ+PGtleXdvcmQ+

ZmVicmlsZSBuZXV0cm9wZW5pYTwva2V5d29yZD48a2V5d29yZD5mZXZlcjwva2V5d29yZD48a2V5

d29yZD5nZW5lcmFsIGNvbmRpdGlvbiBkZXRlcmlvcmF0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPmhl

bWF0b2xvZ2ljIGRpc2Vhc2U8L2tleXdvcmQ+PGtleXdvcmQ+aGVtYXR1cmlhPC9rZXl3b3JkPjxr

ZXl3b3JkPmh1bWFuPC9rZXl3b3JkPjxrZXl3b3JkPmluc29tbmlhPC9rZXl3b3JkPjxrZXl3b3Jk

Pm1ham9yIGNsaW5pY2FsIHN0dWR5PC9rZXl3b3JkPjxrZXl3b3JkPm1hbGU8L2tleXdvcmQ+PGtl

eXdvcmQ+bXVsdGljZW50ZXIgc3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+bXVzY2xlIHdlYWtuZXNz

PC9rZXl3b3JkPjxrZXl3b3JkPm5hdXNlYTwva2V5d29yZD48a2V5d29yZD5uZXV0cm9wZW5pYTwv

a2V5d29yZD48a2V5d29yZD5vdmVyYWxsIHN1cnZpdmFsPC9rZXl3b3JkPjxrZXl3b3JkPnBhdGhv

bG9naWMgZnJhY3R1cmU8L2tleXdvcmQ+PGtleXdvcmQ+cGVyaXBoZXJhbCBlZGVtYTwva2V5d29y

ZD48a2V5d29yZD5waGFzZSAzIGNsaW5pY2FsIHRyaWFsPC9rZXl3b3JkPjxrZXl3b3JkPnBuZXVt

b25pYTwva2V5d29yZD48a2V5d29yZD5wcmlvcml0eSBqb3VybmFsPC9rZXl3b3JkPjxrZXl3b3Jk

PnF1YWxpdHkgb2YgbGlmZTwva2V5d29yZD48a2V5d29yZD5yYW5kb21pemVkIGNvbnRyb2xsZWQg

dHJpYWw8L2tleXdvcmQ+PGtleXdvcmQ+c2lkZSBlZmZlY3Q8L2tleXdvcmQ+PGtleXdvcmQ+c3Bp

bmFsIGNvcmQgY29tcHJlc3Npb248L2tleXdvcmQ+PGtleXdvcmQ+dGhyb21ib2N5dG9wZW5pYTwv

a2V5d29yZD48a2V5d29yZD50cmVhdG1lbnQgb3V0Y29tZTwva2V5d29yZD48a2V5d29yZD51bnNw

ZWNpZmllZCBzaWRlIGVmZmVjdDwva2V5d29yZD48a2V5d29yZD51cmluYXJ5IHRyYWN0IGluZmVj

dGlvbjwva2V5d29yZD48a2V5d29yZD51cmluZSByZXRlbnRpb248L2tleXdvcmQ+PGtleXdvcmQ+

dm9taXRpbmc8L2tleXdvcmQ+PGtleXdvcmQ+d2VpZ2h0IHJlZHVjdGlvbjwva2V5d29yZD48L2tl

eXdvcmRzPjxkYXRlcz48eWVhcj4yMDEzPC95ZWFyPjwvZGF0ZXM+PGlzYm4+MDAyOC00NzkzJiN4

RDsxNTMzLTQ0MDY8L2lzYm4+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cuZW1i

YXNlLmNvbS9zZWFyY2gvcmVzdWx0cz9zdWJhY3Rpb249dmlld3JlY29yZCZhbXA7ZnJvbT1leHBv

cnQmYW1wO2lkPUwzNjkzNzc4OTg8L3VybD48dXJsPmh0dHA6Ly9keC5kb2kub3JnLzEwLjEwNTYv

TkVKTW9hMTIxMzc1NTwvdXJsPjx1cmw+aHR0cDovL3NmeC5saWJyYXJ5LnV1Lm5sL3V0cmVjaHQ/

c2lkPUVNQkFTRSZhbXA7aXNzbj0wMDI4NDc5MyZhbXA7aWQ9ZG9pOjEwLjEwNTYlMkZORUpNb2Ex

MjEzNzU1JmFtcDthdGl0bGU9QWxwaGErZW1pdHRlcityYWRpdW0tMjIzK2FuZCtzdXJ2aXZhbCtp

bittZXRhc3RhdGljK3Byb3N0YXRlK2NhbmNlciZhbXA7c3RpdGxlPU5ldytFbmdsLitKLitNZWQu

JmFtcDt0aXRsZT1OZXcrRW5nbGFuZCtKb3VybmFsK29mK01lZGljaW5lJmFtcDt2b2x1bWU9MzY5

JmFtcDtpc3N1ZT0zJmFtcDtzcGFnZT0yMTMmYW1wO2VwYWdlPTIyMyZhbXA7YXVsYXN0PVBhcmtl

ciZhbXA7YXVmaXJzdD1DaHJpc3RvcGhlciZhbXA7YXVpbml0PUMuJmFtcDthdWZ1bGw9UGFya2Vy

K0MuJmFtcDtjb2Rlbj1ORUpNQSZhbXA7aXNibj0mYW1wO3BhZ2VzPTIxMy0yMjMmYW1wO2RhdGU9

MjAxMyZhbXA7YXVpbml0MT1DJmFtcDthdWluaXRtPTwvdXJsPjwvcmVsYXRlZC11cmxzPjxwZGYt

dXJscz48dXJsPmh0dHA6Ly93d3cubmVqbS5vcmcvZG9pL3BkZi8xMC4xMDU2L05FSk1vYTEyMTM3

NTU8L3VybD48L3BkZi11cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5S

YXRoa29wZjwvQXV0aG9yPjxZZWFyPjIwMTQ8L1llYXI+PFJlY051bT4xOTg1PC9SZWNOdW0+PHJl

Y29yZD48cmVjLW51bWJlcj4xOTg1PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9

IkVOIiBkYi1pZD0ienp0OTU1c3c1MmR2dGdlZXN2NjVyMHBnZHd2dDlldmZ3d2VlIiB0aW1lc3Rh

bXA9IjE0MzcwNTUxMTgiPjE5ODU8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0i

RWxlY3Ryb25pYyBBcnRpY2xlIj40MzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48

YXV0aG9yPlJhdGhrb3BmLCBELiBFLjwvYXV0aG9yPjxhdXRob3I+U21pdGgsIE0uIFIuPC9hdXRo

b3I+PGF1dGhvcj5Cb25vLCBKLiBTLjwvYXV0aG9yPjxhdXRob3I+TG9nb3RoZXRpcywgQy4gSi48

L2F1dGhvcj48YXV0aG9yPlNob3JlLCBOLiBELjwvYXV0aG9yPjxhdXRob3I+U291emEsIFAuPC9h

dXRob3I+PGF1dGhvcj5GaXphemksIEsuPC9hdXRob3I+PGF1dGhvcj5NdWxkZXJzLCBQLiBGLiBB

LjwvYXV0aG9yPjxhdXRob3I+TWFpbndhcmluZywgUC48L2F1dGhvcj48YXV0aG9yPkhhaW5zd29y

dGgsIEouIEQuPC9hdXRob3I+PGF1dGhvcj5CZWVyLCBULiBNLjwvYXV0aG9yPjxhdXRob3I+Tm9y

dGgsIFMuPC9hdXRob3I+PGF1dGhvcj5GcmFkZXQsIFkuPC9hdXRob3I+PGF1dGhvcj5Qb3BwZWws

IEguPC9hdXRob3I+PGF1dGhvcj5DYXJsZXMsIEouPC9hdXRob3I+PGF1dGhvcj5GbGFpZywgVC4g

Vy48L2F1dGhvcj48YXV0aG9yPkVmc3RhdGhpb3UsIEUuPC9hdXRob3I+PGF1dGhvcj5ZdSwgRS4g

WS48L2F1dGhvcj48YXV0aG9yPkhpZ2FubywgQy4gUy48L2F1dGhvcj48YXV0aG9yPlRhcGxpbiwg

TS4gRS48L2F1dGhvcj48YXV0aG9yPkdyaWZmaW4sIFQuIFcuPC9hdXRob3I+PGF1dGhvcj5Ub2Rk

LCBNLiBCLjwvYXV0aG9yPjxhdXRob3I+WXUsIE0uIEsuPC9hdXRob3I+PGF1dGhvcj5QYXJrLCBZ

LiBDLjwvYXV0aG9yPjxhdXRob3I+S2hlb2gsIFQuPC9hdXRob3I+PGF1dGhvcj5TbWFsbCwgRS4g

Si48L2F1dGhvcj48YXV0aG9yPlNjaGVyLCBILiBJLjwvYXV0aG9yPjxhdXRob3I+TW9saW5hLCBB

LjwvYXV0aG9yPjxhdXRob3I+UnlhbiwgQy4gSi48L2F1dGhvcj48YXV0aG9yPlNhYWQsIEYuPC9h

dXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPlVwZGF0ZWQgaW50

ZXJpbSBlZmZpY2FjeSBhbmFseXNpcyBhbmQgbG9uZy10ZXJtIHNhZmV0eSBvZiBhYmlyYXRlcm9u

ZSBhY2V0YXRlIGluIG1ldGFzdGF0aWMgY2FzdHJhdGlvbi1yZXNpc3RhbnQgcHJvc3RhdGUgY2Fu

Y2VyIHBhdGllbnRzIHdpdGhvdXQgcHJpb3IgY2hlbW90aGVyYXB5IChDT1UtQUEtMzAyKTwvdGl0

bGU+PHNlY29uZGFyeS10aXRsZT5FdXJvcGVhbiB1cm9sb2d5PC9zZWNvbmRhcnktdGl0bGU+PC90

aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+RXVyIFVyb2w8L2Z1bGwtdGl0bGU+PGFiYnIt

MT5FdXJvcGVhbiB1cm9sb2d5PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxwYWdlcz44MTUtMjU8L3Bh

Z2VzPjx2b2x1bWU+NjY8L3ZvbHVtZT48bnVtYmVyPjU8L251bWJlcj48a2V5d29yZHM+PGtleXdv

cmQ+YWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+YWdlZDwva2V5d29yZD48a2V5d29yZD5hbGFuaW5l

IGFtaW5vdHJhbnNmZXJhc2UgYmxvb2QgbGV2ZWw8L2tleXdvcmQ+PGtleXdvcmQ+YXJ0aHJhbGdp

YS9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPmFydGljbGU8L2tleXdvcmQ+PGtl

eXdvcmQ+YXNwYXJ0YXRlIGFtaW5vdHJhbnNmZXJhc2UgYmxvb2QgbGV2ZWw8L2tleXdvcmQ+PGtl

eXdvcmQ+YmFja2FjaGUvc2kgW1NpZGUgRWZmZWN0XTwva2V5d29yZD48a2V5d29yZD5ib25lIHBh

aW4vc2kgW1NpZGUgRWZmZWN0XTwva2V5d29yZD48a2V5d29yZD5jYW5jZXIgY29tYmluYXRpb24g

Y2hlbW90aGVyYXB5PC9rZXl3b3JkPjxrZXl3b3JkPmNhbmNlciBwYXRpZW50PC9rZXl3b3JkPjxr

ZXl3b3JkPmNhbmNlciBwcm9nbm9zaXM8L2tleXdvcmQ+PGtleXdvcmQ+Y2FzdHJhdGlvbiByZXNp

c3RhbnQgcHJvc3RhdGUgY2FuY2VyL2R0IFtEcnVnIFRoZXJhcHldPC9rZXl3b3JkPjxrZXl3b3Jk

PmNvbnN0aXBhdGlvbi9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPmNvbnRyb2xs

ZWQgc3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+Y291Z2hpbmcvc2kgW1NpZGUgRWZmZWN0XTwva2V5

d29yZD48a2V5d29yZD5kaWFycmhlYS9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3Jk

PmRpc2Vhc2UgY291cnNlPC9rZXl3b3JkPjxrZXl3b3JkPmRvdWJsZSBibGluZCBwcm9jZWR1cmU8

L2tleXdvcmQ+PGtleXdvcmQ+ZHJ1ZyBlZmZpY2FjeTwva2V5d29yZD48a2V5d29yZD5kcnVnIHNh

ZmV0eTwva2V5d29yZD48a2V5d29yZD5keXNwbmVhL3NpIFtTaWRlIEVmZmVjdF08L2tleXdvcmQ+

PGtleXdvcmQ+ZmF0aWd1ZS9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPmZsdWlk

IHJldGVudGlvbjwva2V5d29yZD48a2V5d29yZD5mb2xsb3cgdXA8L2tleXdvcmQ+PGtleXdvcmQ+

aGVhcnQgYXJyaHl0aG1pYS9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPmhlYXJ0

IGRpc2Vhc2Uvc2kgW1NpZGUgRWZmZWN0XTwva2V5d29yZD48a2V5d29yZD5oZWFydCBmYWlsdXJl

L3NpIFtTaWRlIEVmZmVjdF08L2tleXdvcmQ+PGtleXdvcmQ+aG90IGZsdXNoL3NpIFtTaWRlIEVm

ZmVjdF08L2tleXdvcmQ+PGtleXdvcmQ+aHVtYW48L2tleXdvcmQ+PGtleXdvcmQ+aHlwZXJnbHlj

ZW1pYS9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPmh5cGVydGVuc2lvbi9zaSBb

U2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPmh5cG9rYWxlbWlhL3NpIFtTaWRlIEVmZmVj

dF08L2tleXdvcmQ+PGtleXdvcmQ+aW5zb21uaWEvc2kgW1NpZGUgRWZmZWN0XTwva2V5d29yZD48

a2V5d29yZD5pc2NoZW1pYyBoZWFydCBkaXNlYXNlL3NpIFtTaWRlIEVmZmVjdF08L2tleXdvcmQ+

PGtleXdvcmQ+bGltYiBwYWluL3NpIFtTaWRlIEVmZmVjdF08L2tleXdvcmQ+PGtleXdvcmQ+bGlt

YiBwYWluL3NpIFtTaWRlIEVmZmVjdF08L2tleXdvcmQ+PGtleXdvcmQ+bWFqb3IgY2xpbmljYWwg

c3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+bWFsZTwva2V5d29yZD48a2V5d29yZD5tZXRhc3Rhc2lz

L2R0IFtEcnVnIFRoZXJhcHldPC9rZXl3b3JkPjxrZXl3b3JkPm11c2NsZSBzcGFzbS9zaSBbU2lk

ZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPm11c2N1bG9za2VsZXRhbCBwYWluL3NpIFtTaWRl

IEVmZmVjdF08L2tleXdvcmQ+PGtleXdvcmQ+bmF1c2VhL3NpIFtTaWRlIEVmZmVjdF08L2tleXdv

cmQ+PGtleXdvcmQ+b3V0Y29tZSBhc3Nlc3NtZW50PC9rZXl3b3JkPjxrZXl3b3JkPm92ZXJhbGwg

c3Vydml2YWw8L2tleXdvcmQ+PGtleXdvcmQ+cGVyaXBoZXJhbCBlZGVtYS9zaSBbU2lkZSBFZmZl

Y3RdPC9rZXl3b3JkPjxrZXl3b3JkPnByb2dyZXNzaW9uIGZyZWUgc3Vydml2YWw8L2tleXdvcmQ+

PGtleXdvcmQ+cmFuZG9taXplZCBjb250cm9sbGVkIHRyaWFsPC9rZXl3b3JkPjxrZXl3b3JkPnNp

ZGUgZWZmZWN0L3NpIFtTaWRlIEVmZmVjdF08L2tleXdvcmQ+PGtleXdvcmQ+d2VpZ2h0IGdhaW48

L2tleXdvcmQ+PGtleXdvcmQ+YWJpcmF0ZXJvbmUvZHQgW0RydWcgVGhlcmFweV08L2tleXdvcmQ+

PGtleXdvcmQ+YWJpcmF0ZXJvbmUgYWNldGF0ZS9hZSBbQWR2ZXJzZSBEcnVnIFJlYWN0aW9uXTwv

a2V5d29yZD48a2V5d29yZD5hYmlyYXRlcm9uZSBhY2V0YXRlL2NiIFtEcnVnIENvbWJpbmF0aW9u

XTwva2V5d29yZD48a2V5d29yZD5hYmlyYXRlcm9uZSBhY2V0YXRlL2NtIFtEcnVnIENvbXBhcmlz

b25dPC9rZXl3b3JkPjxrZXl3b3JkPmFiaXJhdGVyb25lIGFjZXRhdGUvY20gW0RydWcgQ29tcGFy

aXNvbl08L2tleXdvcmQ+PGtleXdvcmQ+YWJpcmF0ZXJvbmUgYWNldGF0ZS9kdCBbRHJ1ZyBUaGVy

YXB5XTwva2V5d29yZD48a2V5d29yZD5hYmlyYXRlcm9uZSBhY2V0YXRlL2N0IFtDbGluaWNhbCBU

cmlhbF08L2tleXdvcmQ+PGtleXdvcmQ+YWxhbmluZSBhbWlub3RyYW5zZmVyYXNlL2VjIFtFbmRv

Z2Vub3VzIENvbXBvdW5kXTwva2V5d29yZD48a2V5d29yZD5hc3BhcnRhdGUgYW1pbm90cmFuc2Zl

cmFzZS9lYyBbRW5kb2dlbm91cyBDb21wb3VuZF08L2tleXdvcmQ+PGtleXdvcmQ+Y2FiYXppdGF4

ZWwvZHQgW0RydWcgVGhlcmFweV08L2tleXdvcmQ+PGtleXdvcmQ+ZG9jZXRheGVsL2R0IFtEcnVn

IFRoZXJhcHldPC9rZXl3b3JkPjxrZXl3b3JkPmtldG9jb25hem9sZS9kdCBbRHJ1ZyBUaGVyYXB5

XTwva2V5d29yZD48a2V5d29yZD5wbGFjZWJvPC9rZXl3b3JkPjxrZXl3b3JkPnByZWRuaXNvbmUv

YWUgW0FkdmVyc2UgRHJ1ZyBSZWFjdGlvbl08L2tleXdvcmQ+PGtleXdvcmQ+cHJlZG5pc29uZS9j

YiBbRHJ1ZyBDb21iaW5hdGlvbl08L2tleXdvcmQ+PGtleXdvcmQ+cHJlZG5pc29uZS9jbSBbRHJ1

ZyBDb21wYXJpc29uXTwva2V5d29yZD48a2V5d29yZD5wcmVkbmlzb25lL2NtIFtEcnVnIENvbXBh

cmlzb25dPC9rZXl3b3JkPjxrZXl3b3JkPnByZWRuaXNvbmUvZHQgW0RydWcgVGhlcmFweV08L2tl

eXdvcmQ+PGtleXdvcmQ+cHJlZG5pc29uZS9wbyBbT3JhbCBEcnVnIEFkbWluaXN0cmF0aW9uXTwv

a2V5d29yZD48a2V5d29yZD5wcmVkbmlzb25lL2N0IFtDbGluaWNhbCBUcmlhbF08L2tleXdvcmQ+

PGtleXdvcmQ+c2lwdWxldWNlbCBUL2R0IFtEcnVnIFRoZXJhcHldPC9rZXl3b3JkPjwva2V5d29y

ZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8L3llYXI+PC9kYXRlcz48YWNjZXNzaW9uLW51bT5DTi0wMTAx

NDE4NjwvYWNjZXNzaW9uLW51bT48d29yay10eXBlPkpvdXJuYWw6IEFydGljbGU8L3dvcmstdHlw

ZT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL29ubGluZWxpYnJhcnkud2lsZXkuY29t

L28vY29jaHJhbmUvY2xjZW50cmFsL2FydGljbGVzLzE4Ni9DTi0wMTAxNDE4Ni9mcmFtZS5odG1s

PC91cmw+PHVybD5odHRwOi8vYWMuZWxzLWNkbi5jb20vUzAzMDIyODM4MTQwMDE4NTcvMS1zMi4w

LVMwMzAyMjgzODE0MDAxODU3LW1haW4ucGRmP190aWQ9NTg4YWM3NWEtMmM2NS0xMWU1LTk1YmIt

MDAwMDBhYWIwZjAxJmFtcDthY2RuYXQ9MTQzNzEyNTEyOV9lMzRkMWZiZjQ5YTk4ZTI1OTRkMzMx

ODhjNjU4YWE4OTwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJj

ZS1udW0+MTAuMTAxNi9qLmV1cnVyby4yMDE0LjAyLjA1NjwvZWxlY3Ryb25pYy1yZXNvdXJjZS1u

dW0+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+UnlhbjwvQXV0aG9yPjxZZWFyPjIwMTM8

L1llYXI+PFJlY051bT4xOTYxPC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xOTYxPC9yZWMt

bnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0ienp0OTU1c3c1MmR2dGdl

ZXN2NjVyMHBnZHd2dDlldmZ3d2VlIiB0aW1lc3RhbXA9IjE0MzcwNTUxMTgiPjE5NjE8L2tleT48

L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iRWxlY3Ryb25pYyBBcnRpY2xlIj40MzwvcmVm

LXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlJ5YW4sIEMuIEouPC9hdXRob3I+

PGF1dGhvcj5TbWl0aCwgTS4gUi48L2F1dGhvcj48YXV0aG9yPkJvbm8sIEouIFMuPC9hdXRob3I+

PGF1dGhvcj5Nb2xpbmEsIEEuPC9hdXRob3I+PGF1dGhvcj5Mb2dvdGhldGlzLCBDLiBKLjwvYXV0

aG9yPjxhdXRob3I+U291emEsIFAuPC9hdXRob3I+PGF1dGhvcj5GaXphemksIEsuPC9hdXRob3I+

PGF1dGhvcj5NYWlud2FyaW5nLCBQLjwvYXV0aG9yPjxhdXRob3I+UGl1bGF0cywgSi4gTS48L2F1

dGhvcj48YXV0aG9yPk5nLCBTLjwvYXV0aG9yPjxhdXRob3I+Q2FybGVzLCBKLjwvYXV0aG9yPjxh

dXRob3I+TXVsZGVycywgUC4gRi48L2F1dGhvcj48YXV0aG9yPkJhc2NoLCBFLjwvYXV0aG9yPjxh

dXRob3I+U21hbGwsIEUuIEouPC9hdXRob3I+PGF1dGhvcj5TYWFkLCBGLjwvYXV0aG9yPjxhdXRo

b3I+U2NocmlqdmVycywgRC48L2F1dGhvcj48YXV0aG9yPlBvcHBlbCwgSC48L2F1dGhvcj48YXV0

aG9yPk11a2hlcmplZSwgUy4gRC48L2F1dGhvcj48YXV0aG9yPlN1dHRtYW5uLCBILjwvYXV0aG9y

PjxhdXRob3I+R2Vycml0c2VuLCBXLiBSLjwvYXV0aG9yPjxhdXRob3I+RmxhaWcsIFQuIFcuPC9h

dXRob3I+PGF1dGhvcj5HZW9yZ2UsIEQuIEouPC9hdXRob3I+PGF1dGhvcj5ZdSwgRS4gWS48L2F1

dGhvcj48YXV0aG9yPkVmc3RhdGhpb3UsIEUuPC9hdXRob3I+PGF1dGhvcj5QYW50dWNrLCBBLjwv

YXV0aG9yPjxhdXRob3I+V2lucXVpc3QsIEUuPC9hdXRob3I+PGF1dGhvcj5IaWdhbm8sIEMuIFMu

PC9hdXRob3I+PGF1dGhvcj5UYXBsaW4sIE0uIEUuPC9hdXRob3I+PGF1dGhvcj5QYXJrLCBZLjwv

YXV0aG9yPjxhdXRob3I+S2hlb2gsIFQuPC9hdXRob3I+PGF1dGhvcj5HcmlmZmluLCBULjwvYXV0

aG9yPjxhdXRob3I+U2NoZXIsIEguIEkuPC9hdXRob3I+PGF1dGhvcj5SYXRoa29wZiwgRC4gRS48

L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+QWJpcmF0ZXJv

bmUgaW4gbWV0YXN0YXRpYyBwcm9zdGF0ZSBjYW5jZXIgd2l0aG91dCBwcmV2aW91cyBjaGVtb3Ro

ZXJhcHk8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+VGhlIE5ldyBFbmdsYW5kIGpvdXJuYWwgb2Yg

bWVkaWNpbmU8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs

ZT5OIEVuZ2wgSiBNZWQ8L2Z1bGwtdGl0bGU+PGFiYnItMT5UaGUgTmV3IEVuZ2xhbmQgam91cm5h

bCBvZiBtZWRpY2luZTwvYWJici0xPjwvcGVyaW9kaWNhbD48cGFnZXM+MTM4LTQ4PC9wYWdlcz48

dm9sdW1lPjM2ODwvdm9sdW1lPjxudW1iZXI+MjwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5B

bmRyb3N0YWRpZW5lcyBbYWR2ZXJzZSBlZmZlY3RzXSBbdGhlcmFwZXV0aWMgdXNlXTwva2V5d29y

ZD48a2V5d29yZD5BbnRpbmVvcGxhc3RpYyBBZ2VudHMsIEhvcm1vbmFsIFthZHZlcnNlIGVmZmVj

dHNdIFt0aGVyYXBldXRpYyB1c2VdPC9rZXl3b3JkPjxrZXl3b3JkPkFudGluZW9wbGFzdGljIENv

bWJpbmVkIENoZW1vdGhlcmFweSBQcm90b2NvbHMgW2FkdmVyc2UgZWZmZWN0c10gW3RoZXJhcGV1

dGljIHVzZV08L2tleXdvcmQ+PGtleXdvcmQ+RGlzZWFzZS1GcmVlIFN1cnZpdmFsPC9rZXl3b3Jk

PjxrZXl3b3JkPkRvdWJsZS1CbGluZCBNZXRob2Q8L2tleXdvcmQ+PGtleXdvcmQ+TmVvcGxhc20g

TWV0YXN0YXNpczwva2V5d29yZD48a2V5d29yZD5QcmVkbmlzb25lIFthZHZlcnNlIGVmZmVjdHNd

IFt0aGVyYXBldXRpYyB1c2VdPC9rZXl3b3JkPjxrZXl3b3JkPlByb3N0YXRpYyBOZW9wbGFzbXMg

W2RydWcgdGhlcmFweV0gW21vcnRhbGl0eV0gW3NlY29uZGFyeV08L2tleXdvcmQ+PGtleXdvcmQ+

U3Vydml2YWwgQW5hbHlzaXM8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zW2NoZWNrd29yZF08L2tl

eXdvcmQ+PGtleXdvcmQ+TWFsZVtjaGVja3dvcmRdPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVz

Pjx5ZWFyPjIwMTM8L3llYXI+PC9kYXRlcz48YWNjZXNzaW9uLW51bT5DTi0wMDg0MDEzMDwvYWNj

ZXNzaW9uLW51bT48d29yay10eXBlPk11bHRpY2VudGVyIFN0dWR5OyBSYW5kb21pemVkIENvbnRy

b2xsZWQgVHJpYWw7IFJlc2VhcmNoIFN1cHBvcnQsIE5vbi1VLlMuIEdvdiZhcG9zO3Q8L3dvcmst

dHlwZT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL29ubGluZWxpYnJhcnkud2lsZXku

Y29tL28vY29jaHJhbmUvY2xjZW50cmFsL2FydGljbGVzLzEzMC9DTi0wMDg0MDEzMC9mcmFtZS5o

dG1sPC91cmw+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcG1jL2FydGljbGVzL1BN

QzM2ODM1NzAvcGRmL25paG1zNDcyMjc1LnBkZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48

Y3VzdG9tMz5QdWJtZWQgMjMyMjgxNzI8L2N1c3RvbTM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVt

PjEwLjEwNTYvTkVKTW9hMTIwOTA5NjwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+

PC9DaXRlPjxDaXRlPjxBdXRob3I+UnlhbjwvQXV0aG9yPjxZZWFyPjIwMTU8L1llYXI+PFJlY051

bT4xOTU1PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xOTU1PC9yZWMtbnVtYmVyPjxmb3Jl

aWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0ienp0OTU1c3c1MmR2dGdlZXN2NjVyMHBnZHd2

dDlldmZ3d2VlIiB0aW1lc3RhbXA9IjE0MzcwNTUxMTgiPjE5NTU8L2tleT48L2ZvcmVpZ24ta2V5

cz48cmVmLXR5cGUgbmFtZT0iRWxlY3Ryb25pYyBBcnRpY2xlIj40MzwvcmVmLXR5cGU+PGNvbnRy

aWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlJ5YW4sIEMuIEouPC9hdXRob3I+PGF1dGhvcj5TbWl0

aCwgTS4gUi48L2F1dGhvcj48YXV0aG9yPkZpemF6aSwgSy48L2F1dGhvcj48YXV0aG9yPlNhYWQs

IEYuPC9hdXRob3I+PGF1dGhvcj5NdWxkZXJzLCBQLiBGLjwvYXV0aG9yPjxhdXRob3I+U3Rlcm5i

ZXJnLCBDLiBOLjwvYXV0aG9yPjxhdXRob3I+TWlsbGVyLCBLLjwvYXV0aG9yPjxhdXRob3I+TG9n

b3RoZXRpcywgQy4gSi48L2F1dGhvcj48YXV0aG9yPlNob3JlLCBOLiBELjwvYXV0aG9yPjxhdXRo

b3I+U21hbGwsIEUuIEouPC9hdXRob3I+PGF1dGhvcj5DYXJsZXMsIEouPC9hdXRob3I+PGF1dGhv

cj5GbGFpZywgVC4gVy48L2F1dGhvcj48YXV0aG9yPlRhcGxpbiwgTS4gRS48L2F1dGhvcj48YXV0

aG9yPkhpZ2FubywgQy4gUy48L2F1dGhvcj48YXV0aG9yPlNvdXphLCBQLjwvYXV0aG9yPjxhdXRo

b3I+Qm9ubywgSi4gUy48L2F1dGhvcj48YXV0aG9yPkdyaWZmaW4sIFQuIFcuPC9hdXRob3I+PGF1

dGhvcj5Qb3JyZSwgUC48L2F1dGhvcj48YXV0aG9yPll1LCBNLiBLLjwvYXV0aG9yPjxhdXRob3I+

UGFyaywgWS4gQy48L2F1dGhvcj48YXV0aG9yPkxpLCBKLjwvYXV0aG9yPjxhdXRob3I+S2hlb2gs

IFQuPC9hdXRob3I+PGF1dGhvcj5OYWluaSwgVi48L2F1dGhvcj48YXV0aG9yPk1vbGluYSwgQS48

L2F1dGhvcj48YXV0aG9yPlJhdGhrb3BmLCBELiBFLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRy

aWJ1dG9ycz48dGl0bGVzPjx0aXRsZT5BYmlyYXRlcm9uZSBhY2V0YXRlIHBsdXMgcHJlZG5pc29u

ZSB2ZXJzdXMgcGxhY2VibyBwbHVzIHByZWRuaXNvbmUgaW4gY2hlbW90aGVyYXB5LW5haXZlIG1l

biB3aXRoIG1ldGFzdGF0aWMgY2FzdHJhdGlvbi1yZXNpc3RhbnQgcHJvc3RhdGUgY2FuY2VyIChD

T1UtQUEtMzAyKTogZmluYWwgb3ZlcmFsbCBzdXJ2aXZhbCBhbmFseXNpcyBvZiBhIHJhbmRvbWlz

ZWQsIGRvdWJsZS1ibGluZCwgcGxhY2Viby1jb250cm9sbGVkIHBoYXNlIDMgc3R1ZHk8L3RpdGxl

PjxzZWNvbmRhcnktdGl0bGU+VGhlIExhbmNldC4gT25jb2xvZ3k8L3NlY29uZGFyeS10aXRsZT48

L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5MYW5jZXQgT25jb2w8L2Z1bGwtdGl0bGU+

PGFiYnItMT5UaGUgTGFuY2V0LiBPbmNvbG9neTwvYWJici0xPjwvcGVyaW9kaWNhbD48cGFnZXM+

MTUyLTYwPC9wYWdlcz48dm9sdW1lPjE2PC92b2x1bWU+PG51bWJlcj4yPC9udW1iZXI+PGtleXdv

cmRzPjxrZXl3b3JkPkFuZHJvc3RlbmVzIFt0aGVyYXBldXRpYyB1c2VdPC9rZXl3b3JkPjxrZXl3

b3JkPkFudGluZW9wbGFzdGljIEFnZW50cywgSG9ybW9uYWwgW3RoZXJhcGV1dGljIHVzZV08L2tl

eXdvcmQ+PGtleXdvcmQ+QW50aW5lb3BsYXN0aWMgQ29tYmluZWQgQ2hlbW90aGVyYXB5IFByb3Rv

Y29sczwva2V5d29yZD48a2V5d29yZD5Cb25lIE5lb3BsYXNtcyBbZHJ1ZyB0aGVyYXB5XSBbbW9y

dGFsaXR5XSBbc2Vjb25kYXJ5XTwva2V5d29yZD48a2V5d29yZD5EaXNlYXNlIFByb2dyZXNzaW9u

PC9rZXl3b3JkPjxrZXl3b3JkPkRvdWJsZS1CbGluZCBNZXRob2Q8L2tleXdvcmQ+PGtleXdvcmQ+

Rm9sbG93LVVwIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+TmVvcGxhc20gU3RhZ2luZzwva2V5

d29yZD48a2V5d29yZD5QcmVkbmlzb25lIFt0aGVyYXBldXRpYyB1c2VdPC9rZXl3b3JkPjxrZXl3

b3JkPlByb2dub3Npczwva2V5d29yZD48a2V5d29yZD5Qcm9zdGF0aWMgTmVvcGxhc21zLCBDYXN0

cmF0aW9uLVJlc2lzdGFudCBbZHJ1ZyB0aGVyYXB5XSBbbW9ydGFsaXR5XSBbcGF0aG9sb2d5XTwv

a2V5d29yZD48a2V5d29yZD5TdXJ2aXZhbCBSYXRlPC9rZXl3b3JkPjxrZXl3b3JkPkFnZWRbY2hl

Y2t3b3JkXTwva2V5d29yZD48a2V5d29yZD5IdW1hbnNbY2hlY2t3b3JkXTwva2V5d29yZD48a2V5

d29yZD5NYWxlW2NoZWNrd29yZF08L2tleXdvcmQ+PGtleXdvcmQ+YWR1bHQ8L2tleXdvcmQ+PGtl

eXdvcmQ+YWdlZDwva2V5d29yZD48a2V5d29yZD5hcnRpY2xlPC9rZXl3b3JkPjxrZXl3b3JkPmNh

bmNlciBtb3J0YWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+Y2FuY2VyIHByb2dub3Npczwva2V5d29y

ZD48a2V5d29yZD5jYW5jZXIgcmVzaXN0YW5jZTwva2V5d29yZD48a2V5d29yZD5jYXN0cmF0aW9u

IHJlc2lzdGFudCBwcm9zdGF0ZSBjYW5jZXIvZHIgW0RydWcgUmVzaXN0YW5jZV08L2tleXdvcmQ+

PGtleXdvcmQ+Y2FzdHJhdGlvbiByZXNpc3RhbnQgcHJvc3RhdGUgY2FuY2VyL2R0IFtEcnVnIFRo

ZXJhcHldPC9rZXl3b3JkPjxrZXl3b3JkPmNvbXB1dGVyIGFzc2lzdGVkIHRvbW9ncmFwaHk8L2tl

eXdvcmQ+PGtleXdvcmQ+Y29udHJvbGxlZCBzdHVkeTwva2V5d29yZD48a2V5d29yZD5jcm9zc292

ZXIgcHJvY2VkdXJlPC9rZXl3b3JkPjxrZXl3b3JkPmRvdWJsZSBibGluZCBwcm9jZWR1cmU8L2tl

eXdvcmQ+PGtleXdvcmQ+ZHJ1ZyBkb3NlIHJlZHVjdGlvbjwva2V5d29yZD48a2V5d29yZD5kcnVn

IGVmZmVjdDwva2V5d29yZD48a2V5d29yZD5kcnVnIGVmZmljYWN5PC9rZXl3b3JkPjxrZXl3b3Jk

PmRydWcgaW5kaWNhdGlvbjwva2V5d29yZD48a2V5d29yZD5kcnVnIHNhZmV0eTwva2V5d29yZD48

a2V5d29yZD5kcnVnIHdpdGhkcmF3YWw8L2tleXdvcmQ+PGtleXdvcmQ+ZWRlbWEvc2kgW1NpZGUg

RWZmZWN0XTwva2V5d29yZD48a2V5d29yZD5mb2xsb3cgdXA8L2tleXdvcmQ+PGtleXdvcmQ+aGVh

cnQgYXRyaXVtIGZpYnJpbGxhdGlvbi9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3Jk

PmhlYXJ0IGRpc2Vhc2Uvc2kgW1NpZGUgRWZmZWN0XTwva2V5d29yZD48a2V5d29yZD5odW1hbjwv

a2V5d29yZD48a2V5d29yZD5oeXBlcnRlbnNpb24vc2kgW1NpZGUgRWZmZWN0XTwva2V5d29yZD48

a2V5d29yZD5oeXBva2FsZW1pYS9zaSBbU2lkZSBFZmZlY3RdPC9rZXl3b3JkPjxrZXl3b3JkPmlu

dGVudGlvbiB0byB0cmVhdCBhbmFseXNpczwva2V5d29yZD48a2V5d29yZD5tYWpvciBjbGluaWNh

bCBzdHVkeTwva2V5d29yZD48a2V5d29yZD5tYWxlPC9rZXl3b3JkPjxrZXl3b3JkPm1ldGFzdGFz

aXMvZHIgW0RydWcgUmVzaXN0YW5jZV08L2tleXdvcmQ+PGtleXdvcmQ+bWV0YXN0YXNpcy9kdCBb

RHJ1ZyBUaGVyYXB5XTwva2V5d29yZD48a2V5d29yZD5udWNsZWFyIG1hZ25ldGljIHJlc29uYW5j

ZSBpbWFnaW5nPC9rZXl3b3JkPjxrZXl3b3JkPm92ZXJhbGwgc3Vydml2YWw8L2tleXdvcmQ+PGtl

eXdvcmQ+cGhhc2UgMyBjbGluaWNhbCB0cmlhbDwva2V5d29yZD48a2V5d29yZD5wcm9ncmVzc2lv

biBmcmVlIHN1cnZpdmFsPC9rZXl3b3JkPjxrZXl3b3JkPnJhbmRvbWl6ZWQgY29udHJvbGxlZCB0

cmlhbDwva2V5d29yZD48a2V5d29yZD5yaXNrIGJlbmVmaXQgYW5hbHlzaXM8L2tleXdvcmQ+PGtl

eXdvcmQ+dHJlYXRtZW50IGR1cmF0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPnVuc3BlY2lmaWVkIHNp

ZGUgZWZmZWN0L3NpIFtTaWRlIEVmZmVjdF08L2tleXdvcmQ+PGtleXdvcmQ+YWJpcmF0ZXJvbmUg

YWNldGF0ZS9jdCBbQ2xpbmljYWwgVHJpYWxdPC9rZXl3b3JkPjxrZXl3b3JkPmFiaXJhdGVyb25l

IGFjZXRhdGUvYWUgW0FkdmVyc2UgRHJ1ZyBSZWFjdGlvbl08L2tleXdvcmQ+PGtleXdvcmQ+YWJp

cmF0ZXJvbmUgYWNldGF0ZS9jYiBbRHJ1ZyBDb21iaW5hdGlvbl08L2tleXdvcmQ+PGtleXdvcmQ+

YWJpcmF0ZXJvbmUgYWNldGF0ZS9jbSBbRHJ1ZyBDb21wYXJpc29uXTwva2V5d29yZD48a2V5d29y

ZD5hYmlyYXRlcm9uZSBhY2V0YXRlL3BvIFtPcmFsIERydWcgQWRtaW5pc3RyYXRpb25dPC9rZXl3

b3JkPjxrZXl3b3JkPmFiaXJhdGVyb25lIGFjZXRhdGUvZHQgW0RydWcgVGhlcmFweV08L2tleXdv

cmQ+PGtleXdvcmQ+YWxhbmluZSBhbWlub3RyYW5zZmVyYXNlL2VjIFtFbmRvZ2Vub3VzIENvbXBv

dW5kXTwva2V5d29yZD48a2V5d29yZD5hc3BhcnRhdGUgYW1pbm90cmFuc2ZlcmFzZS9lYyBbRW5k

b2dlbm91cyBDb21wb3VuZF08L2tleXdvcmQ+PGtleXdvcmQ+cGxhY2Vibzwva2V5d29yZD48a2V5

d29yZD5wcmVkbmlzb25lL3BvIFtPcmFsIERydWcgQWRtaW5pc3RyYXRpb25dPC9rZXl3b3JkPjxr

ZXl3b3JkPnByZWRuaXNvbmUvY3QgW0NsaW5pY2FsIFRyaWFsXTwva2V5d29yZD48a2V5d29yZD5w

cmVkbmlzb25lL2NiIFtEcnVnIENvbWJpbmF0aW9uXTwva2V5d29yZD48a2V5d29yZD5wcmVkbmlz

b25lL2R0IFtEcnVnIFRoZXJhcHldPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIw

MTU8L3llYXI+PC9kYXRlcz48YWNjZXNzaW9uLW51bT5DTi0wMTA0ODUzNDwvYWNjZXNzaW9uLW51

bT48d29yay10eXBlPkNsaW5pY2FsIFRyaWFsLCBQaGFzZSBJSUk7IENvbXBhcmF0aXZlIFN0dWR5

OyBNdWx0aWNlbnRlciBTdHVkeTsgUmFuZG9taXplZCBDb250cm9sbGVkIFRyaWFsOyBSZXNlYXJj

aCBTdXBwb3J0LCBOb24tVS5TLiBHb3YmYXBvczt0PC93b3JrLXR5cGU+PHVybHM+PHJlbGF0ZWQt

dXJscz48dXJsPmh0dHA6Ly9vbmxpbmVsaWJyYXJ5LndpbGV5LmNvbS9vL2NvY2hyYW5lL2NsY2Vu

dHJhbC9hcnRpY2xlcy81MzQvQ04tMDEwNDg1MzQvZnJhbWUuaHRtbDwvdXJsPjx1cmw+aHR0cDov

L3d3dy50aGVsYW5jZXQuY29tL2pvdXJuYWxzL2xhbm9uYy9hcnRpY2xlL1BJSVMxNDcwLTIwNDUo

MTQpNzEyMDUtNy9hYnN0cmFjdDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48Y3VzdG9tMz5Q

dWJtZWQgMjU2MDEzNDE8L2N1c3RvbTM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwMTYv

UzE0NzAtMjA0NSgxNCk3MTIwNS03PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48

L0NpdGU+PENpdGU+PEF1dGhvcj5TYXJ0b3I8L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFyPjxSZWNO

dW0+MTM2ODwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+MTM2ODwvcmVjLW51bWJlcj48Zm9y

ZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9Inp6dDk1NXN3NTJkdnRnZWVzdjY1cjBwZ2R3

dnQ5ZXZmd3dlZSIgdGltZXN0YW1wPSIxNDM3MDQ3NjY3Ij4xMzY4PC9rZXk+PC9mb3JlaWduLWtl

eXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmli

dXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5TYXJ0b3IsIE8uPC9hdXRob3I+PGF1dGhvcj5Db2xlbWFu

LCBSLjwvYXV0aG9yPjxhdXRob3I+Tmlsc3NvbiwgUy48L2F1dGhvcj48YXV0aG9yPkhlaW5yaWNo

LCBELjwvYXV0aG9yPjxhdXRob3I+SGVsbGUsIFMuIEkuPC9hdXRob3I+PGF1dGhvcj5PJmFwb3M7

U3VsbGl2YW4sIEouIE0uPC9hdXRob3I+PGF1dGhvcj5Gb3NzYSwgUy4gRC48L2F1dGhvcj48YXV0

aG9yPkNob2RhY2tpLCBBLjwvYXV0aG9yPjxhdXRob3I+V2llY2hubywgUC48L2F1dGhvcj48YXV0

aG9yPkxvZ3VlLCBKLjwvYXV0aG9yPjxhdXRob3I+V2lkbWFyaywgQS48L2F1dGhvcj48YXV0aG9y

PkpvaGFubmVzc2VuLCBELiBDLjwvYXV0aG9yPjxhdXRob3I+SG9za2luLCBQLjwvYXV0aG9yPjxh

dXRob3I+SmFtZXMsIE4uIEQuPC9hdXRob3I+PGF1dGhvcj5Tb2xiZXJnLCBBLjwvYXV0aG9yPjxh

dXRob3I+U3luZGlrdXMsIEkuPC9hdXRob3I+PGF1dGhvcj5Wb2dlbHphbmcsIE4uIEouPC9hdXRo

b3I+PGF1dGhvcj5PJmFwb3M7QnJ5YW4tVGVhciwgQy4gRy48L2F1dGhvcj48YXV0aG9yPlNoYW4s

IE0uPC9hdXRob3I+PGF1dGhvcj5CcnVsYW5kLCBULiBTLjwvYXV0aG9yPjxhdXRob3I+UGFya2Vy

LCBDLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPk8uIFNh

cnRvciwgTWVkaWNhbCBEaXJlY3RvciBUdWxhbmUgQ2FuY2VyIENlbnRlciwgRGVwYXJ0bWVudHMg

b2YgTWVkaWNpbmUgYW5kIFVyb2xvZ3ksIFR1bGFuZSBNZWRpY2FsIFNjaG9vbCwgTmV3IE9ybGVh

bnMsIExBIDcwMTEyLCBVbml0ZWQgU3RhdGVzPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+

RWZmZWN0IG9mIHJhZGl1bS0yMjMgZGljaGxvcmlkZSBvbiBzeW1wdG9tYXRpYyBza2VsZXRhbCBl

dmVudHMgaW4gcGF0aWVudHMgd2l0aCBjYXN0cmF0aW9uLXJlc2lzdGFudCBwcm9zdGF0ZSBjYW5j

ZXIgYW5kIGJvbmUgbWV0YXN0YXNlczogUmVzdWx0cyBmcm9tIGEgcGhhc2UgMywgZG91YmxlLWJs

aW5kLCByYW5kb21pc2VkIHRyaWFsPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPlRoZSBMYW5jZXQg

T25jb2xvZ3k8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs

ZT5UaGUgTGFuY2V0IE9uY29sb2d5PC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+NzM4

LTc0NjwvcGFnZXM+PHZvbHVtZT4xNTwvdm9sdW1lPjxudW1iZXI+NzwvbnVtYmVyPjxrZXl3b3Jk

cz48a2V5d29yZD5OQ1QwMDY5OTc1MTwva2V5d29yZD48a2V5d29yZD5hbGthbGluZSBwaG9zcGhh

dGFzZTwva2V5d29yZD48a2V5d29yZD5kb2NldGF4ZWw8L2tleXdvcmQ+PGtleXdvcmQ+cGxhY2Vi

bzwva2V5d29yZD48a2V5d29yZD5yYWRpdW0gY2hsb3JpZGUgcmEgMjIzPC9rZXl3b3JkPjxrZXl3

b3JkPnpvbGVkcm9uaWMgYWNpZDwva2V5d29yZD48a2V5d29yZD5hZHVsdDwva2V5d29yZD48a2V5

d29yZD5hZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPmFydGljbGU8L2tleXdvcmQ+PGtleXdvcmQ+Ym9u

ZSBtZXRhc3Rhc2lzPC9rZXl3b3JkPjxrZXl3b3JkPmJvbmUgcGFpbjwva2V5d29yZD48a2V5d29y

ZD5jYW5jZXIgY2hlbW90aGVyYXB5PC9rZXl3b3JkPjxrZXl3b3JkPmNhc3RyYXRpb24gcmVzaXN0

YW50IHByb3N0YXRlIGNhbmNlcjwva2V5d29yZD48a2V5d29yZD5jbGluaWNhbCBlZmZlY3RpdmVu

ZXNzPC9rZXl3b3JkPjxrZXl3b3JkPmNvbnRyb2xsZWQgc3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+

ZG91YmxlIGJsaW5kIHByb2NlZHVyZTwva2V5d29yZD48a2V5d29yZD5kcnVnIGVmZmVjdDwva2V5

d29yZD48a2V5d29yZD5kcnVnIGVmZmljYWN5PC9rZXl3b3JkPjxrZXl3b3JkPmRydWcgc2FmZXR5

PC9rZXl3b3JkPjxrZXl3b3JkPmRydWcgdG9sZXJhYmlsaXR5PC9rZXl3b3JkPjxrZXl3b3JkPmRy

dWcgd2l0aGRyYXdhbDwva2V5d29yZD48a2V5d29yZD5ldmVudCBmcmVlIHN1cnZpdmFsPC9rZXl3

b3JkPjxrZXl3b3JkPmV4dGVybmFsIGJlYW0gcmFkaW90aGVyYXB5PC9rZXl3b3JkPjxrZXl3b3Jk

PmhlYWx0aCBjYXJlIHF1YWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+aHVtYW48L2tleXdvcmQ+PGtl

eXdvcmQ+aW50ZW50aW9uIHRvIHRyZWF0IGFuYWx5c2lzPC9rZXl3b3JkPjxrZXl3b3JkPm1ham9y

IGNsaW5pY2FsIHN0dWR5PC9rZXl3b3JkPjxrZXl3b3JkPm1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+

bXVsdGljZW50ZXIgc3R1ZHk8L2tleXdvcmQ+PGtleXdvcmQ+b3J0aG9wZWRpYyBzdXJnZXJ5PC9r

ZXl3b3JkPjxrZXl3b3JkPm92ZXJhbGwgc3Vydml2YWw8L2tleXdvcmQ+PGtleXdvcmQ+cGF0aG9s

b2dpYyBmcmFjdHVyZTwva2V5d29yZD48a2V5d29yZD5waGFzZSAzIGNsaW5pY2FsIHRyaWFsPC9r

ZXl3b3JkPjxrZXl3b3JkPnBvc3QgaG9jIGFuYWx5c2lzPC9rZXl3b3JkPjxrZXl3b3JkPnByaW9y

aXR5IGpvdXJuYWw8L2tleXdvcmQ+PGtleXdvcmQ+cmFuZG9taXplZCBjb250cm9sbGVkIHRyaWFs

PC9rZXl3b3JkPjxrZXl3b3JkPnJpc2sgcmVkdWN0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPnNwaW5h

bCBjb3JkIGNvbXByZXNzaW9uPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8

L3llYXI+PC9kYXRlcz48aXNibj4xNDc0LTU0ODgmI3hEOzE0NzAtMjA0NTwvaXNibj48dXJscz48

cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5lbWJhc2UuY29tL3NlYXJjaC9yZXN1bHRzP3N1

YmFjdGlvbj12aWV3cmVjb3JkJmFtcDtmcm9tPWV4cG9ydCZhbXA7aWQ9TDUzMTM0MDMzPC91cmw+

PHVybD5odHRwOi8vZHguZG9pLm9yZy8xMC4xMDE2L1MxNDcwLTIwNDUoMTQpNzAxODMtNDwvdXJs

Pjx1cmw+aHR0cDovL3NmeC5saWJyYXJ5LnV1Lm5sL3V0cmVjaHQ/c2lkPUVNQkFTRSZhbXA7aXNz

bj0xNDc0NTQ4OCZhbXA7aWQ9ZG9pOjEwLjEwMTYlMkZTMTQ3MC0yMDQ1JTI4MTQlMjk3MDE4My00

JmFtcDthdGl0bGU9RWZmZWN0K29mK3JhZGl1bS0yMjMrZGljaGxvcmlkZStvbitzeW1wdG9tYXRp

Yytza2VsZXRhbCtldmVudHMraW4rcGF0aWVudHMrd2l0aCtjYXN0cmF0aW9uLXJlc2lzdGFudCtw

cm9zdGF0ZStjYW5jZXIrYW5kK2JvbmUrbWV0YXN0YXNlcyUzQStSZXN1bHRzK2Zyb20rYStwaGFz

ZSszJTJDK2RvdWJsZS1ibGluZCUyQytyYW5kb21pc2VkK3RyaWFsJmFtcDtzdGl0bGU9TGFuY2V0

K09uY29sLiZhbXA7dGl0bGU9VGhlK0xhbmNldCtPbmNvbG9neSZhbXA7dm9sdW1lPTE1JmFtcDtp

c3N1ZT03JmFtcDtzcGFnZT03MzgmYW1wO2VwYWdlPTc0NiZhbXA7YXVsYXN0PVNhcnRvciZhbXA7

YXVmaXJzdD1PbGl2ZXImYW1wO2F1aW5pdD1PLiZhbXA7YXVmdWxsPVNhcnRvcitPLiZhbXA7Y29k

ZW49TE9BTkImYW1wO2lzYm49JmFtcDtwYWdlcz03MzgtNzQ2JmFtcDtkYXRlPTIwMTQmYW1wO2F1

aW5pdDE9TyZhbXA7YXVpbml0bT08L3VybD48dXJsPmh0dHA6Ly93d3cudGhlbGFuY2V0LmNvbS9q

b3VybmFscy9sYW5vbmMvYXJ0aWNsZS9QSUlTMTQ3MC0yMDQ1KDE0KTcwMTgzLTQvYWJzdHJhY3Q8

L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE.DATA [1-16] ADDIN EN.REFLIST 1.Akaza, H., et al., Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer, 2009. 115(15): p. 3437-45.2.Arai, Y., et al., Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study. J Cancer Res Clin Oncol, 2008. 134(12): p. 1385-96.3.Basch, E., et al., Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: Patient-reported outcome results of a randomised phase 3 trial. The Lancet Oncology, 2013. 14(12): p. 1193-1199.4.Beer, T.M., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. The New England journal of medicine, 2014. 371, 424-33 DOI: 10.1056/NEJMoa1405095.5.Hoskin, P., et al., Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. The Lancet Oncology, 2014. 15(12): p. 1397-1406.6.Kantoff, P.W., et al., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 2010. 363(5): p. 411-22.7.Loriot, Y., et al., Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol, 2015. 16(5): p. 509-21.8.Morris, M.J., et al., Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. Journal of Clinical Oncology, 2015. 33(12): p. 1356-1363.9.Nilsson, S., et al., Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clinical Genitourinary Cancer, 2013. 11(1): p. 20-26.10.Nilsson, S., et al., Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol, 2007. 8(7): p. 587-94.11.Nome, R., et al., Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223. Scand J Urol, 2015. 49(3): p. 211-7.12.Parker, C., et al., Alpha emitter radium-223 and survival in metastatic prostate cancer. New England Journal of Medicine, 2013. 369(3): p. 213-223.13.Rathkopf, D.E., et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). European urology, 2014. 66, 815-25 DOI: 10.1016/j.eururo.2014.02.056.14.Ryan, C.J., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England journal of medicine, 2013. 368, 138-48 DOI: 10.1056/NEJMoa1209096.15.Ryan, C.J., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology, 2015. 16, 152-60 DOI: 10.1016/S1470-2045(14)71205-7.16.Sartor, O., et al., Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial. The Lancet Oncology, 2014. 15(7): p. 738-746. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download